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ABSTRACT
MEF2C-related disorders are characterized by intellectual disability,
developmental delay, lack of speech, seizures, stereotypic movements, hypotonia, and
brain abnormalities and are caused by pathogenic alterations involving the MEF2C gene.
Despite published cases, MEF2C-related disorders are difficult to recognize clinically.
These studies sought to further characterize MEF2C-related disorders by investigating the
genotypes, phenotypes, and gene functions (or dysfunctions) associated with the disorder.
Tremors have been reported in some patients with MEF2C-related disorders, but
the concept of tremors has been complicated by vague definitions and numerous
categorization methods. We performed a concept analysis following the Walker and
Avant method to clarify the concept and develop an operational definition of tremors. We
concluded that tremors are a movement disorder characterized by shaking motions that
are involuntary, oscillatory, rhythmic, non-painful, always present although vary in
severity, and can be repressed by changing posture or going into a rest position.
We then performed a systematic literature review to record the genotypes and
comprehensive phenotype of MEF2C-related disorders reported in the literature. Fortythree articles characterizing 117 patients met the inclusion criteria. Common features
included intellectual disability, developmental delay, seizures, hypotonia, absent speech,
inability to walk, stereotypic movements, and MRI abnormalities. Nonclassical findings
included question mark ear, jugular pit, and a unique neuroendocrine finding.
Next, we developed a survey based on validated instruments to gather
developmental and clinical information from the parents of children with MEF2C-related
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disorders. Seventy-three parents completed the survey. Limited speech, seizures,
bruxism, repetitive movements, and high pain tolerance were some of the prominent
features identified from the survey data. Statistical analyses showed that patients with
MEF2C variants were similarly affected as patients with deletions and females showed
higher verbal abilities. This natural history study details phenotypic and developmental
information of the largest single cohort reported to date.
Lastly, we discussed current techniques used to investigate the mouse Mef2c gene
expression and regulation in the brain. Previous unbiased RNA sequencing of whole
cortex from Mef2c global heterozygous mice showed hundreds of dysregulated genes,
particularly autism risk genes and microglial genes. The Cowan lab is currently
performing single nuclei RNA sequencing (snRNAseq) to better understand the role of
Mef2c in neurons and microglia. Techniques used include nuclei dissociation,
fluorescence-activated cell sorting, library preparation and sequencing, and bioinformatic
analysis of the snRNAseq data. Additional research techniques include perfusion fixation,
brain extraction and slicing, and immunohistochemistry.
These studies characterize the phenotype and document the severity of the
disorder. The information reported will help providers diagnose and care for patients with
MEF2C-related disorders. Additionally, the systematic review and survey data can be
useful for further genotype-phenotype correlations, as baseline data for treatment trials,
and to develop future studies.
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CHAPTER ONE
INTRODUCTION

Overview
MEF2C-related disorders, also known as MEF2C haploinsufficiency syndrome or
chromosome 5q14.3 deletion syndrome (OMIM #613443), are characterized by
intellectual disability, developmental delay, lack of speech, seizures, stereotypic
movements, hypotonia, and brain abnormalities. The disorders were first associated with
a loss (deletion) of a region of the long arm of chromosome 5. Occasional gains
(duplications) of this region have also been reported. Early publications reported patients
having deletions of various sizes in this region and one patient having a 216-kb deletion
only encompassing the MEF2C gene (Le Meur et al., 2010). The reports indicated that
the causative minimal critical region for this disorder is the MEF2C gene. Additionally,
patients with the same phenotype have been reported to have point pathogenic variants in
the MEF2C gene (Zweier et al., 2010), making an even stronger case that MEF2C is
responsible.
Despite published case studies, MEF2C-related disorders are difficult to recognize
clinically. Additionally, most manuscripts report one or only a few patients with a total of
117 patients reported to date in the literature (Cooley Coleman et al., 2021). This
introduction chapter describes what is known about the MEF2C gene, MEF2C-related
disorders, and methods to investigate the genotype, phenotype, and gene functions (or
dysfunctions) associated with the disorder. These methods include theoretical,
observational, and experimental designs including concept analyses, literature reviews,
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surveys, and laboratory studies using animal models. These methods are useful not only
for MEF2C-related disorders but also for other rare genetic disorders that have not yet
been fully characterized.

MEF2C Gene
MEF2 Family
The MEF2 (myocyte enhancer factor 2) family of proteins are transcription
factors within the MADS family. The MADS-box region is highly conserved across
various organisms, with the name stemming from the first four identified protein
members in this group: MCM1 (pheromone receptor transcription factor; yeast), AG
(Agamous; Arabidopsis), DEFA (Deficiens; snapdragon), and SRF (serum response
factor; human) (Shore & Sharrocks, 1995). In vertebrates, there are four MEF2 genes:
MEF2A (chromosome 15q26.3), MEF2B (chromosome 19p13.11), MEF2C (chromosome
5q14.3), and MEF2D (chromosome 1q22). The MADS-box domain is located at the Nterminus of each MEF2 protein and is highly homologous to other MADS family
members (including non-MEF2 genes) across multiple organisms. In the MEF2 family,
the MEF2 domain lies directly adjacent to the MADS-box domain. The MEF2 domain is
a region that is only conserved within the MEF2 family (McDermott et al., 1993). After
the MEF2 domain, the C-terminal of the various MEF2 members diverge. The MADS
and MEF2 domains are responsible for dimerization, cofactor binding, and DNA binding
while the C-terminal region is responsible for transcription regulation and nuclear
localization (Assali et al., 2019).
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MEF2 proteins rely on the recruitment and binding to other transcription factors
to activate transcription. They form homo- and heterodimers prior to binding to DNA
containing the sequence C/TTA(A/T)4TAG/A (also seen as YTA(A/T)4TAR in the
literature) (Molkentin et al., 1996). This consensus sequence is found in control regions
of genes responsible for driving tissue-specific gene expression. When studying MEF2C
specifically, Molkentin et al. (1996) found that MEF2C pathogenic variants of either a
deletion within the MADS or MEF2 domain failed to dimerize or bind to DNA;
therefore, both the MADS and MEF2 domains are required for dimerization and DNA
binding. Additionally, they found that the MADS and MEF2 domains alone were not
sufficient to activate transcription: the C terminal portion was required as deletions within
this portion of the protein did abolish transcriptional activation.
Pathogenic variants in MEF2A have been associated with coronary artery disease
and myocardial infarction (L. Wang et al., 2003). Additionally, patients with congenital
diaphragmatic hernia often have chromosomal abnormalities involving 15q24-q26, which
includes the MEF2A gene (Biggio et al., 2004). MEF2B somatic mutations have been
found in diffuse large B-cell lymphomas and follicular lymphomas, but otherwise have
not been associated with any germline genetic disorders (Morin et al., 2011). MEF2C is
the only gene in the MEF2 family that is a causative gene in a deletion syndrome:
Chromosome 5q14.3 deletion syndrome. MEF2C alterations (point mutations and indels)
have also been identified in patients with the same phenotype as those with larger
chromosomal alterations (Zweier et al. 2010). Lastly, fusions involving the MEF2D gene
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have been associated with lymphoblastic leukemia (Gu et al., 2016), and MEF2D
overexpression has been linked to pancreatic and ovarian cancer (Li et al., 2019).

MEF2C History
MEF2C was first discovered by Leifer’s team in 1993 while screening skeletal
muscle cDNA libraries using a DNA probe containing the MEF2 DNA-binding domain
(Leifer et al., 1993). Using this method, they isolated cDNA clones that had high
homology to the MEF2 DNA-binding domain; however, the region following the MEF2
domain differed from the previously described MEF2A gene. The team called the gene
hMEF2C (where h stands for human). Using reverse transcription PCR (RT-PCR) and
Northern blotting, the team screened clones and discovered four MEF2C isoforms
resulting from the alternative splicing of two regions (McDermott et al., 1993). Some
clones found in both muscle and brain lacked a 32 amino acid region (later termed
gamma, or γ). Other brain-specific clones included an 8 amino acid region (later termed
beta, or β). These 8 amino acids were not found in any muscle clones. All four isoforms
were shown to bind to MEF2 DNA targets using electrophoretic mobility shift assays to
test the protein-DNA interactions. Additionally, the isoforms’ ability to activate
transcription was tested via cotransfection of HeLa cells with hMEF2C cDNAs and a
reporter containing a promoter and MEF2 binding site to activate transcription of the
CAT gene. All four isoforms were shown to activate transcription (Leifer et al., 1993;
McDermott et al., 1993).

MEF2C Structure
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The MEF2C gene (isoform 1, NM_002397.5) is located on chromosome 5
positions 88,717,117-88,883,184 (hg38, UCSC Genome Browser) and consists of
166,068 nucleotides (including coding regions and untranslated region (UTRs)). MEF2C
has 11 exons, one of which is non-coding (isoform 1). Figure 1.1 shows the gene
location, expression, and location of commonly reported single nucleotide
polymorphisms (SNPs) per dbSNP (build 153) as displayed on the UCSC genome
browser. The 10 coding exons produce a protein that is 473 amino acids long with a
molecular mass of 51,221 Da (Figure 1.2).

Figure 1.1: MEF2C gene location and commonly reported single nucleotide
polymorphisms (SNPs) per dbSNP (build 153) as displayed on the UCSC genome
browser.
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Figure 1.2:
A. MEF2C protein model depicting two MEF2C protein molecules dimerizing
(homodimer) at the N terminal portion of the protein. The image shows protein regions
from Glycine at amino acid position 2 (dark blue strand) through Lysine at amino acid
position 91 (red strand). B. Surface or spacefill representation of dimer portion shown in
(A). C. Entire MEF2C protein monomer. D. Surface / spacefill representation of the
entire MEF2C protein monomer in the same orientation as (C).
(images from Swiss-Model, Bienert et al., 2017)
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MEF2C undergoes vast alternative splicing. This process increases the diversity
of mRNAs expressed from the genome, allows for tissue-specific gene variants, and has
been proposed to control which target genes that MEF2C activates (Janson, Chen, Li, &
Leifer, 2001). MEF2C has a total of 18 isoforms, some of which have multiple transcript
variants (Table 1.1). For example, transcript variants 1, 6, and 9-11 all encode for isoform
1. These transcript variants differ at the nucleotide level (for example, transcript variants
1 and 6 differ in the 5’ UTR), but they still encode the same amino acid sequence (and
therefore are characterized as isoform 1). The various isoforms differ at the amino acid
sequence level. Isoform 1 variant 1 is the longest MEF2C variant. All the transcript
variants include the MADS domain (amino acids 1 to 57,
MGRKKIQITRIMDERNRQVTFTKRKFGLMKKAYELSVLCDCEIALIIFNSTNKLFQ
Y) followed by the MEF2 domain (amino acids 58 to 86,
ASTDMDKVLLKYTEYNEPHESRTNSDIVE), with the exceptions of isoforms 17
(which lacks the MADs domain and most of the MEF2 domain) and isoform 18 (which
lacks both domains).
Alternative splicing of MEF2C involves the inclusion or exclusion of the
following exonic regions: mutually exclusive alpha1 or alpha2 (α1:
TLRKKGLNGCDSPDPDADDSVGHSPESEDKYRKINEDIDLMISRQRLC or α2:
ALNKKENKGCESPDPDSSYALTPRTEEKYKKINEEFDNMIKSHKIP), the cassette
exon beta (β: SEDVDLLL), and the region called gamma (γ:
ACTSTHLSQSSNLSLPSTQSLNIKSEPVSPPR) (Figure 1.3) (Zhang, Zhu, & Davie,
2015). Isoforms with α1 are found in heart tissues, while isoforms with α2 are found in
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muscle tissues. The β exon is found exclusively in isoforms expressed in the brain, and
the inclusion of this region has been found to enhance MEF2C activity (Zhang, Zhu, &
Davie, 2015).

Figure 1.3: Schematic of MEF2C including alternatively spliced exons.

Table 1.1: Human isoforms of MEF2C showing which alternatively spliced exons they
contain and the length of the resulting protein sequence.
2
α2
γ

3
α2
γ

4
γ

5
β

6
α1
γ

7
α1
β

Human Isoforms of MEF2C
8
9
10
11
12
α2 α1 α2 β
α1
γ
β

Exons

1
α1
β
γ

13
α1

14
α2

15
β
γ

16
β

# of
Amino
Acids

473 463 483 417 393 465 441 451 433 431 424 388 380 378 347 340 315 291

MEF2C Expression
MEF2C is expressed in multiple tissue types, with the highest levels of expression
in the brain and skeletal muscle (Figure 1.4). In the brain, MEF2C is particularly
expressed in the cerebral cortex. In cell culture experiments, MEF2C was not expressed
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17
β

18
-

in precursor cells but was expressed in differentiating neurons leading to the hypothesis
that MEF2C was necessary for neuronal differentiation (Mao et al., 1999). In skeletal
muscle, MEF2C plays a role in myocyte differentiation during myogenesis and is also
recruited by muscle-specific basic-helix-loop-helix (bHLH) factors to activate musclespecific transcription (Chen et al., 2000). MEF2C is also expressed in the heart and may
be involved in familial and sporadic congenital heart disease (Ghosh et al., 2009). In both
mice and zebrafish, Mef2c homozygous mutants undergo embryonic death due to cardiac
looping defects that prevent the right ventricle from forming (Ghosh et al., 2009; Potthoff
& Olson, 2007).

Figure 1.4: MEF2C expression across various tissue types as reported in the GTEx
portal.
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MEF2C Protein Function
Being a transcription factor, MEF2C plays a role in regulating DNA transcription
into RNA. Harrington et al. (2020) performed RNAseq on Mef2c heterozygous mice as
compared to wild-type mice to identify differentially expressed genes (DEGs) resulting
from the lack of Mef2c. A total of 490 significantly dysregulated genes were detected,
many of which were excitatory neuron and microglia genes. Many of the downregulated
genes were ASD-risk genes and FMRP binding genes, while microglial genes were
upregulated. These results show that Mef2c acts as a gene-specific repressor or activator,
particularly regulating microglial and neuronal genes.

MEF2C-Related Disorders and Testing Strategies
Some of the earliest cases of MEF2C-related disorders were of subjects sharing a
similar phenotype of seizures, developmental delay, absent speech, and abnormal
magnetic resonance imaging (MRI) that was attributed to a deletion of the 5q14.3-q15
region (Engels et al., 2009; Cardoso et al., 2009). At the time, MEF2C was not suspected
as the causative gene as it was not deleted in one of the three cases described by Engels et
al. and two of the three described by Cardoso et al. Shortly after these publications, seven
additional patients were reported with the same phenotype (Le Meur et al., 2010). Five of
these patients had deletions encompassing MEF2C, one patient had a duplication
encompassing MEF2C, and the last patient had a single nonsense variant in MEF2C. Le
Meur proposed that MEF2C was the causative gene and suggested that a positional effect
on MEF2C could be responsible for the cases where MEF2C itself was not deleted. A
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few months later, Zweier et al. (2010) reported four additional patients with point
pathogenic variants in MEF2C. Additionally, Zweier’s team performed expression
studies on their patients and the three patients reported by Engels et al. This study showed
that MEF2C expression was significantly decreased in patients with MEF2C truncating
variants, patients with deletions encompassing MEF2C, and in the Engels patient who
had a deletion not encompassing MEF2C, indicating that a positional effect was indeed
likely.
Since these initial reports, a total of at least 117 patients have been reported in the
literature (Cooley Coleman et al., 2021). Patients with MEF2C-related disorders have a
phenotype of intellectual disability, developmental delay, hypotonia, absent speech,
limited walking, abnormal MRI, abnormal electroencephalogram (EEG), and seizures.
Dysmorphic features, including a broad forehead, downslanting palpebral fissures, large
ears with prominent lobes, short philtrum, depressed nasal bridge, and tenting of the
upper lip have been reported in some patients (Cooley Coleman et al., 2021).
Additionally, sleep, feeding, gastrointestinal, and cardiac issues have been reported.
Testing procedures to detect MEF2C-related disorders typically include
microarray, Sanger sequencing, and next-generation sequencing (NGS), with some
patients having chromosomes and fluorescence in situ hybridization (FISH). Microarray
technology involves fluorescently tagging patient DNA and hybridizing the DNA to
probes on an array chip. An array chip may contain thousands to millions of probes to
cover several genes or the entire genome. A computer records the pattern of fluorescence
on the chip to determine which genomic regions are present. Patient data can be
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compared to data obtained from a control subject to determine copy number variants
(deletions or duplications). This assay is often a first-tier test for patients with intellectual
disability and developmental delay and has diagnosed many of the patients with deletions
and duplications involving MEF2C. Some chromosomal deletions can be seen by
chromosome staining but due to the resolution, FISH or qPCR is often used to confirm
MEF2C is included in the affected region.
Sanger sequencing is a method to determine the nucleotide sequence of a single
gene. This method uses a DNA primer, DNA polymerase, normal deoxynucleotides
(dNTPs), and fluorescently labeled dideoxynucleotides (ddNTPs). When ddNTPs are
incorporated, the elongating DNA chain is terminated, resulting in numerous fragments
of various lengths each with a ddNTP at the 3’ end. The fragments undergo capillary
electrophoresis where the fragments move at different speeds depending on size. A
computer detects which fluorescent dye is present on the end of each fragment to
determine the specific nucleotides, with software aligning the nucleotide calls to annotate
the DNA strand’s sequence. This method is used when the MEF2C gene is suspected or
when researchers particularly want to study MEF2C and can detect single nucleotide
variants and small deletions or duplications.
Next-generation sequencing also involves sequencing by termination (like
Sanger); however, this method sequences millions of fragments simultaneously. Patient
DNA samples undergo preparations, including tagging with a patient-specific barcode,
allowing for the sequencing of multiple patients and multiple genes at once. After
sequencing, the data is separated out for each patient using their known barcode. This
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assay is often used when a condition that can be caused by multiple different genes is
expected, or for exome or genome sequencing. Many patients with MEF2C-related
disorders had a targeted NGS panel performed for genes associated with epilepsy (Cooley
Coleman et al., 2021).

Rare Disease Research
Rare diseases are those that affect a small number of individuals as compared to
the general population (About rare diseases, 2012). In the United States, rare diseases are
defined by the Orphan Drug Act of 1983 as “any disease or condition which affects fewer
than 200,000 people in the United States” (Orphan Drug Act—Relevant Excerpts, 2019).
Other countries use different definitions; for example, countries in the European Union
define rare diseases as those affecting ≤1 per 2000 persons. There is a general lack of
medical awareness and knowledge on these rare diseases, which makes diagnosis
difficult. One study surveyed 12,000 patients having one of eight rare diseases found that
25% waited between 5 and 30 years for the correct diagnosis, and 40% received an
incorrect initial diagnosis (EURODIS, 2009). Although each disease affects a small
number of people, with the roughly 7000 reported rare diseases, a large collective
population is affected (About rare diseases, 2012). Research on rare diseases has
immense impacts on those individuals, their families, and the entire rare disease
community. Additionally, research helps spread knowledge of the disorder, aids in new
diagnoses, and paves the way for disease management or future treatment strategies.
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There are numerous methods to research rare diseases, including randomized
designs (such as randomized, double-blind, placebo-controlled trials), nonrandomized
controlled trials (risk-based allocation, delayed start), observational designs (pre-post
studies, case reports, natural history studies), analytic methods (such as Bayesian analysis
or instrumental variables), and other research designs (such as a literature review or metaanalysis) (Whicher, Philbin, & Aronson, 2018). Before treatments can be developed and
tested, one must fully understand the disorder. To better understand rare disorders such as
the ones associated with MEF2C for this dissertation, a number of different research
methods were undertaken including conducting concept analysis, conducting a literature
review, developing a natural history study, and using animal models.
Concept Analyses
Concept analyses are one type of theoretical-based research used to clearly define
and differentiate a concept. Concept analyses are used to clarify vague, overused, or
misused concepts. This analysis results in a precise, comprehensive, and standardized
operational definition of the concept. There are various concept analysis methodologies
described in the literature. One of the earliest contributors to the concept analysis was
John Wilson, who developed an 11-step method of analysis (Wilson, 1963). These 11
steps included: 1) isolating questions of concept, 2) right answers, 3) model cases, 4)
contrary cases, 5) related cases, 6) borderline cases, 7) invented cases, 8) social context,
9) underlying anxiety, 10) practical results, and 11) results in language.
Many researchers (Walker and Avant, Chinn and Kramer, and Rodgers, among
others) have since developed their own methods or modified the Wilson method. The
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Walker and Avant method is perhaps the most frequently used one in nursing science and
is self-stated the “easiest to understand and master, especially for beginners” (Walker &
Avant, 2005). Walker and Avant modified Wilson’s method to have a total of eight steps,
instead of eleven, while still capturing all relevant components. These steps include: 1)
select a concept, 2) determine the aims and purpose of the analysis, 3) identify uses of the
concept, 4) determine defining attributes, 5) identify a model case, 6) identify other cases
(borderline, related, contrary, etc.), 7) identify antecedents and consequences, and 8)
define empirical referents.
Concept analyses not only result in clarified terms and operational definitions but
can lead to the development of tools or identification of gaps in the literature for future
research. Additionally, they are an excellent exercise in critical thinking.
Systematic Literature Reviews
Literature reviews are a type of research that collects data from published
scholarly work for the researcher to familiarize themselves with the topic, identify gaps in
existing research, and propose new studies and methods (Purdue University, 2021).
Traditional narrative literature reviews are broad in the topic and do not have a
standardized methodology or search strategy (Sevetson, 2021). There are other types of
literature reviews, including rapid, scoping, umbrella, meta-analysis, and systematic, with
each having its own approach and purpose. Systematic literature reviews are considered
the gold standard as they have a defined question to answer, must include inclusion and
exclusion criteria, and follow a rigorous search, evaluation, data extraction, and analysis
of the literature (Purdue University, 2021). The steps of a systematic review include
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identifying the research question, defining the inclusion and exclusion criteria,
performing the search, selecting studies based on the defined inclusion criteria, extracting
data from those studies, performing an assessment, and presenting the results. The
research question often follows a framework, such as PICO (Patient/Population problem,
Intervention, Comparison or Control, Outcome), to narrow the focus and facilitate the
literature search. In systematic reviews, the quality of the studies included must be
assessed, and conclusions from the studies should include addressing gaps, proposing
future studies, and giving recommendations for practice (Purdue University, 2021).
Natural History Study Surveys
A natural history study is an “observational study intended to track the course of
the disease” (U.S. Food and Drug Administration, 2019). These studies collect
demographic, genetic, and environmental information that may correlate with the disease
with the goal of developing treatment. Types of natural history studies include
retrospective, prospective, cross-sectional, and longitudinal (U.S. Food and Drug
Administration, 2019). Retrospective studies use patient information from evaluations
that have already happened, whereas prospective studies are planned for a future date.
Cross-sectional studies consist of collecting data at one point in time to gather
information on the disease, describe the severity of symptoms, and provide information
for therapies to aid the patient population. Lastly, longitudinal studies are those in which
data is collected across several time points to observe disease progression (U.S. Food and
Drug Administration, 2019).
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Surveys are one method used to collect patient information and can result in both
quantitative data (due to the questions having either numerical or set answer choices) and
qualitative data (from open-ended response questions). When developing the survey,
questions should focus on a single concept and be understandable, clear, succinct,
nonjudgmental, and unbiased (Burns et al., 2008). Technical jargon and double-barreled
questions (single questions that ask about more than one issue) should be avoided to
prevent confusion (Decarlo, 2018). Question types can include close-ended with a set of
response options, open-ended, and filter questions to determine if participants should be
asked additional questions. After the questions are finalized, the survey should be
reviewed by experts and piloted by a small group of the target participants to obtain
feedback on the questions, overall survey length, and subject matter (McInroy, 2016).
Before launching the survey, it may need to be reviewed and approved by an Institutional
Review Board (IRB) to ensure the rights and welfare of participants are protected
throughout the research.
Animal Models
Animal models are non-human animals used for scientific research, observation,
experiments, and treatment testing in place of performing these investigations on humans
(Simmons, 2008). Certain research can pose a significant risk to human life. Since
animals have genetic, anatomic, and physiologic similarities to humans, they can be used
for research in the place of humans. According to the Model Organism Aggregated
Resources for Rare Variant ExpLoration (MARRVEL), there are orthologs to the human
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MEF2C gene in mice (Mef2c), zebrafish (mef2cb), drosophila (Mef2), and C. Elegans
(mef-2) (J. Wang et al., 2017).
Dichoso et al. (2000) concluded that mef-2 has a different role in C. elegans
development and is not essential for myogenesis as compared to drosophila and
vertebrates (Dichoso et al., 2000). In humans, there are four genes in the MEF2-family
(A-D); however, there is only one gene, Mef2, in drosophila. Mef2 expression begins
early during embryogenesis in heart and muscle precursor cells. Loss-of-function Mef2
variants result in a lack of heart and muscle differentiation in drosophila embryos (Olson
et al., 1995). A recent study used RNA interference to knock down Mef2 in the neurons
of drosophila and found decreased sleep and increased night activity compared to wildtype flies (Klein et al., 2020).
Zebrafish are an excellent model for the research of human diseases. Zebrafish
have external fertilization leading to transparent embryos and larvae, facilitating the
observance of development (Lieschke & Currie, 2007). Interestingly, the MEF2C gene
has been duplicated in the zebrafish genome as mef2ca and mef2cb (Adrião, Conceição,
& Cancela, 2016). Both the mef2ca and mef2cb genes are expressed in several tissues,
including brain, heart, vertebral column, branchial arches, muscle, kidney, mandibula,
and cleithrum and operculum; however, mef2ca is most highly expressed in the vertebral
column and mef2cb most highly expressed in the brain (Adrião, Conceição, & Cancela,
2016). Both mef2cb and mef2cb MEF2 domains have 100% homology compared to the
human MEF2C MEF2 domain. Additionally, mef2cb MADS domain is 100%
homologous to the human MEF2C MADS domain, whereas mef2ca is slightly less

18

similar at 98.3% homology of the human MEF2C MADS domain. Additionally, mef2cb
is surrounded by many of the same genes that surround MEF2C in humans (including
TMEM161B, CCNH, RASA1, COX7C, EDIL3, and HAPLN1 downstream of MEF2C and
MBLAC2, POLR3G, LYSMD3, ADGRV1, ARRDC3, and NR2F1 upstream of MEF2C).
Five of the genes surrounding mef2cb are also duplicated and surround mef2ca (Adrião,
Conceição, & Cancela, 2016). Studies have shown that double mutant zebrafish (those
lacking both mef2ca and mef2cb) lack proper cardiomyocyte differentiation and heart
formation (Hinits et al., 2012). Some human patients with MEF2C alterations also
present with cardiac findings, including ventricular septal defects (Lu et al., 2018; Qiao et
al., 2017), myocardial hypertrophy (Engels et al., 2009), moderate tricuspid valve
insufficiency (Cesaretti et al., 2016), and other cardiac issues.
Perhaps an even better model for human disease would be the mouse, as it is a
mammal that shares a similar developmental pathway and organ systems (Why Are Mice
Considered Excellent Models for Humans?, n.d.), and is more genetically similar to
humans compared to other animal models, having >90% gene homology for human
diseases (“A Comparison of Common Model Organisms — Part 1 - NemaMetrix,” 2017).
Mef2c homozygous null mice died in utero by embryonic day 10 due to severe heart
defects: heart looping did not occur and, therefore, the right ventricle did not form (Lin et
al., 1997). In order to study the role of Mef2c role in the developing brain, Li et al. (2008)
created conditional knockout mice lacking Mef2c in neural progenitor cells. The mutant
embryonic mice had a smaller brain size, less cortical thickness, and abnormal
postmitotic neuron distribution but, overall, there was no change in cell proliferation (Li
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et al., 2008). In adult mutant mice, the Mef2c-null neurons exhibited immature
electrophysiological properties likely due to fewer synapses and postsynaptic receptors.
Additionally, the Mef2c mutant mice exhibited behavioral phenotypes including anxiety,
decreased cognitive function, and abnormal paw movement stereotypies (Li et al., 2008).
The behavioral phenotypes are also seen in humans with genetic alterations involving
MEF2C, thus providing more evidence for the use of mice as an animal model for human
MEF2C-related disorders.

Conclusion
MEF2C-related disorders are rare neurodevelopmental disorders characterized by
developmental delay, seizures, absent speech, hypotonia, and brain abnormalities. At
least 117 patients have been reported worldwide; however, this disorder is difficult to
diagnose clinically. Methods to research rare disease include theoretical and
observational designs, such as concept analyses, literature reviews, natural history
studies, and surveys, and experimental designs such as laboratory studies with animal
models. In subsequent chapters, we show how these methods were used to gain further
knowledge on MEF2C-related disorders. Specifically, we sought to elucidate the
comprehensive phenotype of MEF2C-related disorders. In chapter 2, we use the concept
analysis method to highlight, clarify, and define one of the disorder’s features, tremors. In
chapter 3, we perform a systematic literature review to answer the research question:
“What is the comprehensive phenotype of all human patients reported with a MEF2Crelated disorder?” In chapter 4, we further characterize the phenotype of the disorder
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through a natural history study parent survey. Lastly, in chapter 5 we show how
laboratory methods using MEF2C animal models can translate to knowledge on the
human phenotype. These methods help illuminate the features of MEF2C-related
disorders and other such rare disorders and aid in future diangosis, management, and
treatment of patients.
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Abstract
Aim. This article seeks to clarify and define the concept of tremors.
Design. The Walker & Avant (2005) concept analysis method was followed.
Methods. A search of PubMed, Academic Search Complete, CINAHL, ERIC, Google,
and Google Scholar was performed.
Results. Through this process, uses of the concept were assessed including definitions
and categories of tremors. Defining attributes were found to include “movement
disorder”, “shaking motions”, “involuntary”, “oscillatory”, “rhythmic”, “not painful or
life threatening”, “always present but variable”, and “can sometimes be repressed”. We
identified two model cases and a borderline case, antecedents, consequences, and
empirical referents (including measurement tools) of tremors.
Conclusion. The concept analysis process has clarified and illuminated an operational
definition of tremors: that tremors are a movement disorder characterized by shaking
motions that are involuntary, oscillatory, rhythmic, non-painful, always present although
vary in severity, and can be repressed by changing posture or going into a rest position.
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CHAPTER TWO:
TREMORS: A CONCEPT ANALYSIS

Background
Tremors are one of the most common types of movement disorders, with essential
tremor (ET) being the most common of all adult movement disorders (Hess & Pullman,
2012). Tremors have been described equally in men and women and can affect a person
at any age, although they are more common in adults middle-aged and older. Tremors can
be a primary disorder, as seen in ET, a symptom of an underlying disorder like Parkinson
disease, or they can be idiopathic (Kamble & Pal, 2018).
Of interest, tremors are present in many genetic disorders. A February 2020
search of OMIM for the term “tremor” identified 594 potential genetic conditions or
genes associated with tremors (Online Mendelian Inheritance in Man, OMIM). Results at
the top of the list contain the most qualities of the search term. These included hereditary
ET, epilepsies, Fragile X-associated tremor/ataxia syndrome (FXTAS), Parkinson
disease, and neurodegenerative conditions (Table 2.1). Tremors can be associated with
metabolic conditions; examples of which include glutaric aciduria type I, Wilson disease,
Niemann-Pick disease, and Krabbe disease (Online Mendelian Inheritance in Man,
OMIM).

Table 2.1: Top Entries of Genetic Conditions Associated with Tremors Returned by
OMIM from a 6 February 2020 search.
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Result #

MIM Number
#190300, %602134,
%611456, #614782, #616736
#618524

Disorder
TREMOR, HEREDITARY ESSENTIAL, 1, 2, 3,
1
4, 5; ETM1, ETM2, ETM3, ETM4, ETM5
MYOPATHY, CONGENITAL, WITH TREMOR
2
(MYOTREM); MYBPC1
#300623
FRAGILE X TREMOR/ATAXIA SYNDROME
3
(FXTAS); FMR1
#601068, #607876, #613608, EPILEPSY, FAMILIAL ADULT MYOCLONIC,
4
#615127, #615400, #618074, 1, 2, 3, 4, 5, 6, 7; FAME1, FAME2, FAME3,
#618075
FAME4, FAME5, FAME6, FAME7
%190310
TREMOR, NYSTAGMUS, AND DUODENAL
5
ULCER
190200
TREMOR OF INTENTION, ATAXIA, AND
6
LIPOFUSCINOSIS
*603967
SODIUM CHANNEL, VOLTAGE-GATED,
7
TYPE IV, ALPHA SUBUNIT; SCN4A
#612126
GLUT1 DEFICIENCY SYNDROME 2
8
(GLUT1DS2); SLC2A1
#254900
EPILEPSY, PROGRESSIVE MYOCLONIC, 4,
9
WITH OR WITHOUT RENAL FAILURE; EPM4
#607060
PARKINSON DISEASE 8, AUTOSOMAL
10
DOMINANT (PARK8); LRRK2
OMIM Symbols:
#: Descriptive entry that does not represent a unique locus
%: Confirmed mendelian phenotype or phenotype locus with an unknown molecular
basis
*: Gene
No symbol: Mendelian basis suspected but not confirmed

Most disorders on this list have tremors as one of many symptoms. The essential
tremor disorder is different in that the only symptom is the tremor. Studies comparing
monozygotic to dizygotic twins have shown that there is high genetic heritability for ET
(Lorenz et al., 2004 and Tanner et al., 2001). Several genes, including DRD3, FUS,
TENM4, HTRA2, SCN4A, SORT1, SCN11A, NOS3, KCNS2, HAPLN4, USP45, and
CACNA1G were found to have some minor association, risk factor, or segregation in
families with ET, but none are definitive. Variants found in many of these genes occur
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only within certain ethnic groups (e.g. variants in TENM4 were identified in Spanish
families, but not in Chinese families). It is likely that ET is genetically heterogeneous
with incomplete penetrance and is influenced by environmental and epigenetic factors.
The lack of definitive causative genes is likely a result of these factors along with clinical
misdiagnosis of ET (Deng, Wu, & Jankovic, 2019).
MEF2C-related disorders, also referred to as MEF2C haploinsufficiency
syndrome, were not among the search result list in OMIM. However, an extensive review
of the literature reveals cases of children with a MEF2C-related disorder also having
tremors. One patient was reported to have a periodic tremor during infancy
(Nowakowska et al., 2010) and a second patient was reported to have a hand tremor at
seven years of age (Paciorkowski et al., 2013). Recently, there has been a growing
interest of researching MEF2C-related disorders. This new connection between the
disorder and tremors prompted interest in the analysis of the concept of tremors.
Although the term “tremors” may seem simple, the definition of the word is often
quite vague (Tremor, 2019. In Merriam-Webster.com; Tremor, 2019. In Cambridge
Dictionary; Tremor, 2019. In Lexico Oxford Dictionary), which may lead to a
misunderstanding of the concept. Additionally, the concept is complicated by the various
ways tremors are categorized and methods by which they are assessed clinically (Bhatia
et al., 2018; Elias & Shah, 2014); therefore, it is important that researchers and healthcare
providers understand how to distinguish between various tremor types, sometimes in
combination with other symptoms, to properly measure, diagnose, and provide the most
effective treatment to the patient.
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To clarify the concept of tremors, the Walker and Avant (2005) concept analysis
method was chosen due to its well-defined steps and prominent use in nursing science
(Nuopponen, 2010). A concept analysis is a process in which the concept term is
thoroughly explored to describe the essence and uses of the term and distinguish it from
other closely related concepts (Walker & Avant, 2005). The research question undertaken
with this process is: What is the conceptual and operational definition of the term tremor
as it is applied in clinical practice?
Method
The Walker and Avant (2005) concept analysis method is a thorough process used
to define a concept and distinguish it from other closely related concepts. This method
consists of the following steps: 1) select a concept, 2) determine the aims and purpose of
the analysis, 3) identify uses of the concept, 4) determine defining attributes, 5) identify a
model case, 6) identify other cases (borderline, related, contrary, etc.), 7) identify
antecedents and consequences, and 8) define empirical referents.
With the concept and aims identified, the next step was to identify uses of the
concept. For this step, a search of the literature was performed. Walker and Avant (2005)
recommends “only looking for the definitions and uses of the term”, while making notes
of characteristics (attributes), preceding events or incidents (antecedents), and outcomes
(consequences) of the concept. The search is not for the purpose of performing a
systematic literature review. The search included PubMed, Academic Search Complete,
CINAHL, ERIC, Google, and Google Scholar, and used search terms “tremor”,
“tremors”, “tremor concept”, and “tremor concept analysis”. These search terms were
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used individually or in combination with each other. Search terms were general to
entertain a broad perspective of the concept and to ensure a concept analysis did not
already exist for the chosen concept. The search was limited to peer-reviewed scholarly
articles published in the English language. Magazines, dissertations, and continuing
education units were excluded. Additionally, the search results were limited to the past 20
years, spanning 01-01-2000 to 09-23-2019, to allow for more recent and relevant findings
(Figure 2.1).

FIGURE 2.1
A literature search via PubMed, Academic Search Complete, CINAHL and ERIC
was performed. Search terms used were “tremor”, “tremors”, “tremor concept”,
and “tremor concept analysis”. The search was limited to peer-reviewed scholarly
articles published in the English language. To allow for more recent and relevant
findings, search terms were limited to the past 20 years. Next, search terms were
applied specifically for the Title to narrow down results.

Of note, about one-fourth of the articles from PubMed mentioned ET and about
one-eighth mentioned Parkinson in the title. Individually applying “tremor concept
analysis” as the only search term within titles yielded no results in any of the searched
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databases. The focus on results were limited to those featuring the biological and medical
concept of tremors, and final analysis included articles, case studies, websites, and
general and medical dictionaries. Definitions of “tremors” were obtained online from the
Merriam-Webster Dictionary, the Cambridge Dictionary, the Lexico Oxford Dictionary,
and the Mosby's Medical, Nursing, & Allied Health Dictionary.
Each step in the concept analysis process was an exercise in rigor via reading,
rereading, and making critical decisions on content while avoiding topical drift (Walker
& Avant, 2005). Rigor was also achieved through reflexivity by being self-aware of the
content, direction, and potential biases. Additionally, this work was carefully critiqued by
the coauthors who have experience in clinical genetics, qualitative research and other
research methodologies. The concept analysis method consists of reviewing available
literature, therefore ethical approval was not required.

Results
Aims and Purpose of Analysis
The purpose of this analysis is to clarify and develop a comprehensive operational
definition of the biological and medical term and concept “tremor”. Sample cases will be
presented to illustrate the concept and to facilitate developing a strong operational
definition. The relationship between the antecedents, defining attributes, consequences,
and empirical referents of tremors can be seen in Figure 2.2, as well as thoroughly
described in subsequent sections. The results of this analysis will improve knowledge and
communication of the concept across many disciplines, such as education, research,
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nursing, and medicine. Additionally, this information will aid healthcare providers in
diagnosing and treating patients with tremors.

FIGURE 2.2
Schematic of the relationship between the antecedents, defining attributes,
consequences, and empirical referents of tremors.

Definitions of Tremors from Dictionaries
The earliest use of the word tremor meant a feeling of terror, in line with its Latin
roots, originating from the verb “tremere” (to tremble). In the 1600s and onward, tremor
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was used to mean a shaking motion (Louis & Palmer, 2017). The Merriam-Webster
Dictionary defines tremor as “1a) a trembling or shaking usually from physical weakness,
emotional stress, or disease, 1b) nervous excitement; 2) a quivering or vibratory motion,
especially: a discrete small movement following or preceding a major seismic event; 3a)
a feeling of uncertainty or insecurity, 3b) a cause of such a feeling” (Tremor, 2019. In
Merriam-Webster.com). The Cambridge Dictionary defines tremor as “1) a shaking
movement in a person’s body, usually because of fright, excitement, or illness; 2) a slight
earthquake (sudden, violent movement of the earth’s surface)” (Tremor, 2019. In
Cambridge Dictionary). The Lexico Oxford Dictionary defines tremor as “1) an
involuntary quivering movement, 1.1) a tremble or quiver in a person’s voice, 1.2) a
sudden feeling of fear or excitement; 2) a slight earthquake” (Tremor, 2019. In Lexico
Oxford Dictionary). As seen in definitions from various dictionaries, the word “tremor” is
associated with a geological concept and as a feeling; however, these two versions of the
concept will not be a focus in this analysis. Instead, we will focus on the biological and
medical concept of tremors. Both the Merriam-Webster and Cambridge dictionaries
include “shaking” but they differ in why a tremor takes place, except for each mentioning
disease/illness. The Lexico Oxford dictionary goes a step further by clarifying these
movements are “involuntary”.
Lastly, the Mosby's Medical, Nursing, & Allied Health Dictionary was consulted
for a medical definition. In this dictionary, tremors are defined as “rhythmic, purposeless,
quivering movements resulting from the involuntary alternating contraction and
relaxation of opposing groups of skeletal muscles occurring in some elderly individuals,
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certain families, and patients with various neurodegenerative disorders” (Tremors, 2001.
In Mosby's Medical, Nursing, & Allied Health Dictionary).
Categories of Tremors in Literature and Practice
One common classification method is resting tremors versus action tremors
(Table 2.2). Resting tremors occur in a body part that is supported against gravity with no
voluntary movements taking place. Action tremors are those that take place with
voluntary movements. There are further subcategories of action tremors including
postural, kinetic, intention, task-specific, and isometric. Postural tremors are those that
occur when a person holds a position against gravity, such as outstretching one’s arms.
Kinetic tremors occur during any voluntary movement. Intention tremors increase in
severity as the person completes the movement. Task-specific tremors are ones that occur
during specific tasks, such as writing. Lastly, isometric tremors appear after voluntary
muscle contraction in an otherwise stationary body part, such as when one makes a fist
(Elias & Shah, 2014).

Table 2.2: Common Classification Scheme for Tremors (Elias & Shah, 2014)
Tremor Type
Resting
Action
Postural
Kinetic
Intention
Task-specific
Isometric

Description
Occur in a body part that is supported against gravity with no voluntary
movements taking place
Takes place with voluntary movements
Occur when a person holds a position against gravity
Occur during any voluntary movement
Tend to increase in severity as the person completes the movement
Occur during specific tasks
Occur after voluntary muscle contraction in an otherwise stationary body part

41

Another classification method distinguishes among physiological, exaggerated
physiological, or pathological tremors (Table 2.3). Physiological tremors are present in
everyone and are generally small scale and not readily detectable. These tremors are
normal and occur with the transition of rest and movements of the muscles. Exaggerated,
or enhanced, physiological tremors are normal tremors that worsen due to certain factors
(such as age, hyperthyroidism, caffeine, stress, or anxiety) to the point of being visible.
Pathological tremors are ones that impair and hinder a person’s everyday life and are
often a part of a disorder. The most common pathological tremors are ET and
Parkinsonian tremor (Elias & Shah, 2014).

Table 2.3: Additional Classification Method for Tremors (Elias & Shah, 2014)
Tremor Type
Physiological
Exaggerated physiological
Pathological

Description
Generally small-scale tremors present in most everyone but are not
readily detectable
Physiological tremors that are worsened due to certain factors to the
point of being visible
Tremors that impair and hinder a person’s everyday life and are
often a part of a disorder

On other occasions, tremors are classified solely on their etiology, such as
Parkinsonian tremor, or based on the anatomical origin of the tremors, such as cerebellar
tremor. Others may be based on the situational occurrence of the tremor, such as primary
writing tremor. It can often be difficult to distinguish between tremor conditions, and the
matter can be complicated even more given the various ways to categorize tremors. The
Task Force on “Tremor of the International Parkinson and Movement Disorder Society”
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had published consensus criteria for tremors in 1988. They reconvened in 2018 to resolve
inconsistencies and release their updated classification system. The task force proposed
classification along two axes. Axis 1 included clinical characteristics and features, such
as family history, age of onset, and location of the tremors in the body. Axis 2 consisted
of the etiology of the tremors, such as being either acquired, genetic, or idiopathic (Bhatia
et al., 2018).

Distinguishing Tremors from Other Related Disorders
Many movement disorders appear similar to tremors, but they too have their own
defining attributes to differentiate them from tremors. Seizures, myoclonus, shivering,
tics, and akathisia all have some overlapping features to tremors, most noticeable would
be the shaking movement, but there are also clues that help distinguish them. Mostly,
tremors are constant but may be so slight that one does not notice it happening. However,
there are a few tremor disorders that appear intermittently, such as tremors caused by
some metabolic disorders, Leigh syndrome, migraines, and dominant episodic ataxias
(Torres-Russotto, 2019). Seizures may come in spells, and then the shaking disappears.
During a seizure, the person may be cognitively impaired and also cannot control the
seizure by simply changing their position or posture. Myoclonus movements are
characterized by a “jerk-release” movement, therefore are not oscillatory. Shivering often
occurs only as a single spell and can involve trunk muscles, which is not typically a
feature of tremors. Tics are episodic and fast but can be voluntarily withheld by the
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person at times. Akathisia consists of oscillatory movements, but they are irregular,
episodic, and like tics, can be voluntarily withheld (Torres-Russotto, 2019).

Defining Attributes of Tremors
Defining attributes are the characteristics of the concept that define it and
distinguish it from other concepts. Through this analysis, several defining attributes of
tremors emerged. Tremors are 1) a movement disorder, characterized by 2) shaking
motions that are 3) involuntary, 4) oscillatory, which is to repeat back and forth around a
central point, 5) rhythmic, or having a regular pattern or motion, 6) are not painful or life
threatening, and 7) the majority are always present but can vary in severity, including to
the point where they do not seem noticeable by the person experiencing them; 8) lastly,
tremors can sometimes be repressed by changing the body’s posture, or by putting the
affected body part into a rest position.
Model Case, Borderline Case, and Contrary Case
A model case is one that displays all the defining attributes and is considered a
definitive example of the concept (Walker & Avant, 2005). A borderline case exhibits
some but not all the defining attributes of the concept, and therefore is similar but not
exactly the same. The contrary case does not exhibit any of the defining attributes,
showing clearly what the concept is not. The following case reports were found in the
literature and are used here to demonstrate and differentiate the concept.
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Model Case 1: Essential Tremor
Hawkins-Walsh (2003) reported a 21-year-old male who saw his physician for a
routine checkup. He stated he was well with no illnesses but has noticed his arms and
hands were shaking quite often recently. He was unsure of exactly when the shaking
started, but it has been a few years and has gotten worse lately to the point that his friends
have expressed concern. He reported taking 10 mg Ritalin (methylphenidate) twice daily
for attention-deficit/hyperactivity disorder, but no other medications, illegal drugs, or
tobacco. He noted that alcohol consumption contributed to decreasing the shaking and
reported having three to four beers a night on the weekends. He also reported drinking
one to two caffeinated sodas daily. Upon physical examination, his speech was clear,
there were no gait abnormalities, no clonus present, and his posture was normal, but there
was shaking present upon finger-to-nose test, handwriting test, and when extending his
arms against gravity. His cranial nerves and tendon reflexes were also normal. He
reported no family history of Parkinson, multiple sclerosis, or seizures, but it was
revealed that his father also had shaking in his hands. His father said he always thought
the shaking ran in the family, indicating a larger family history (Hawkins-Walsh, 2003).
Parkinson disease was ruled out since the patient did not have any other
neurological issues. The clinician tested the patient’s thyrotropin levels (also known as
thyroid-stimulating hormone), which came back normal. Based on the physical
examination and family history, the clinician diagnosed the patient with ET. ET is the
most common form of tremor and movement disorder. The upper limbs are most
affected, followed by the head, lower limbs, voice, face, and trunk. ET can run in
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families, indicating an autosomal dominant genetic pattern. There have been some genes
linked to ET in certain populations, such as DRD3 and TENM4; however, ET is very
heterogeneous and many of the genes are still unknown (Online Mendelian Inheritance in
Man, OMIM). ET often improves with consumption of alcohol, but it is important to note
the risk of abuse if a person relies on alcohol to control the tremor, as greater amounts of
alcohol will eventually be needed to achieve the same result. The patient was advised to
decrease his caffeine intake and was told of potential medications that could help with
ET. He was informed that Ritalin could also be aggravating the tremor. He was advised
on the risks of relying on alcohol to improve his symptoms (Hawkins-Walsh, 2003). The
patient was going to be able to continue his college career and said he would be sure to
limit factors that would aggravate his tremors.
In conclusion, the physician was able to see the involuntary shaking in the
patient’s hands and arms upon physical examination. The physician would have seen that
the movements were rhythmic and oscillatory. The tremors were not painful or life
threatening to the patient but were always present at some level to the point that his
friends had noticed. The shaking could be repressed enough to manage his academic
career, but the tremors still happened quite often. It is clear to see that the patient
exhibited all the defining attributes of tremors.

Model Case 2: Fragile X-associated tremor/ataxia
Another clear model case was described by Cerquera’s group in their 2016 case
report. A patient came to the clinic due to his disabling tremors. Upon examination, the
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clinicians noted a resting tremor in his right hand, as well as rigidity, bradykinesia, or
slowness of movement, and hypomimia, or reduced facial expressions. A dopamine
transporter single-photon emission computerized tomography (SPECT) analysis was
abnormal, showing less uptake of the injected tracer in the dopamine receptors in the
brain, indicative of Parkinson disease. The patient was diagnosed with Parkinson disease.
However, it was also revealed that his daughter was a premutation carrier for Fragile-X
syndrome, and his grandson had a full mutation and was affected with Fragile-X
syndrome. A person in the normal range would have up to 54 CGG repeats in the 5’
untranslated region of the FMR1 gene. A premutation would contain 55-200 repeats, and
a full mutation is over 200 repeats (Willemsen, Levenga, & Oostra, 2011). Upon testing,
it was shown that the patient had a premutation of 90 CGG repeats, which lead to the
diagnosis of Fragile X-associated tremor/ataxia (FXTAS). The authors mentioned that it
is possible this patient presented with parkinsonism only because of the FXTAS;
however, the authors noted two other cases in the literature of patients with both
Parkinson disease and FXTAS (Cerquera et al., 2016).
Upon being diagnosed with Parkinson disease, the patient was prescribed
levodopa, which improved the patient’s rigidity but did not have a large impact on the
tremors. Over the following four years, the patient developed bilateral postural and action
tremor of his hands. Additionally, his gait was affected, and he became confined to a
wheelchair. The clinicians prescribed several other drugs, which he also responded to
poorly (Cerquera et al., 2016). The patient opted for another form of treatment, which
will be discussed in a subsequent section.
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The patient has a movement disorder characterized involuntary, rhythmic, and
oscillatory shaking motions. Although the tremors have affected his daily life, they were
not reported to be painful or life threatening. It was not stated if the patient’s tremors
could be suppressed, but the tremors had increased in severity over the years. The
patient’s condition meets all the defining attributes of tremors.
Borderline Case: Seizures
A case report was published by Hayashi, Miura, Uzawa, Baba, and Yamamoto
(2018) in which they describe a 34-year-old male with reduced vision and night
blindness. The patient was being seen for a complete ophthalmic examination, including
several ophthalmologic examinations, and full-field electroretinograms recordings
(ERGs). During the ERG process, pupils are dilated and then electrical signals from the
retina are recorded during dark and light exposure. Both dark-adapted and light-adapted
ERG were performed, followed by 30 Hz light flicker light-adapted ERG (Hayashi et al.,
2018).
Before transitioning to long-duration flashing ERG recordings, the patient alerted
the clinician that he was developing paralysis in his upper limbs. Directly after, he started
having lower limb convulsions and then lost consciousness. The patient was given an
injection of diazepam, and the convulsions ceased. Later, he had magnetic resonance
imaging (MRI), computed tomography of the head, and electroencephalogram
examination, all of which were normal. After the ordeal, the patient mentioned that he
had lost consciousness with seizures in the past. These seizures were caused by the
flashing light of the ERG exam. Flickering of artificial and even natural light has been
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known to induce seizures, therefore the patient was diagnosed with photosensitive
epileptic seizures. The authors stress that providers should obtain a detailed seizure
history about a patient before conducting ERG recordings to avoid an ordeal like this
patient experienced (Hayashi et al., 2018).
The convulsions were an involuntary shaking movement disorder; however, they
were not rhythmic or oscillatory and instead were very jerky movements. The flashing
lights of the ERG exam led to abnormal neuronal discharges in the patient’s brain,
resulting in seizures and loss of consciousness. Light as a trigger and loss of
consciousness are not traits that are associated with tremors. The patient’s seizures only
come about with certain stimuli (light), whereas tremors are usually a constant presence.
The patient’s condition meets the defining attributes of movement disorder, shaking
motions, and involuntariness. However, oscillatory, rhythmic, not life threatening,
constant presence, and ability to repress were defining attributes that were not met.
Contrary Case
Cinotti, Trovato, Fimiani, & Rubegni (2018) published a case report about a 58year-old patient with a previous diagnosis and 20-year history of systemic lupus
erythematosus. The patient came to the emergency department with multiple cutaneous
hematomas that arose without any traumatic event occurring. Clinicians tested her
platelet count, and the results were normal. Additionally, her lupus anticoagulant and
antiphospholipid antibodies were negative. No hemorrhage was seen on abdominal
ultrasound or skull computed tomography. Her partial thromboplastin time was elongated
at greater than 54 seconds (normally between 20 and 34 seconds). All intrinsic factors of
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coagulation (FXII, FXI, FX, FVII, FVIII) were tested. The patient’s FVIII activity level
was less than 1%, and a level below 50% can be indicative of hemophilia A. A Bethesda
assay was performed and yielded a result of 15.2 Bethesda units (BU), whereas the
normal value should be less than 0.5 BU (Cinotti et al., 2018).
The patient was diagnosed with acquired hemophilia A (AHA). Her immune
system created antibodies against her own FVIII proteins, thus depleting her FVIII levels
and causing the severe presentation that prompted her to go to the emergency room. The
clinicians prescribed prednisolone at a dose of 1 mg/kg/day with decreasing dosage over
a three-month period, and her FVIII levels returned to normal and symptoms vastly
improved. The authors advise that providers consider AHA if patients with systemic
lupus erythematosus also present with hematomas and prolonged partial thromboplastin
time (Cinotti et al, 2018).
The patient’s condition has its own set of attributes, but none match the attributes
of tremors. She was not exhibiting a movement disorder and was not shaking
involuntarily in a rhythmic and oscillatory fashion. It is not mentioned if the patient was
having pain, but likely she was sore at the sites of the hematomas. As tremors are not
painful, this is another attribute that does not match. Tremors are also not life threatening,
but the patient’s condition could have been if she had a traumatic event and could not
stop the bleeding. Lastly, the patient’s condition would not be improved simply by
changing her posture or trying to prevent it. With none of the defining attributes of
tremors, this is just one of the many potential examples of a contrary case to tremors.
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Antecedents of Tremors
Antecedents are conditions or events that happen before the concept occurs
(Walker & Avant, 2005). Antecedents of tremors include injury, genetic disorders, nongenetic medical issues, and medications or substances. Injury to the brain, such as stroke
or trauma from a blow or accident, can cause a person to have tremors (Tremor Fact
Sheet, NINDS, 2017). Tremors are common in patients with certain genetic disorders
(Table 2.1). Some have been previously mentioned, but can include Parkinson disease,
familial ET, Fragile X-associated tremor/ataxia syndrome (FXTAS), spinal muscular
atrophy, spinocerebellar ataxia, as well as other perhaps less known genetic disorders
such as Wilson disease, Perry syndrome, Wiedemann-Rautenstrauch syndrome, and
Partington syndrome, among others (Tremors. (n.d.). In National Library of Medicine
(US)). Tremors can also be caused by other non-genetic medical conditions, including
anxiety, hyperthyroidism, hypoglycemia, fever, liver or kidney failure, multiple sclerosis,
and vitamin E, vitamin B12, zinc, or magnesium deficiency. Lastly, tremors can be the
result of certain medications or substances. Medications such as selective serotonin
reuptake inhibitors (SSRIs), beta agonists, and amphetamines may have side effects of
tremors (Warren, 2017). Substances such as an excess of caffeine or mercury poisoning
can also cause tremors (Tremor Fact Sheet, NINDS, 2017).
Consequences of Tremors
Consequences are the events that happen after the concept has occurred (Walker
& Avant, 2005). Although tremors are not life threatening, they could become so
debilitating that the person’s daily life is severely affected. Tremors may affect a person’s
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ability to feed, bathe, and dress themselves. Tremors could also affect a person’s ability
to write and type, which could lead to decreased job performance or termination. The
tremor may be so debilitating that a caretaker is required, which would be quite an
expense for the person. Tremors could also affect the person’s social life as they may
limit their exposure to others due to embarrassment.
Management or treatment could be a consequence of tremors. Physical, speech,
and occupational therapies can help with managing tremors. Reducing external
substances that cause or exaggerate tremors, such as caffeine, should be considered.
Medications, including beta blockers, anti-seizure drugs, or tranquilizers can be
prescribed to help with tremors. However, tranquilizers are to be used with care due to
their side effects of sleepiness, poor concentration and coordination, and developing
dependence. There are medications available specifically for treating tremors due to
Parkinson disease. Botulinum toxin injections can also help control tremors; however, the
toxin can cause muscle weakness (Tremor Fact Sheet, NINDS, 2017).
Surgical interventions may be necessary or chosen to help treat tremors. Two
surgical methods include deep brain stimulation (DBS) and thalamotomy. During DBS,
electrodes are surgically implanted in the brain and electrical signals are sent to the
thalamus, the region of the brain responsible for involuntary body movement. A
thalamotomy involves surgically destroying a small portion of the thalamus. This
procedure is a last resort when medications and other treatments are not working.
Thalamotomies are rarely performed today due to alternate non-surgical treatments that
are available. Non-surgical interventions include radiofrequency ablation and focused
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ultrasound. Radiofrequency ablation is often used to treat pain but can also treat tremors.
It uses an electrical signal to heat nerve tissue, which blocks the tremor signal to the
body. This method is not permanent and would have to be repeated. Focused ultrasound
uses ultrasound waves guided by MRI to create a lesion in the thalamus (Tremor Fact
Sheet, NINDS, 2017).
Recall the model case patient with FXTAS and Parkinson disease who developed
worsening tremors over the years. The patient was not a candidate for deep brain
stimulation (DBS) due to his age, cognitive impairment, and brain atrophy. Due to these
issues, it was predicted that DBS would have a poor outcome and higher risk of
complications. Therefore, he opted for MRI guided focused ultrasound. The patient had
remarkable improvement: 83% relief of tremor severity according to two rating scales
(right limbs score and Fahn-Tolosa-Marin tremor rating scale), 50% increase in motor
tasks, and 40% improvement in his disability. The patient’s tremor was vastly improved,
and he was again able to feed himself and use utensils after having previously lost that
ability (Cerquera et al., 2016).
Empirical Referents
Empirical referents are events that prove the concept occurred (Walker & Avant,
2005). The empirical referents do not measure the concept itself but identify and measure
the defining attributes. A person would know the difference between normal movement
and a tremor just by observation (self-assessment or observation by another person, like a
family member). A healthcare provider could also be seen to confirm tremors in the
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patient. Assessment may also include drawing tests, computerized tremor analysis using
special devices, questionnaires, and standardized scales (Table 2.4).

Table 2.4: Empirical Referents: events that measure the tremors’ defining attributes
Empirical Referents

Transducer Devices

Assessment

Standardized Scales

Questionnaires

PhenX Toolkit

Types
Accelerometers: measures tremors by linear acceleration (Elble &
McNames, 2016)
Gyroscopes: measures tremors by angular momentum to sense
rotation (Elble & McNames, 2016)
Digitizing tablets: assesses writing and drawing to measure effects
of tremor (Elble & McNames, 2016)
Smart phones: apps can measure acceleration, degree and speed of
rotation (Kubben, Kuijf, Ackermans, Leentjes, & Temel, 2016)
Self or clinical. Includes observation, writing and drawing tests.
Fahn-Tolosa-Marin Tremor Rating Scale (FTM): 5-point scale to
rate tremors on severity and body part (Fahn, Tolosa, & Marin,
1988)
The Essential Tremor Rating Assessment Scale (TETRAS): scale
that assesses ET (Elble, 2016)
Quality of Life in Essential Tremor Questionnaire (QUEST):
questions on tremor severity, impact, perceived health and quality
of life (Tröster, Pahwa, Fields, Tanner, & Lyons, 2005)
Hand Tremor Questionnaire: questions to differentiate between ET
and Parkinson Disease (Kwon et al., 2018)
Washington Heights-Inwood Genetic Study of Essential Tremor
(WHIGET) Tremor Rating Scale: 23-item exam for the rating of
tremors (Hamilton et al., 2011)
Movement Disorder Society United Parkinson’s Disease Rating
Scale (MDS-UPDRS): measures the symptom severity for
Parkinson Disease (Hamilton et al., 2011)

Digital tablets can be used to access writing and drawing tests instead of using the
naked eye to score these tests (Elble & McNames, 2016). The frequency and amplitude of
the tremors can be measured, which will also help classify what type of tremor is
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occurring. For example, action and dystonic tremors often have a low frequency (4-8 Hz),
physiologic and other types of action tremors may have a medium frequency (7-11 Hz),
and orthostatic tremor will have a high frequency (>12 Hz) (Torres-Russotto, 2019).
Transducer devices are used to measure the tremor in units of hertz (Hz). These devices
are often portable and can include accelerometers, gyroscopes, digitizing tablets, and,
most recently, smart phones. An accelerometer measures linear acceleration, whereas a
gyroscope can sense rotation by measuring angular momentum. The use of smart phones
could lead to a more rapid evaluation of the patient’s tremor. TREMOR12 app was
developed by Pieter L. Kubben to measure acceleration, degree of rotation, rotation speed
of the tremors, and gravity to standardize. Raw data can be exported from the app for
analysis (Kubben, Kuijf, Ackermans, Leentjes, & Temel, 2016).
Standardized scales, such as the Fahn-Tolosa-Marin Tremor Rating Scale (FTM)
or The Essential Tremor Rating Assessment Scale (TETRAS), can be used to measure
tremors. The FTM scale is a 5-point scale used to rate tremors on severity, body part, and
assesses handwriting, drawing, pouring water, speaking, feeding solids and liquids,
hygiene, dressing, and working (Fahn, Tolosa, & Marin, 1988). TETRAS assesses ET,
especially focusing on the upper limbs which play a larger role in ET. This scale
examines head, face, voice, and lower limb tremors, as well as handwriting, and standing
performance, and rates each section from 0 to 4 (Elble, 2016). Differences between these
two scales are that TETRAS includes a wing-beating upper limb assessment that the
FTM does not include. Conversely, the FTM has a measure for rest tremor, which is
omitted by the TETRAS since rest tremor is typically not a main hindrance in ET.
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TETRAS may be better suited for measuring ET and severe tremors, while FTM may be
better for tremor disorders that have a rest tremor component (Ondo et al., 2018).
There are also questionnaires available, such as the Quality of Life in Essential
Tremor Questionnaire (QUEST) and the Hand Tremor Questionnaire. The QUEST
Questionnaire has questions about tremor severity, tremor impact, and perceived health
and quality of life (Tröster, Pahwa, Fields, Tanner, & Lyons, 2005). The Hand Tremor
Questionnaire includes five questions in which a person with Parkinson disease would
answer “yes”, and seven questions in which a person with ET would answer “yes”;
therefore, this scale is used to differentiate between Parkinson disease and ET (Kwon et
al., 2018). The PhenX toolkit, which is a catalog of recommended measurement
protocols, includes the Signs of Essential Tremors Washington Heights-Inwood Genetic
Study of Essential Tremor (WHIGET) Tremor Rating Scale and Parkinsons Disease
Symptoms Movement Disorder Society United Parkinson’s Disease Rating Scale (MDSUPDRS). The WHIGET tremor rating scale is a 23-item exam with items performed
while seated and standing. The exam is meant to be videotaped and scored as
recommended in the protocol. The MDS-UPDRS is specifically to measure severity of
Parkinson disease by examining motor and non-motor exercises (Hamilton et al., 2011).
Conclusion
Tremors have been reported as a primary disorder as well as secondary symptoms
of other underlying disorders, including many genetic disorders. Due to the ongoing and
upcoming research on MEF2C-related disorders, where tremors have been occasionally
reported as a symptom, the concept of tremors was chosen for this concept analysis. In
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addition to clarifying the concept, an operational definition, antecedents, defining
attributes, consequences, and empirical referents of the concept of tremors have emerged.
The operational definition developed by this concept analysis is that tremors are a
movement disorder characterized by shaking motions that are involuntary, oscillatory,
rhythmic, non-painful, always present although vary in severity, and can be repressed by
changing posture or going into a rest position. Additionally, two model cases, a
borderline case, and a contrary case have been discussed to further illuminate and
delineate the concept, and assessment tools were reviewed.
The rigorous Walker and Avant method was used to distinguish the concept of
tremors, but this method has some limitations. Given the focus was on the Walker and
Avant steps, information that did not fall into those specific categories could be missing.
Another limitation was the number of sources returned by the literature search. Although
titles were sorted and reviewed, and select sources were fully read to conduct the concept
analysis steps, there is the possibility that other sources not fully read could have
included helpful information for the concept analysis. Although English is considered the
universal language of science, limiting the sources to English alone could be another
limitation. Lastly, the concept analysis focused on the medical term of tremors, and
therefore this narrower focus could be a potential limitation.
This is the first concept analysis applied to tremors. Future research could include
reviewing diagnostic criteria of the empirical referents (such as the FTM or TETRAS) or
performing an assessment of the knowledge and understanding of tremors in current
practicing providers in order to verify the definition developed by this concept analysis.
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This clarification of the concept will assist healthcare providers, researchers, and nurses
in categorizing and recognizing the various types of tremors, as well as distinguishing
between other closely related concepts, such as tics and seizures. This is especially
important when tremors interfere with the patients’ quality of life. Lastly, this
information will help these professionals provide a comprehensive assessment of the type
and severity of tremor, gauge the level of patient concern, and provide the best treatment
and care to the patient.
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ABSTRACT
MEF2C-related disorders (aka MEF2C-haploinsufficiency) are caused by
variations in or involving the MEF2C gene and are characterized by intellectual
disability, developmental delay, lack of speech, limited walking, and seizures. Despite
these findings, the disorder is not easily recognized clinically. We performed a systematic
review following PRISMA guidelines to assemble the most comprehensive list of
patients and their phenotypes. Through searching PubMed, Web of Science, and
MEDLINE, 43 articles met the inclusion criteria and were fully reviewed. One hundred
and seventeen patients were identified from these publications with most having a
phenotype of intellectual disability, developmental delay, seizures, hypotonia, absent
speech, inability to walk, stereotypic movements, and MRI abnormalities. Non-classical
findings included one patient with a question mark ear, two patients with a jugular pit,
one patient with a unique neuroendocrine finding, and nine patients that did not have
MEF2C deletions or disruptions but may be affected due to a positional effect on
MEF2C. This systematic review characterizes the phenotype of MEF2C-related
disorders, documents the severity of this condition, and will help providers to better
diagnose and care for patients and their families. Additionally, this compiled information
provides a comprehensive resource for investigators interested in pursuing specific
genotype-phenotype correlations.
Keywords: MEF2C, MEF2C haploinsufficiency, phenotype, systematic review
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CHAPTER THREE
COMPREHENSIVE INVESTIGATION OF THE PHENOTYPE OF MEF2CRELATED DISORDERS IN HUMAN PATIENTS: A SYSTEMATIC REVIEW
Introduction
The MEF2C gene is a member of the myocyte enhancer factor 2 (MEF2)
subfamily of the MADS (MCM1-agamous-deficiens-serum response factor) gene family
of transcription factors. Transcription factors in the MEF2 family consist of a highly
conserved N-terminal MADS-box that is adjacent to a MEF2 domain. These domains
facilitate dimerization, interaction with other transcription factors, and DNA binding.
MEF2C is particularly crucial during embryogenesis as it plays a role in myogenesis,
neural crest formation, anterior heart field development, lymphoid development,
neurogenesis, and synaptic formation, among other functions (Zweier et al., 2010).
Quite a few microdeletions encompassing chromosome region 5q14.3 have been
reported in the literature over the past decade. Initially, some patients with similar
phenotypes were reported to have microdeletions that did not include MEF2C (Cardoso
et al., 2009; Engels et al., 2009). A year later, additional patients with deletions were
reported, one of which had MEF2C as the only deleted gene (Le Meur et al., 2010). In the
same study, a patient with a nonsense variant in MEF2C was reported. A few months
later, another study reported two additional patients with deletions in this 5q14.3 region
including the MEF2C gene, and four patients with point mutations in MEF2C (Zweier et
al., 2010). This led to the determination that MEF2C was likely the causative gene of the
phenotype in these 5q14.3 deletions.
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Zweier et al. (2010) isolated RNA from blood and performed expression studies
by quantitative real-time PCR on their six patients as well as the three patients reported
by Engels et al. (2009), one of which had a deletion ending 329 kb upstream of MEF2C.
Of the total nine patients, seven had MEF2C expression levels that were significantly
decreased (five patients with microdeletions and two patients with truncating variants),
one had levels that were significantly increased (a patient with a missense variant), and
one had relatively normal expression levels (another patient with a missense variant). The
Engels et al. patient that had a microdeletion not encompassing the MEF2C gene itself
was among those with decreased MEF2C expression. It is likely that deletions distal or
proximal to the MEF2C gene may have a positional effect that disrupts the expression of
MEF2C (Zweier et al., 2010). However, there have been other reports of downstream
deletions (1.1Mb away from MEF2C, Shimojima et al., 2012) and a translocation
upstream of MEF2C (121.5kb away from MEF2C, Saitsu et al., 2011) that did not affect
MEF2C gene expression. Saitsu et al. (2011) hypothesized that the expression could be
tissue-specific (i.e., the developing brain), which may explain why expression was not
altered in lymphoblasts in these two cases. Additional studies will need to be performed
to elucidate the exact mechanism of these positional effects.
MEF2C-related disorders and haploinsufficiency are reported to have a clinical
presentation of intellectual disability, developmental delay, lack of speech, limited
walking, and seizures (Paciorkowski et al., 2014). MEF2C-related disorders are rare, not
fully characterized, and hard to distinguish clinically. Many manuscripts report one or
only a few patients. Our aim was to conduct a systematic review to assemble the most
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comprehensive list of patients with a MEF2C-related disorder and thoroughly investigate
their phenotypes. This review will further characterize the disorder, highlight the defining
features, and assist healthcare providers in diagnosing and delivering the best clinical
care for patients and their families.

Methods
Editorial Policies and Ethical Considerations
Ethical approval was not required as data included in this systematic review
comes from peer-reviewed, published literature.
Systematic Review Protocol
We conducted a systematic literature review following PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Moher,
Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009). The search strategy and
inclusion and exclusion criteria were developed by the first author and are described
below. A protocol was developed for registration to PROSPERO (supplementary
document 1). The screening was performed in two stages: first on titles and abstracts and
second on the full text. The PRISMA flow diagram map and Zotero Citation Manager
(Version 5.0.90; Roy Rosenzweig Center for History and New Media, 2020) were used to
manage the screening process and articles. Necessary data were extracted from the
articles allowing final conclusions to be produced.

Systematic Review Research Question
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We used the CoCoPop approach to frame our research question. The abbreviation
CoCoPop stands for Condition, Context, and Population (Munn, 2018). Our research
question for this systematic review was: What is the comprehensive phenotype of all
human patients reported with a MEF2C-related disorder? The condition would be
MEF2C-related disorders, the context would be the phenotype, and the population is
human patients. This format lends itself to systematic reviews on the prevalence and/or
incidence of a certain condition. Although prevalence and incidence were not addressed
directly, gathering a comprehensive list of patients and their phenotypes elucidated how
rare the disorder truly is.

Search Strategy
The following electronic databases were searched: Web of Science, PubMed, and
MEDLINE. The search strategy included terms relating to the research question from the
CoCoPop framework. Search terms were adapted for database-specific filters. Database
searches were conducted using the keywords, MeSH terms, and combinations of each
with specific Boolean operators as shown in Table 3.1. Other articles were selected after
screening the bibliography of articles meeting the inclusion criteria.

Table 3.1: Search terms and strategy.
Concept (CoCoPop)
Co: Condition
MEF2C-related disorder

Co: Context
Phenotype

Keywords
“MEF2C” OR “MEF2Crelated disorder” OR
“MEF2C
haploinsufficiency”
“phenotype” OR “present*”
OR “presentation” OR
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MeSH terms
Haploinsufficiency (MeSH
term to only be used in
conjunction with “AND
MEF2C”)
Phenotype

Pop: Population
Human Patients

“clinical presentation” OR
“feature*” OR “character*”
“human” OR “patient” OR
“male” OR “female”
Overall Search

Humans OR Patients OR
Male or Female

PubMed:
((((MEF2C[Title/Abstract] OR MEF2C-related disorder[Title/Abstract] OR
MEF2C haploinsufficiency[Title/Abstract] OR (MEF2C[Title/Abstract] AND
Haploinsufficiency[MeSH Terms])) AND (phenotype OR present* OR
presentation OR clinical presentation OR feature* OR character* OR
phenotype[MeSH Terms])) AND (human OR patient OR male OR female OR
Humans[MeSH Terms] OR Patients[MeSH Terms] OR Male[MeSH Terms] OR
Female[MeSH Terms])))
MEDLINE:
AB ( MEF2C OR “MEF2C-related disorder” OR “MEF2C haploinsufficiency” OR
(MH haploinsufficiency AND MEF2C)) AND ( phenotype OR present* OR
presentation OR “clinical presentation” OR feature* OR character* OR MH Phenotype
) AND (human OR patient OR male OR female OR MH humans OR MH patients OR
MH Male OR MH Female )
Web of Science:
TOPIC: (MEF2C OR “MEF2C-related disorder” OR "MEF2C haploinsufficiency")
AND TOPIC: (phenotype OR present* OR presentation OR clinical presentation OR
feature* OR character*) AND TOPIC: (human OR patient OR male OR female)

Inclusion and Exclusion Criteria
Only peer-reviewed publications in the English language were considered for
inclusion. All scientific journals and article types were considered. Gray literature and
dissertation material were not included. There was no restriction to publication dates:
articles reviewed included those from the very first publication on the search criteria up
until the search date of May 9th, 2021. Article title and abstracts were scanned for
mention of phenotype information on a human patient case having a MEF2C-related
disorder. Only articles that included phenotypic information on a human patient were
considered for inclusion. Studies available in meeting abstract format only were excluded
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due to lack of information. Articles focusing solely on animal or cell culture studies and
lacking a human case report were excluded. Articles that met the inclusion criteria by title
and abstract review were then subjected to full-text review.

Data Extraction
The first author extracted data from the articles under full-text review. A
summary table was created for data extraction with the following column headers: study
type, authors, year published, location published, verification of human case, number of
patients, patient sex, patient age, phenotype, and clinical information reported, how
phenotype was reported, variation reported, inheritance pattern, methods used to detect
variation, and article citation in APA format (supplementary document 2). Special focus
was given to extract all phenotype information reported. The summary table was then
used to create a phenotype table (supplementary document 3).

Results
The systematic review identified 917 records using the search terms previously
described. There were 542 duplicates across the three databases. An additional 13 articles
were found after reviewing the bibliographies of articles meeting the inclusion criteria.
After duplicates were removed, 375 records remained. The title and abstract of these
articles were scanned for relevance considering the inclusion criteria. A total of 317
articles were excluded because they did not meet the inclusion criteria. After reading the
remaining 58 articles, 15 were excluded. Five of these excluded records were actually
meeting abstracts only. Two articles were not in the English language, one article could
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not be obtained, two articles did not thoroughly describe the patient phenotype and
instead focused on another subject, two articles were review articles without mention of
new patients, and lastly, three articles described patients previously reported. A full
summary of the PRISMA process is included in Figure 3.1. Most of the studies were case
reports (67.4%). Additionally, the majority were conducted in either the US or Europe
(Table 3.2).
Table 3.2: Characteristics of Included Studies
Included Studies
(N=43)
N
(%)
Study Type
Case Report
Cohort study
Review
Review with a case report
Multicenter study
Location of Study
US
France
China
Italy
Germany
Japan
UK
Portugal
Canada
Cyprus
Ireland
Mexico
Norway
Poland
South Korea
Spain
Multicenter study (Italy,
Demark, UK)

29
6
4
3
1

(67.4%)
(14.0%)
(9.3%)
(7.0%)
(2.3%)

7
6
5
5
3
4
2
2
1
1
1
1
1
1
1
1

(16.3%)
(14.0%)
(11.6%)
(11.6%)
(7.0%)
(9.3%)
(4.7%)
(4.7%)
(2.3%)
(2.3%)
(2.3%)
(2.3%)
(2.3%)
(2.3%)
(2.3%)
(2.3%)

1

(2.3%)

73

FIGURE 3.1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram

Demographic Information and Variant Types
A total of 117 patients with a MEF2C-related disorder were identified in our
systematic literature search (supplementary document 3). There were 59 females
(50.4%), 56 males (47.9%), and 2 (1.7%) patients with an unknown gender in the cohort.
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The average age was 8.52 years (SD 9.33 years). Two fetuses were terminated at 20
weeks gestation after considering ultrasound and magnetic resonance imagining
abnormalities. The youngest living patient was five months old and the oldest 52 years
old (Table 3.3).

Table 3.3: Demographic Information and Variant Types from Patients with
Reported MEF2C-Related Disorders
Gender
Female
Male
Unknown
Age Group
Fetus (Fetus)
Newborn (Birth to 1 month)
Infant (>1 month to < 24 months)
Preschool (2 years to < 6 years)
Child (6 years to < 13 years)
Adolescent (13 years to < 19 years)
Adult (19 years to < 45 years)
Middle age (45 years to < 65 years)
Type
MEF2C affected/altered/disrupted
Possible Positional Regulatory Effect
Type
Deletion

No. (%)
59 (50.4%)
56 (47.9%)
2 (1.7%)
No. (%)
2 (1.7%)
0 (0.0%)
20 (17.1%)
31 (26.5%)
40 (34.2%)
14 (12.0%)
7 (6.0%)
3 (2.6%)
No. (%)
108 (92.3%)
9 (7.7%)
No. (%)
58 (59.8%)

Translocation
Deletion with Translocation
Insertion
Duplication
Point Variant (Missense, Nonsense, Frameshift)
Nonsense
Missense
Frameshift
Stop Loss
Splicing
Not provided
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6 (5.1%)
1 (0.9%)
1 (0.9%)
3 (2.6%)
35 (29.9%)
8/35 (22.9%)
16/35 (45.7%)
8/35 (22.9%)
1/35 (2.9%)
2/35 (5.7%)
1 (0.9%)

Over half of the patients (59.8%) presented with deletions encompassing part or
the entire MEF2C gene, or with a deleted region near MEF2C that may cause a positional
regulatory effect disrupting expression of MEF2C. The second most common group of
variants were point mutations, including missense, nonsense, splicing, and frameshift
variants. Insertions, duplications, and translocations were also reported, although not as
often. The alteration types for reported patients can be found in Table 3.3. Variant
locations can be found in Figure 3.2.

FIGURE 3.2: Variant locations from patients with reported MEF2C-related disorders. (a)
Locations of point variants (nonsense, missense, frameshift, splicing, stop loss) across the
MEF2C coding region. (b) Map of microdeletions and duplications involving or
associated with MEF2C, using UCSC hg18 genome build. Black = deletion; blue =
duplication; pink = MEF2C not involved, possible regulatory positional effect; pink and
gray stripes = deleted region (MEF2C not involved) compounded with a translocation in
the patient.
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Common Symptoms
The majority of patients presented with features typically described for MEF2Crelated disorders. For articles reporting the following information, patients presented with
intellectual disability (97.6%), developmental delay (99.0%), hypotonia (98.3%), absent
speech (92.9%), and seizures and spasms (87.3%) (Table 3.4). Of patients three years of
age and older, only five were able to speak several words (7.1%); however, their
language skills were severely delayed. Speech was absent in the remaining patients over
three years of age, but some patients did know a few words, or were able to babble, have
vocalizations, mimic sounds, and use body language. Seizure types included feverinduced (or febrile), infantile spasms, generalized tonic-clonic, myoclonic, and focal.
Thirty-nine patients presented with multiple seizure types. The two most common seizure
types reported were febrile (31/89, 34.8%) and myoclonic (30/89, 33.7%). Tonic-clonic
and spasms were both present in 17 of 89 patients (19.1%), followed by focal seizures in
14 patients (15.7%). Less prevalent were absence (5.6%), afebrile (3.4%), and atonic
(2.2%). Seizure type was broadly characterized as “epilepsy” or “generalized” in 13
patients (14.6%), and “unspecified” in 5 patients (5.6%). Seizures typically had an
infantile onset of less than one year of age (61.6%), and 87.7% had an onset under 2
years of age. Many patients were not able to walk independently (N=31, 56.4%). These
31 patients were all over 18 months of age, with the youngest being 20 months and the
oldest 46 years. Additionally, two patients were reported to have spastic quadriplegia,
one of which had hypotonia during the early infantile period (Saitsu et al., 2011;
Shimojima et al., 2012). Stereotypic movements, including hand flapping, hand
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mouthing, hand clapping, hand biting, hand washing, grasping the midline, and head
banging, were reported in 83.6% of patients.

Table 3.4: Phenotypes Found in Patients with Reported MEF2C-Related Disorder
Not all phenotypes were reported for all patients and thus sample size varies.
Type
Developmental delay
Seizures
Intellectual disability
Hypotonia
Absent speech (age > 3 years)
Social and behavioral issues
Dysmorphic features
Stereotypic movements
Abnormal MRI
Feeding and digestion issues
Abnormal EEG
Inability to walk (age > 18 months)
Vision issues
Sleeping issues
Cardiac issues

No. (%)
96/97 (99.0%)
89/102 (87.3%)
83/85 (97.6%)
58/59 (98.3%)
65/70 (92.9%)
62/71 (87.3%)
68/69 (98.6%)
46/55 (83.6%)
58/86 (67.4%)
35/36 (97.2%)
50/73 (68.5%)
31/55 (56.4%)
24/24 (100.0%)
20/28 (71.4%)
17/17 (100.0%)

Physical Features
Head circumference information was reported for 67 patients, of which 16
patients had a head circumference size consistent with microcephaly (23.9%). Only two
patients were reported to have macrocephaly (3.0%) (Cardoso et al., 2009; Mikhail et al.,
2011). Dysmorphic features when reported were typically mild and included a broad
forehead, down-slanting palpebral fissures, large ears, prominent ear lobes, short
philtrum, depressed nasal bridge, and tenting of the upper lip. One patient presented with
a question mark ear but had normal ear canals (Gordon et al., 2018). Two patients
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presented with a jugular pit (Al-Shehhi et al., 2016; Berland & Houge, 2010). Two
patients presented with capillary malformation-arteriovenous malformation (CM-AVM)
syndrome in addition to features of the MEF2C-related disorders (Carr et al., 2011; Ilari
et al., 2016). CM-AVM is characterized by small pink round or oval-shaped vascular
lesions, many with telangiectatic vessels in the center. One of the patients had 17 typical
CMs on her head, trunk, and extremities, as well as two irregular CMs on the popliteal
fossa and upper left posterior thigh. The patient did not present with any AVMs or
arteriovenous fistulas on cranial MRI (Carr et al., 2011). The second patient had CMs on
the trunk and extremities as well, including the right arm and thorax. This patient had two
reported AVMs, one on the right frontal area and the second on the basilar artery. This
syndrome is typically caused by variations in RASA1, a gene in close proximity to
MEF2C. For the two patients that presented with these features, each had one deletion
that included both the RASA1 and MEF2C genes. Two additional patients with deletions
encompassing both MEF2C and RASA1 presented with hemangiomas (Vrečar et al.,
2017). Another patient with a MEF2C plus RASA1 deletion presented with characteristic
capillary malformation of the skin and atrophic skin adjacent to the suprasternal notch
(Paciorkowski et al., 2013).
MRI and EEG
Abnormal electroencephalograms (EEGs) were reported in 68.5% of patients and
findings included hypsarrhythmia, high voltage spike, poly-spike, and slow waves, focal
or multifocal bilateral spikes, and a generalized epileptiform pattern. Abnormal MRI
findings were reported in 67.4% of cases, typically including abnormalities of the corpus
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callosum (thinning, shortening, hypoplasia, aplasia, partial agenesis, thickening) (Carr et
al., 2011; Ilari et al, 2016; Engels et al., 2009; Toral-López et al., 2012; Raviglione et al.,
2021; Saitsu et al., 2011; Shimojima et al., 2012; Vrečar et al., 2017; Yang et al., 2015;
Al-Shehhi et al., 2016; Paciorkowski et al., 2013; Cesaretti et al., 2016; Nowakowska et
al., 2010). Abnormalities of the white matter (delayed myelination, reduced volume)
were not uncommon (Engels et al., 2009; Novara et al., 2010; Raviglione et al., 2021;
Saitsu et al., 2011; Shimojima et al., 2012; Vrečar et al., 2017; Paciorkowski et al., 2013;
Shim et al., 2015; Borlot et al., 2019; Zweier et al., 2010; Nowakowska et al., 2010;
Sobreira et al., 2009). Other findings included simplified gyri (Carr et al., 2011; Hotz et
al., 2013), aplasia of the cerebellar vermis, moderate atrophy of supra- and infratentorial
region, and prominence of arachnoid spaces (Engels et al., 2009), leukomalacia (Novara
et al., 2010; Floris et al., 2007), ventriculomegaly (Engels et al, 2009; Toral-López et al.,
2012; Raviglione et al., 2021; Shimojima et al., 2012; Vrečar et al., 2017; Novara et al.,
2013; Hotz et al., 2013; Zweier et al., 2010; Cesaretti et al., 2016; Nowakowska et al.,
2010), Dandy-Walker malformation (Toral-López et al., 2012), reduced brainstem
volume (Shimojima et al., 2012; Hotz et al., 2013), cortical atrophy (Vrečar et al., 2017;
Toral-López et al., 2012; Paciorkowski et al., 2013), cerebellar vermis hypoplasia
(Paciorkowski et al., 2013; Raviglione et al., 2021), small forebrain and frontal lobes
(Hotz et al., 2013), periventricular heterotopia (Cardoso et al., 2009), abnormalities in the
posterior fossa including Chiari Type 1 malformation, enlarged cisterna magna, and
hippocampal abnormalities (Raviglione et al., 2021), and cysts (septum pellucidum,
pineal) (Yang et al., 2015; Wang et al., 2018; Nowakowska et al., 2010).
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Social, Behavioral and Sleep Issues
Autistic traits or behaviors were reported in 24 patients (Berland & Houge, 2010;
Boutry-Kryza et al., 2015; Floris et al., 2007; Hotz et al., 2013; Nowakowska et al., 2010;
Raviglione et al., 2021; Schluth-Bolard et al., 2019; Vidal et al., 2019; Vrečar et al.,
2017; Wang et al., 2018; Zweier et al., 2010). Additionally, other social and behavioral
issues were reported. Most patients displayed a lack of social smile and interest in
surroundings, or limited social interactions (Engels et al., 2009; Ilari et al., 2016; Novara
et al., 2010; Rocha et al., 2016; Shim et al., 2015; Wang et al., 2018) and poor eye
contact (Berland & Houge, 2010; Bienvenu et al., 2013; Gordon et al., 2018; Le Meur et
al., 2010; Novara et al., 2010; Paciorkowski et al., 2013; Rocha et al., 2016; Wang et al.,
2018; Yang et al., 2015). Some patients had a lack of social interaction (Ilari et al., 2016;
Nowakowska et al., 2010; Vrečar et al., 2017), whereas a few were reported to enjoy
human contact, especially with other children (Vrečar et al., 2017). Many patients were
described as having a generally happy disposition (Berland & Houge, 2010; Bienvenu et
al., 2013; Paciorkowski et al., 2013; Raviglione et al., 2021). Only a few patients were
reported to have negative behaviors, including obsessive behaviors, severe attention
deficit hyperactivity disorder and aggressive behaviors (Sobreira et al., 2009), agitation
and self-mutilation (Paciorkowski et al., 2013), and self-biting (Rocha et al., 2016). A
few patients were noted to easily startle with loud noises (Berland & Houge, 2010; Borlot
et al., 2019; Nowakowska et al., 2010; Tanteles et al., 2015). Lastly, some patients had
fascinations with random items and events, including running water or water in general,
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bright objects, and opening and closing doors (Berland & Houge, 2010; Gordon et al.,
2018; Tanteles et al., 2015; Vrečar et al., 2017).
Sleep issues were reported in 41.4% of patients and included sleeping a lot with
short awakening stages, sleep disturbance, and irregular sleep initiation and maintenance
(Engels et al., 2009; Hotz et al., 2013; Le Meur et al., 2010; Paciorkowski et al., 2013;
Vrečar et al., 2017; Wang et al., 2018; Yang et al., 2015; Zweier et al., 2010).
Feeding and Gastrointestinal Issues
Feeding and digestion issues were common and included constipation, feeding
difficulties, poor sucking as an infant, frequent vomiting, inability to feed self, needing
puree foods only, gastrostomy tube fed, slow gastric emptying, dysphagia, episodes of
appetite loss, and gastroesophageal reflux disease (GERD) (Al-Shehhi et al., 2016;
Bienvenu et al., 2013; Engels et al., 2009; Gordon et al., 2018; Le Meur et al., 2010;
Novara et al., 2013; Nowakowska et al., 2010; Paciorkowski et al., 2013; Saitsu et al.,
2011; Sakai et al., 2013; Schluth-Bolard et al., 2019; Shimojima et al., 2012; Vrečar et
al., 2017; Wang et al., 2018; Zweier et al., 2010).
Ophthalmological Issues
Eye concerns included bilateral optic atrophy and hyperopia (Engels et al., 2009;
Novara et al., 2013; Zweier et al., 2010), strabismus (Berland & Houge, 2010; Bienvenu
et al., 2013; Engels et al., 2009; Novara et al., 2010; Zweier et al., 2010) myopia
(Schluth-Bolard et al., 2019; Vrečar et al., 2017), bilateral esotropia (Marashly et al.,
2010; Nowakowska et al., 2010; Shim et al., 2015), nystagmus (Berland & Houge, 2010;
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Zweier et al., 2010), bilateral ptosis (Nowakowska et al., 2010), coloboma of the iris in
two patients (Cardoso et al., 2009; Sobreira et al., 2009), and cortical blindness in one
patient (Le Meur et al., 2010).
Cardiac Phenotype
Cardiac issues have not typically been associated with MEF2Chaploinsufficiency. However, cardiac issues could be expected due to the role of MEF2C
in myogenesis and heart development. Cardiac issues were reported in 17 patients in
total. Cardiac phenotypes included concentric myocardial hypertrophy, patent foramen
ovale, patent ductus arteriosus, abnormal fetal cardiac rhythm, bi-ventricular
hypertrophy, moderate tricuspid valve insufficiency, moderate bilateral ventricular valve
insufficiency, and murmur. Nine patients were reported with cardiac phenotypes in
addition to other features commonly found in MEF2C-related disorders (Cesaretti et al.,
2016; Engels et al., 2009; Le Meur et al., 2010; Novara et al, 2013; Nowakowska et al.,
2010; Stoll et al., 1980; Vrečar et al., 2017). Three articles focused solely on cardiac
studies and did not report any non-cardiac phenotypes in those 10 patients (Lu et al.,
2018; Yuan et al., 2017; Qiao et al., 2017).
Lu et al. (2018) performed Sanger sequencing of the MEF2C gene on a cohort of
186 unrelated patients with congenital heart defects and 300 healthy matched controls.
One patient who had a family history of ventricular septal defect (VSD) and double outlet
right ventricle (DORV) was identified with a heterozygous missense variant (c.43C>T;
p.Arg15Cys) in MEF2C. This variant was not present in any of the 300 controls. Family
studies revealed that the variant was paternally inherited and that the proband’s uncle also

84

carried the variant. All three individuals carried the missense change and had the
phenotype of VSD and DORV. The proband’s grandfather was deceased but shared the
phenotype so may also have carried the variant as well. No other phenotypic information
was reported apart from the cardiac phenotype.
Yuan et al. (2017) also performed Sanger sequencing on a cohort to identify
MEF2C variants associated with dilated cardiomyopathy (DCM). There were 172
unrelated individuals with DCM and 300 healthy controls sequenced. A heterozygous
nonsense variant (c.471C>G; p.Tyr157Ter) was detected in a patient with a positive
family history and phenotype of adult-onset DCM. The patient’s daughter and brother
both carried the variant. The daughter shared the phenotype of DCM, and the patient’s
brother had a phenotype of DCM and ventricular septal defect (VSD). These patients
were also reported to have intellectual disability, childhood epilepsy, stereotypic
movements, and absent speech. These features overlap with the traditionally reported
phenotype of MEF2C-related disorders and haploinsufficiency.
Lastly, Qiao et al. (2017) performed Sanger sequencing on a cohort of 200
unrelated patients with a congenital heart defect and 300 healthy controls. A
heterozygous missense variant (c.113T>C; p.Leu38Pro) was identified in a one-year-old
male with patent ductus arteriosus (PDA) and ventricular septal defect (VSD). The
patient’s father, uncle, and female first-cousin all carried the variant and shared a similar
cardiac phenotype. All family members had PDA. The proband’s father shared the same
phenotype of PDA and VSD. The proband’s uncle had pulmonary stenosis (PS) in
addition to PDA. The proband’s cousin was only reported to have PDA. The proband’s

85

grandfather was reported to have all three cardiac features (PDA, VSD, and PS);
however, the grandfather was deceased therefore carrier status could not be assessed. The
father and uncle were also reported to have intellectual disability, stereotypic movements,
and paroxysmal epilepsy.
Non-classical Findings
There were a number of patients in the literature with either non-classical
symptoms or unique pathogenesis. As previously mentioned, one patient presented with a
question mark ear (Gordon et al., 2018) and two patients presented with a jugular pit (AlShehhi et al., 2016; Berland & Houge, 2010). One other patient was reported to have
mild to moderate hypoglycemia, with a blood glucose level not exceeding 90 mg/dl even
after a meal (Sakai et al., 2013). This is perhaps the only reported neuroendocrine
phenotype related to deletions in the 5q14.3 region that included MEF2C. However, this
phenotype could be present but unrecognized in additional patients due to the severity of
the other features (i.e., intellectual disability and seizures). This patient had a normal
hypothalamus by MRI; therefore, the deficits likely occur within the hypothalamic
signaling pathway. Other genes within this patient’s deletion were not expected to be
expressed in the endocrine system, therefore were deemed not the likely cause of the
neuroendocrine phenotype leaving the authors to suspect MEF2C. The authors performed
expression studies in the mouse brain and found MEF2C was highly expressed in
neuropeptide Y (NPY)-positive hypothalamic interneurons. Conversely, NPY-positive
neurons had lower expression of MECP2, the gene associated with Rett syndrome.
Further analysis showed MECP2 is involved in the repression of MEF2C and NPY. The
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common pathway of MEF2C and MECP2 could explain the phenotypic similarities
between MEF2C-related disorders and Rett syndrome.
Nine patients who did not have a deleted or disrupted MEF2C gene yet presented
with a similar phenotype as the other diagnosed MEF2C patients (Boutry-Kryza et al.,
2015; Cardoso et al., 2009; Engels et al., 2009; Floris et al., 2007; Marashly et al., 2010;
Saitsu et al., 2011; Shimojima et al., 2012; Sobreira et al., 2009; Yauy et al., 2019). It was
hypothesized that there may be a regulatory positional effect for copy number variations
with a breakpoint on either side of the MEF2C gene. Of these nine, six had deletions that
did not encompass MEF2C and three were translocations that did not disrupt MEF2C. In
the patient reported by Engels et al. (2009), MEF2C expression levels were confirmed to
be decreased in an RNA study in collaboration with Zweier et al. (2010). One patient
with a balanced translocation actually had MEF2C overexpression (Yauy et al., 2019).
Two patients had normal MEF2C expression levels by lymphoblast RNA testing, one of
which had a deletion and the other a translocation (Saitsu et al., 2011; Shimojima et al.,
2012). This could be explained by tissue-specific expression where the sample type tested
had normal MEF2C expression, but tissue from another location (i.e., the brain), if tested,
may actually have decreased expression. The remaining five patients had no mention of
expression levels but could still fall within the category of patients affected due to the
positional effect of their deletion to MEF2C.

Discussion
We performed a systematic review to assemble the most comprehensive list of
patients with a MEF2C-related disorder along with their phenotypes. One hundred and
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seventeen patients were identified with a MEF2C-related disorder and the phenotypes
reported included intellectual disability, developmental delay, seizures, hypotonia, absent
speech, inability to walk, stereotypic movements, and MRI abnormalities. Additional
features detected were jugular pit, cardiac issues, and a neuroendocrine phenotype of
hypoglycemia. Although the patients shared many of the same features, differences
between patient phenotypes could be explained by the difference in the type of variants
(point mutations rather than chromosomal rearrangements), variant locations within the
MEF2C gene, or deletion sizes and whether additional genes were involved in the
deletion along with MEF2C. Genotype-phenotype correlation analysis may provide some
insights into the clinical variability across individuals with MEF2C-related disorders.
Other divergencies between the phenotypes reported in the articles could be due to the
purpose of the study. Authors may have focused on only one feature for their study (e.g.,
epilepsy), thereby limiting the phenotypic information presented for other features. For
example, of the six cohort studies, three focused on the cardiac phenotype, one on
infantile spasms, one on developmental disorders, and one on intellectual disability. In
contrast, twenty-nine articles (67.4%) were case reports in which more general
phenotypic information was presented.
Nine patients were reported to have chromosomal rearrangements not
encompassing or disrupting the MEF2C gene; however, these patients still exhibited a
similar phenotype to the other reported patients. This could be explained by a possible
positional regulatory effect. Six patients had no expression studies performed, two
patients had normal MEF2C expression, and one patient had decreased MEF2C
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expression. Further studies will be needed to understand this positional effect and
determine if expression could be tissue-specific.
Several clinical implications can be deduced given the results of this literature
review. Early referral for therapies (such as physical, occupational, and speech) is
recommended. Patients should undergo a full neurological evaluation including an EEG
and brain MRI if concerning neurological symptoms arise. If seizures, constipation, or
gastroesophageal reflux are occurring, treatment should be as per standard care. Also
recommended is an evaluation with a developmental specialist to screen for ASD and
behavioral issues, such as ADHD and anxiety. Given the cardiac findings from this
review, a cardiac evaluation with an echocardiogram and EKG is recommended. Lastly,
the MEF2C gene should be included in all Next Generation Sequencing (NGS)
epilepsy/seizure panels.
There are some limitations to this study. Despite the rigorous method and two
independent article reviewers, relevant articles matching the inclusion criteria might have
been missed. During the review, two articles were excluded as they were not in English
and one other article could not be obtained. Additionally, we only searched three major
databases indexing biomedical literature; therefore, any articles matching the inclusion
criteria in other databases were not included. A final limitation arises from using the
systematic review method where the data of this study relies on the information each
article contained. The articles may have focused only on specific clinical features without
reporting other potentially relevant information. As our study was a review of the
literature, we were not able to pursue additional patient information to fill the gaps. Thus,
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the sample size for each feature assessed varied. Future studies could involve contacting
the authors of the 43 manuscripts included in this study to gather the same clinical
information across all reported patients.
This review characterizes the phenotype of MEF2C-related disorders and
documents the severity of this condition, which can aid healthcare providers in
diagnosing patients and delivering the best care possible to current patients and their
families. Detailed information on the 117 patients is provided in the supplemental table
which may be a valuable resource for investigators interested in pursuing specific
genotype-phenotype correlations.
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ABSTRACT

Introduction
MEF2C-related disorders are characterized by developmental and cognitive delay,
limited language and walking, hypotonia, and seizures. A recent systematic review
identified 117 patients with MEF2C-related disorders across 43 studies. Despite these
reports, the disorder is not easily recognized and assessments are hampered by small
sample sizes. Our objective was to gather developmental and clinical information on a
large number of patients.
Methods
We developed a survey based on validated instruments and subject area experts to gather
information from parents of children with this condition. No personal identifiers were
collected. Surveys and data were collected via REDCap and analyzed using Excel and
SAS v9.4.
Results
Seventy-three parents completed the survey, with 39.7% reporting a MEF2C variant and
54.8% reporting a deletion involving MEF2C. Limited speech (82.1%), seizures (86.3%),
bruxism (87.7%), repetitive movements (94.5%), and high pain tolerance (79.5%) were
some of the prominent features. Patients with MEF2C variants were similarly affected as
those with deletions. Female subjects showed higher verbal abilities.
Conclusion
This is the largest natural history study to date and establishes a comprehensive review of
developmental and clinical features for MEF2C-related disorders. This data can help
providers diagnose patients and form the basis for longitudinal or genotype-phenotype
studies.

Keywords: MEF2C, MEF2C-Related Disorders, natural history study, parent survey,
neurodevelopmental, social media research
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CHAPTER FOUR
CLINICAL FINDINGS FROM THE LANDMARK MEF2C-RELATED DISORDERS
NATURAL HISTORY STUDY

INTRODUCTION
MEF2C-related disorders, also known as MEF2C haploinsufficiency syndrome or
5q14.3 microdeletion syndrome (OMIM #613443), are neurodevelopmental disorders
characterized by developmental delay, intellectual disability, lack of verbal language,
limited walking, hypotonia, and seizures1. Originally, patients with this phenotype were
found to have microdeletions of the 5q14.3 region, with most including the MEF2C gene
(OMIM *600662). Eventually, MEF2C was identified as the causative gene after patients
were reported with microdeletions only encompassing MEF2C2,3 as well as another
patient with a nonsense variant in MEF2C4. There have also been some cases reported of
patients with a similar phenotype that had microdeletions in the proximal or distal region
closely surrounding but not including the MEF2C gene5,6. It is hypothesized that these
deletions may disrupt the regulation and expression of MEF2C, and therefore cause the
same phenotype. Interestingly, some patients with MEF2C variants and microdeletions
not only had diminished MEF2C expression but also diminished CDKL5 and MECP2
expression, indicating a shared molecular pathway7. Although the phenotype has some
overlap to Rett syndrome, patients do not typically have regression and would not meet
current criteria for the diagnosis of Rett syndrome8.
A recent systematic review of the literature revealed 43 manuscripts describing
117 patients with a MEF2C-related disorder reported to date9. Most publications report
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only one or a few patients, with the largest cohort being 17 new patients in one
publication10. Despite the phenotypic information provided, the disorder is not easily
recognized clinically. Additionally, the disorder has only been described for just over a
decade, a much shorter time than other similar, but well-characterized,
neurodevelopmental disorders, such as Rett syndrome, prompting the need to further
characterize the disorder. We conducted a natural history study in the form of a parent
survey to gather additional data and improve the clinical description of the disorder. This
is the largest cohort to date containing parent-reported phenotype information about
MEF2C-related disorders. The information revealed by the survey further characterizes
the disorder, aids providers in recognizing, diagnosing, and treating patients, and
illuminates features not previously reported.

METHODS
Ethical Compliance
The study was approved by the Self Regional Healthcare IRB (Pro00091979). No
personally identifiable information was collected. IRB approval was shared with the
Clemson University IRB. No additional IRB approval was required by Clemson
University.
Survey Development
Survey development commenced in January 2019. The Rett Syndrome Natural
History Study11,12 and the Fragile X Online Registry with Accessible Research Database
(FORWARD)13 surveys were used as guides to help develop appropriate survey
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questions. The draft of the survey was piloted by four parents of children with MEF2Crelated disorder. These parents were asked for feedback and any additional question
suggestions. The final survey contains 81 questions on demographic information,
developmental history, medical issues and symptoms. The survey questions were vetted
by a team of clinical and research experts from the Greenwood Genetic Center (GGC),
Clemson University, and the Medical University of South Carolina (MUSC). The final
version was then loaded into REDCap (Research Electronic Data Capture)14 for online
survey distribution. The questionnaire may be made available upon request.
Recruitment
The survey was opened for online data collection in January 2020. Any patient
with a previously reported MEF2C alteration (variant, deletion, duplication) met the
criteria for this study. The research team had a goal of 50 survey responses. Parents,
relatives, and guardians or caregivers of a child with a MEF2C-related disorder were
made aware of the survey via an IRB-approved advertising script posted to the Facebook
support group “MEF2C Medical Personnel and Families”. As of August 4th, 2021, the
Facebook group had over 350 worldwide members, including medical personnel, parents,
and family. A reminder post was put on the Facebook support group twice, each about
two months apart from the last post, for a total of three advertising posts. Additionally,
two parents shared the advertising script and survey link to the parents-only Facebook
group “MEF2C Parent Support Group” on behalf of the research team. Although the
survey remained anonymous, informed consent was obtained electronically by each
parent prior to starting the survey. The survey was closed in June 2020.
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Data Analysis
Survey results were exported from REDCap into an Excel file. Descriptive
statistical analysis, including percentages, means, and standard deviations (SDs) were
performed using both Excel and SAS v9.4. Categorical analyses (between alteration type
or gender, and anxiety, hyperactivity, seizures, abnormal MRI, use of words for
communication, and walking) were assessed with chi-square tests or, when cell counts
were small, Fisher’s Exact test. Ordinal analyses (between age group and anxiety,
hyperactivity, seizures, abnormal MRI, use of words for communication, and walking)
were assessed using the Cochran–Armitage trend test. For tests of association, alteration
type was divided into two categories of variant (SNV / point mutation / INDEL) or
deletion (large deletion / CNV). There were no participants reporting a large duplication.
Patients with an uncertain type of pathogenic alteration were excluded from the analysis.
Gender was male or female, and age group consisted of infant (9 months to <24 months),
preschool (2 years to <6 years), child (6 years to <13 years), adolescent (13 years to <19
years), and adult (19 years to <45 years). The dichotomous choice for the use of words
for communication, anxiety, hyperactivity, seizures, abnormal MRI, and walking was
either yes or no. Missing data were omitted from the analysis. Chi-square test, Fisher's
Exact test, and Cochran–Armitage trend test were carried out using SAS v9.4. A P-value
<0.05 was considered statistically significant.

RESULTS
Study Population
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A total of 108 survey records were available in REDCap. There were 35
incomplete records of which the majority had only answered one question before closing
the survey. Only three of the incomplete records were at least 50% completed. These
incomplete records were excluded and data analysis proceeded only on the 73 complete
survey responses. All 73 completed responses (100%) were submitted by a parent who
had a child with a MEF2C-related disorder (versus relative or guardian/caregiver).
Of the 73 parent-completed survey results, 35 reported having a female child
(48%) and 38 reported having a male child (52%) with a MEF2C-related disorder. The
majority of children (91.7%) were reported to be of White race and not of Hispanic,
Latino, or Spanish ethnicity. Mother’s age at the child’s birth ranged from 20 to 41 years
of age (mean 31.8 years, SD = 5.12). The children’s current age at the time of the survey
ranged from 9 months to 38 years (mean 8.12 years, SD = 7.21). BMI was calculated
based on parent-reported height and weight, and 46.6% fell within the normal / healthy
weight category (Table 1). Nearly 33% (22/67) had short stature, with a height falling
below the third percentile compared to individuals of the same sex and age in the general
population.
Of the 73 patients, 29 (39.7%) reported a MEF2C variant (point mutation or
INDEL), 40 (54.8%) reported a deletion involving the MEF2C gene, and 4 (5.5%) were
uncertain of the pathogenic alteration at the time of taking the survey. There were no
reported large duplications and only one small duplication (6 base pairs) in the INDEL
category. About 33% of parents provided the specific variant nomenclature or deletion
coordinates (16 variant and 8 deletion). Of the variants reported, seven fell within the
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MADS domain, one was in the MEF2 domain, and the remaining eight variants were
downstream of these two domains. Reported deletions ranged in size from 217KB to
8MB, including anywhere from one or a few exons to the entire gene being deleted.
Other parents gave a description of what they remembered, such as “location of stop
codon is halfway, not at the end of the gene” or “217k deletion of 5q14.3”.

Table 4.1: Demographic, physical, and genetic information reported by parents regarding
their child with MEF2C-related disorder.
Totals (N=73)
Child’s Gender
Female
35 (47.9%)
Male
38 (52.1%)
Ethnicity
Hispanic, Latino, or Spanish origin
6 (8.2%)
Not Hispanic, Latino, or Spanish origin
63 (86.3%)
Unknown
4 (5.5%)
Race
White or Caucasian
67 (91.7%)
Black or African American
3 (4.1%)
Asian
1 (1.4%)
American Indian or Alaskan Native
1 (1.4%)
Unknown
1 (1.4%)
Mother’s Age When Child Was Born
Average
31.8 yr (SD 5.12 yr)
Range
20-41 yr
Father’s Age When Child Was Born
Average
33.6 yr (SD 7.07 yr)
Range
21-57 yr
Child’s Birth Weight
Extremely low birth weight (less than 0.992kg)
1 (1.4%)
Very low birth weight (between 0.993kg and 1.616kg)
0 (0%)
Low birth weight (between 1.617kg and 2.495kg)
13 (17.8%)
Normal birth weight (between 2.496kg and 3.997kg)
57 (78.1%)
High birth weight (greater than 3.997kg)
2 (2.7%)
Child’s Current Age
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Infant (9 months to < 24 months)
Preschool (2 years to < 6 years)
Child (6 years to < 13 years)
Adolescent (13 years to < 19 years)
Adult (19 years to < 45 years)
Average
Range
Child’s Current BMI
Underweight
(Child and Teen: less than 5th percentile;
Adult: BMI below 18.5)
Normal / Healthy Weight
(Child and Teen: 5th to less than 85th percentile;
Adult: BMI of 18.5 to 24.9)
Overweight
(Child and Teen: 85th to less than 95th percentile;
Adult: BMI of 25.0 to 29.9)
Obese
(Child and Teen: 95th percentile or greater;
Adult: BMI of 30.0 or greater)
Genetic Alteration
MEF2C variant (point mutation / INDEL)
Deletion involving the MEF2C gene
Uncertain
Note: SD = Standard Deviation

8 (11.0%)
36 (49.3%)
11 (15.1%)
10 (13.7%)
8 (11.0%)
8.12 yr (SD 7.21 yr)
9 mo – 38 yr
N=58
18 (31.0%)

27 (46.6%)

6 (10.3%)

7 (12.1%)

29 (39.7%)
40 (54.8%)
4 (5.5%)

Maternal Pregnancy History
Twenty-five parents (34.2%) reported pregnancy exposures, which included
tobacco (8.2%), secondhand smoke (8.2%), alcohol (5.5%), chemicals (1.4%),
prescription medicines (12.3%), and other (9.6%; Table S1). Of these exposures, only
tobacco use was higher, albeit only slightly, as compared to the 7.2% in the general
population that reported smoking during pregnancy15. Thirty parents (41.1%) reported
pregnancy complications, including premature labor (8.2%), preeclampsia (5.5%), low

109

amniotic fluid (1.4%), gestational diabetes (4.1%), illness (5.5%), and other (26.0%;
Table S1). These percentages were less than or in range with percentages seen in the
general population. Thirty-five parents (47.9%) reported birth complications, including
breech position (8.2%), failure to progress (11.0%), fetal meconium aspiration (5.5%),
fetal distress (19.2%), and other (21.9%; Table S1). Of note, the percentage of breech
position and fetal distress were higher in our cohort as compared to the general
population (3-4% and about 4%, respectively, in the general population)16,17. Fifty-five
(75.3%) mothers carried their child to full term (delivery between 38-42 weeks), whereas
the remaining 18 (24.7%) reported a gestational age of before 38 weeks.

Early Development
Most children learned to roll over (90.4%), with this activity first occurring
between 3 months of age and 10 years (mean 1.43 years, SD 1.57 years). Most children
also learned to sit up (80.8%), with the first occurrence ranging between 6 months and 12
years (mean of 2.17 years, SD 2.15 years), 61.6% learned to crawl, ranging between 1
year and 16 years (mean of 2.55 years, SD 2.50 years), 50.7% of the children over 18
months of age had learned to walk, with first occurrence ranging between 1.33 and 6
years (mean of 3.15 years, SD 1.27 years).
By the time of the survey, most children learned some useful hand functions;
82.2% learned to reach for objects with first occurrence ranging between 2 months and
14 years (mean 2.04 years of age, SD 2.37 years), 72.6% learned to transfer items from
hand to hand with first occurrence between 6 months and 11 years (mean 2.31 years, SD
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2.13 years), 23.3% developed a pincer grasp with first occurrence between 9 months and
6 years of age (mean 3.25 years, SD 1.70 years), and 45.2% were able to finger feed
themselves with first occurrence between 1 and 8 years of age (mean 2.69 years, SD 1.70
years). Lastly, 21.7% of the children over 18 months of age were able to feed themselves
with utensils with first occurrence between 20 months and 14 years of age (mean 5.98
years, SD 4.31 years) (Table S2; Figure 1).
Only one child (1.4%) was reported to be both bowel and urine trained, and seven
participants (9.6%) were time trained. The remaining 65 (89.0%) were not toilet trained.

Figure 4.1: Developmental milestones. A: Percentages by age group. B: Average age the
milestone was achieved in this patient cohort with MEF2C-related disorders as compared
to the general population18.
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Communication Skills
Of 29 children aged six years and older, 26 (89.7%) were reported to have
intellectual disability. In addition, most were reported to have limited language, with
89.2% of children over two years of age lacking any spoken words (Table 2). When
assessing children over five years of age, the majority (82.1%) lacked any spoken words.
Overall, only eight children were reported to use at least a small number of words for
communication, one of whom was able to use a series of single words or two-word
combinations meaningfully, and one was able to use phrases or sentences of three words
or more.
There was not a significant difference between alteration type (p=0.1194), while
there was a significant difference between gender (p=0.0033) and age groups (p=0.0416)
showing that females and older subjects were more likely to use words to communicate
(Figure 2, Table S3). Interestingly, all eight patients able to use words to communicate
were female with their current ages ranging from infancy (<24 months) to adulthood.
Alternate speech methods used included signing (19.2%), picture exchange
communication system (PECS) or equivalent (26.0%), apps on an iPad/iPhone,
smartphone, or tablet (12.3%), and augmentative communication device (16.4%), with
some patients (18 of 71, or 25.4%) using more than one type. Nearly 18% pointed, 30.1%
used gestures or waves, and 38.4% were reported to follow one-step or simple
commands. Of those over two years of age, 25 (39.1%) were nonverbal and not using
signs. Additionally, 16 of these 25 did not report using any alternate communication
methods.
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Table 4.2: Child’s developmental, language, and motor milestones as reported in the
survey.
Totals
Most Recent Milestone
No. (%)
Developmental

N=73

Roll over

66 (90.4%)

Sit up

59 (80.8%)

Crawl

45 (61.6%)

Reach for objects

60 (82.2%)

Transfer items from hand to hand

53 (72.6%)

Pincer grasp

17 (23.3%)

Finger feed self

33 (45.2%)

Feed self using utensils (>18 months of age)

15 (21.7%)

Toileting

N=73

Both bowel and urine trained

1 (1.4%)

Bowel or urine trained only

0 (0.0%)

Time trained

7 (9.6%)

Not toilet trained
Language
Nonverbal/no signs
Nonverbal but using signing in a meaningful way
Babbling/vocalizations
A small number of words or signs for minimal communication
Series of single words or 2-word combinations used meaningfully
Phrases/sentences of 3 words or more
Alternate Communication Methods
Signing
Picture exchange communication system (PECS) or equivalent
Apps on an iPad/iPhone, smart phone, or tablet
Augmentative communication device
Other (hand leading, singing nursery rhymes, and vocalizations for
agreement, annoyance, and attention)
None of the above
Motor Abilities
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65 (89.0%)
N=73
26 (35.6%)
6 (8.2%)
33 (45.2%)
6 (8.2%)
1 (1.4%)
1 (1.4%)
N=71†
14 (19.2%)
19 (26.0%)
9 (12.3%)
12 (16.4%)
4 (5.5%)
36 (49.3%)
N=73

Unable to Roll
1 (1.4%)
Rolls
4 (5.5%)
Sits with Support
8 (11.0%)
Sits Unaided
9 (12.3%)
Crawls
4 (5.5%)
Stands with Support
7 (9.6%)
Stands Unaided
0 (0.0%)
Walks with Support
12 (16.4%)
Walks Unaided
22 (30.1%)
Runs Unaided
6 (8.2%)
†: A total of 71 parents answered this question with 18 using more than one type of
alternate speech method; therefore, the total counts and percentages look to exceed
71/100%.

Motor Milestones
Assessing the highest motor milestone obtained, 40.5% of children over 18
months of age were able to run or walk without support, 17.4% were able to walk with
support, and the remaining 42.0% were unable to walk (Table 2). A higher percentage of
females (57.1%) compared to males (39.5%) had learned to walk; however, the
difference between males and females learning to walk was not significant (p=0.0867).
Similarly, a higher percentage of patients with variants (58.6%) compared to those with
large deletions (42.5%) had learned to walk but the difference was also not significant
(p=0.2083). There was a significant association between being able to walk and age
group (p=0.0483) (Table S4). This is expected, as walking is a milestone met with
increasing age. With each age group, the percentage of those able to walk generally
increased, with 75% of those in the adult group being able to walk (Figure 2).
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Of those six who were able to run unaided, 50% were unsteady when walking. Of
the 22 who were able to walk unaided, 95.5% were reported to be unsteady when
walking. Of the 12 who were able to walk with support, 100% were reported to be
unsteady when walking. Most had seemingly low muscle tone (72.6%), whereas 19.2%
reported normal muscle tone, and 8.2% reported increased muscle tone.

Figure 4.2: Communication and Walking Milestones by Alteration Type, Gender, and
Age Group. * Significant at p<0.05
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Social Characteristics
Fifty of the children (68.5%) were reported to like giving affection, and 58 liked
receiving affection (79.5%). The majority (71.2%) could recognize family members.
Forty of the children (54.8%) reported to typically resist holding someone’s hand. Fiftythree (79.1%) were reported to have a reduced concern with an environmental threat (i.e.:
walks off, explores, lack of “stranger danger”) and 34 (46.6%) actively sought social
interaction. Poor eye contact and attention problems were reported in over half (60.3%
and 70.4% respectively); however, hyperactivity and anxiety were not as common
(37.5% and 17.1% respectively). For hyperactivity and anxiety, there was not a
significant difference in gender (p=0.9515; p=0.3936), alteration type (p=0.0807;
p=0.3936), or age group (p=0.5971; p=0.6655) (Table S5). Nearly one-fourth (25.7%)
reported that their child had been diagnosed with autism spectrum disorder.

Sensory Systems
Forty-four (61.1%) reported vision impairments, which included myopia
(27.3%), hyperopia (29.5%), problems with depth perception (38.6%), cortical visual
impairment (38.6%), strabismus (47.7%), and other issues (15.9%: esotropia, nystagmus,
astigmatism). Hearing impairments were less common (8.3%), and included bilateral
sensorineural hearing loss, deafness in one ear, mild to moderate loss of certain tones,
and moderate mixed hearing loss. Additionally, 61.6% reported sensitivity to loud noises.
Few reported sensitivity to clothing textures (6.8%). Food textures sensitivities were
slightly more common (36.1%), with those parents noting the child had issues chewing
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and swallowing, and therefore preferred soft or pureed foods. Many reported sensitivity
to heat (27.4%), cold (4.1%), or both (23.3%). Lastly, 58 (79.5%) reported a high pain
tolerance.

Other System Symptoms
Many parents reported their child has trouble falling asleep (42.5%) and staying
asleep (49.3%). Sleep medications were reported by 38.4% and included melatonin,
Zonegran, Cicardin, Clonidine, Gabapentin, Trazadone, Cyproheptadine, in addition to
essential oils and CBD and CBN oil. Medical conditions, digestion issues,
immunological, and neuropsychological issues are reported in Table 3 and Table S1. Two
parents reported that their children are 100% fed via gastrostomy tube.
Puberty typically occurs between 11-14 years of age18. Nineteen (26.0%) parents
reported their child had gone through puberty; seven (36.8%) started puberty before 11
years of age, 10 (52.6%) started puberty between the typical ages of 11-14 years of age,
and 1 (5.3%) started puberty after the age of 14. Of those who had not yet started puberty,
the majority (96.3%) were under the age of 11, one patient (1.85%) was within the 11–
14-year range, and one patient (1.85%) was over the 11-14-year.
Immunological issues are reported in Table 3. “Other” frequent illnesses that the
parents described included respiratory infections, tonsillitis, frequent colds and
pneumonia, and chronic ear infections. Interestingly, a few parents reported some
improvements in developmental skills when the child has a fever (16.4%).
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Seizures were reported by 63 parents (86.3%); there was not a significant
difference between alteration type (p=0.3928), gender (p=0.4114), or age group
(p=0.8165) for having seizures (Table S6). Seizure types included generalized (25.8%),
partial (8.1%), febrile (33.9%), and other (27.4%; multiple seizure types, absence, atonic,
myoclonic seizures, atypical complex febrile, infantile spasms, and generalized tonicclonic). The onset of seizures ranged from the postnatal period up to 9 years of age. The
average onset age of seizures was 1.08 years old (SD 1.28 years). Many parents reported
that their child’s seizures were under control, and they were no longer having seizures
occurring regularly as of the time of the survey (44.4%). For those having seizures
currently, 10 (16.4%) reported their child has more than one seizure a day, seven (11.5%)
reported daily seizures, one (1.6%) reported weekly seizures, two (3.3%) reported
monthly seizures, and 13 (21.3%) reported seizures less than monthly. Thirty-eight
parents (61.3%) reported their child takes medication for seizures and 37 of these parents
(97.4%) reported the medications helped. Nineteen of the 38 (50%) reported the use of
multiple seizure medications. Many (20/38, 52.6%) reported using Keppra
(levetiracetam). Other commonly used seizure medications are reported in Table S1. Two
parents noted that the ketogenic diet has helped with their child’s seizures. Types and
frequencies of certain neuropsychological issues are reported in Table 3.

Table 4.3: Symptoms (including medical, digestive, immunological, and
neuropsychological) as reported by the parents about their child with MEF2C-related
disorder.
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Totals
(N=73)
No. (%)

Symptoms Reported
Sleep Issues
Trouble falling asleep
Trouble staying asleep
Medical Conditions
Diabetes
Congenital Heart Defect
Asthma or Other Respiratory Issues
Thyroid Problems
Sleep Apnea
Other
None
Digestion Issues
Diarrhea
Constipation
Reflux
Gall Bladder Dysfunction
Abdominal Distention/ Bloating
Other
None
Recurrent Immune-related Problems or Frequent Illness
Frequent Illnesses
Frequent Fevers
Severe Allergic Reactions
Joint Inflammation
Skin Issues (such as eczema)
Other
Seizures
Generalized
Partial
Febrile
Other
Unknown
Not Answered
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31 (42.5%)
36 (49.3%)
0 (0.0%)
5 (6.8%)
8 (11.0%)
1 (1.4%)
4 (5.5%)
24 (32.9%)
41 (56.2%)
10 (13.7%)
52 (71.2%)
30 (41.1%)
0 (0.0%)
10 (13.7%)
9 (12.3%)
11 (15.1%)
31 (42.5%)
26/31 (83.9%)
13/31 (41.9%)
3/31 (9.7%)
0/31 (0.0%)
9/31 (29.0%)
6/31 (19.4%)
63 (86.3%)
16/63 (25.4%)
5/63 (7.9%)
21/63 (33.3%)
17/63 (27.0%)
3/63 (4.8%)
1/63 (1.6%)

Puberty
Scoliosis
Hyper-flexibility of fingers, hips, joints, etc
Regressions in Development
Neuropsychological
Tremors
Hyperventilation
Breath Holding
Aerophagia
Food Pocketing
Chewing or Swallowing Problems
Bruxism
Repetitive Hand Movements
Obsessive Fascination with Water

19 (26.0%)
9 (12.3%)
52 (71.2%)
25 (34.2%)
22 (30.1%)
22 (30.1%)
25/72 (34.7%)
19/72 (26.4%)
27/72 (37.5%)
48 (65.8%)
64 (87.7%)
69 (94.5%)
50/72 (69.4%)

Previous Imaging Reported
Most patients (69/72) previously had a brain MRI (95.8%) with 40 (58.8%)
having abnormal results. These abnormal results included thinning of the corpus
callosum, partial agenesis of the corpus callosum, enlarged ventricles, cerebral atrophy,
suggestive Chiari malformation, dysmorphic basal ganglia, flattening of the pons,
myelination delay, white matter atrophy, Blake’s Pouch cyst, grey matter heterotopia,
right amygdala lesion, cortical dysplasia, asymmetrical hippocampi, and excess fluid in
the frontal lobe. There was not a significant difference in gender (p=0.5411), alteration
type (p=0.5951), or age group (p=0.0669) for having an abnormal MRI (Table S7).
Interestingly, 36 of 40 reported both abnormal MRI results and seizures.
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DISCUSSION
We presented phenotypic data collected from the parents of 73 patients with a
MEF2C-related disorder, making this the largest study to date. Both children and adults
were represented in the cohort. The most prominent features were limited speech (82.1%
of children over the age of five not using words for communication), seizures (86.3%),
bruxism (87.7%), repetitive hand movements (94.5%), and high pain tolerance (79.5%).
Only eight patients (11.0%) were reported to use a small number of words, or a
combination of words or phrases, to communicate, all of whom were female.
Additionally, we found communication to be significantly associated with gender
(p=0.0033) and age group (p=0.0416), with females and older subjects more likely to use
words to communicate. Nearly 51% of children over 18 months of age were able to walk;
the percentage generally increased with age, with a significant correlation between age
group and the ability to walk (p=0.0483). Most patients were able to reach for objects and
transfer them from hand to hand, but more fine motor skills (such as pincer grasping and
using utensils to feed oneself) were less common.
Many of these features were also the most prevalent found in a systematic review
that compiled information on 117 patients reported in the literature9. Similar to the results
of our survey, phenotypic information on these 117 patients in the literature included
limited speech in 92.9%, seizures in 87.3%, and stereotypic movements in 83.6% of
patients. Our survey revealed an abnormal MRI in 54.8% of patients, while the
systematic review revealed this feature in 67.4%. For a final comparison, our survey
revealed 59.4% of children over 18 months of age were unable to walk without support,
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while the systematic review revealed 56.4% over the age of 18 months were unable to
walk.
Early studies revealed that MEF2C is highly expressed in neurons and plays a role
in neuronal differentiation19,20. Correlating to the neuron expression, many symptoms in
patients are neurological, including abnormal MRI findings, seizures, speech and motor
impairments, high pain tolerance, and hand stereotypies. Additionally, MEF2C is also
expressed in muscle21, which may relate to the phenotypes of hypotonia, gastrointestinal
issues such as constipation, and walking. Of note, Mef2c heterozygous mice serve as a
valid animal model for MEF2C-related disorders as the mice display phenotypic
similarities to patients including social and communication impairments, repetitive
behaviors, and increased pain tolerance22. In an RNA-seq experiment on cortical tissue,
Harrington et al. (2020) found that hundreds of genes were dysregulated in the Mef2c
heterozygous mice as compared to wildtype. Many of the upregulated genes were
microglial genes, while a large portion of downregulated genes were autism risk-linked
genes. MECP2, the gene responsible for Rett syndrome, was previously found to be
downregulated in patients with MEF2C deletions, truncating mutations, and missense
variants, indicating a common pathway between the two genes7. This may also explain
the phenotypic similarities between Rett syndrome and MEF2C-related disorders,
including seizures, intellectual disability, developmental delay, and stereotypic
movements. However, regression of skills is a requirement for the diagnosis of Rett
syndrome8, whereas regression is not seen in all patients with MEF2C-related disorders
(34.2% of parents reported developmental regression).
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We developed a survey to further characterize MEF2C-related disorders. Our
survey was based upon well-regarded, validated instruments for Rett syndrome (a
condition in the differential diagnosis for MEF2C-related disorders) and fragile X
syndrome. The survey was vetted by experienced clinical geneticists and other genetics
providers and pilot tested by families who have a child with a MEF2C-related disorder.
This study is responsive to the requests of families and the research community. This
survey was made available to two Facebook groups, reaching large numbers of families
with multiple reminders. There was an exceptional response rate, exceeding the goal of
50 with a total of 73 complete responses. This study provided parents the opportunity to
participate across the world without requiring onerous travel and was successful in
obtaining comprehensive information on the largest group of patients to date. The use of
Facebook to conduct research has been established as a time- and cost-effective means of
recruiting hard-to-reach populations23,24. Additionally, using Facebook for recruitment
has facilitated research for our team and others25 in the era of COVID-19 when in-person
evaluations were not feasible.
There are limitations to our study. First, the prevalence of MEF2C-related
disorders is yet to be determined. Although the Facebook group where our study was
advertised contains hundreds of members, it consists of family members and medical
professionals. There is another MEF2C Facebook group in which only parents have
membership and access. Therefore, our study may have missed potential participants by
not being able to routinely advertise in the parents-only group as often as we did in the
family members and medical professionals group. Second, by advertising the survey
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through Facebook, participants from across the world were given the opportunity to
respond; however, the survey was in English and required Internet access. It may have
been difficult for participants to translate if English was not their first language. At least
one parent responded in a different language for the open-ended questions responses,
which had to be translated back to English for analysis. Third, the participants may have
given certain information from memory (such as variant type and nomenclature as well as
early developmental milestones). Future studies may benefit from including instructions
prompting the participants to gather their genetic reports for reference prior to beginning
the study. Lastly, the recent systematic literature review9 illuminated cardiac issues that
have not typically been associated with MEF2C-related disorders, and of note, Mef2c
total knockout mice are embryonic lethal due to heart formation defects26. The parent
survey was developed prior to the publication of the systematic review; therefore,
detailed cardiac-related questions were not considered for inclusion in the survey.
The information collected during this study is a valuable resource to many.
Healthcare providers can use the results to learn more about MEF2C-related disorders,
allowing better diagnosis and care for the patients and families. Families can use this data
to obtain answers and see how their child compares or falls within the 73-patient cohort.
Lastly, researchers may be able to use this data to pursue specific genotype-phenotype
relationships, use it as baseline data for comparison for treatment trials, and for the
development of future patient-centered studies.
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CHAPTER FIVE
CURRENT TECHNIQUES TO INVESTIGATE THE MOUSE Mef2c GENE

Abstract
This chapter describes the laboratory techniques used by the author (Jessica
Cooley Coleman) in Dr. Christopher Cowan’s laboratory at the Medical University of
South Carolina (MUSC) to investigate Mef2c expression and gene regulation in the
mouse brain. The author performed nuclei dissociation, bioinformatics analysis of single
nuclei RNAseq data, perfusion fixation, brain extraction, brain slicing by microtome, and
immunohistochemistry. Following nuclei dissociation, Fluorescence-Activated Cell
Sorting (FACS) was performed by Cowan laboratory graduate students. The dissociated
nuclei were given to the MUSC Translation Science Lab (outside of the Cowan
laboratory) for library preparation with the 10X Genomics Chromium Single Cell 3’
Reagent Kit. The resulting libraries are sent to a core laboratory for Illumina sequencing.
All of these aforementioned techniques (whether performed by the author or not) are
discussed in this manuscript. This information may be helpful to future researchers in
using and understanding the techniques.

Introduction
MEF2C (myocyte enhancer factor 2C) is a transcription factor that is highly
expressed in the nervous, muscular, and immune systems. In the brain, it is expressed in
both excitatory and inhibitory neurons and microglia, and plays a role in neurogenesis,
synaptic formation, and remodeling (Assali et al., 2019). Pathogenic variants and macro-
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and microdeletions involving MEF2C are associated with MEF2C-related disorders, also
known as MEF2C haploinsufficiency syndrome. MEF2C-related disorders are
characterized by intellectual disability, developmental delay, lack of speech, seizures,
hypotonia, brain abnormalities, stereotypic movements, and limited walking. Mef2c
global heterozygous mice (lacking one copy Mef2c exon 2 globally across all tissues) and
conditional heterozygous mice (lacking one copy of Mef2C only in a certain tissue type)
also exhibit repetitive behaviors and social deficits, reduced ultrasonic vocalizations,
reduced sensory sensitivity (pain and hearing), abnormal sleep, and altered
approach/avoidance behavior; therefore, these mice can serve as a face- and constructvalid animal model for the human syndrome.
Harrington, Bridges, et al. (2020) performed unbiased RNA-sequencing on whole
cortex from Mef2c global heterozygous mice compared to control mice and found 490
genes that were significantly dysregulated, including microglial genes and autism
spectrum disorder risk genes. The authors also analyzed single-cell (sc) RNA-seq data
and ChIP-Seq data and found differentially expressed genes associated with excitatory
neurons and microglia. The scRNA-seq data showed an increase in expression of genes
associated with embryonic and immature microglia, suggesting delayed microglial
maturation in Mef2c heterozygous mice.
Of note, single nuclei (sn)RNA-seq has several advantages over scRNA-seq,
including reduced dissociation bias, reduced dissociation stress response, and the ability
to use frozen samples (Wu et al., 2019). To better understand the role that MEF2C plays
in microglial maturation and neurons (specifically GABAergic subtype), we are currently
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performing nuclei dissociation from the prefrontal cortex for snRNA-seq. The laboratory
methods and bioinformatic analyses associated with snRNA-seq are discussed in this
manuscript. Additionally, we discuss other current techniques used to investigate the
mouse Mef2c gene in order to glean insight into the human disorder.

Table 5.1: Key Terms Defined
Key Terms
Barcode

Gel Beads-in-Emulsions (GEMs)

Hemocytometer
Immunohistochemistry (IHC)
Next Generation Sequencing
(NGS)
NGS Library

Nuclei Dissociation
Single Cell RNA Sequencing
Single Nuclei RNA Sequencing

Short nucleotide sequence used to tag each cell or
nuclei’s transcriptome (in the case of RNA
sequencing)
Nanoliter-sized droplet containing a single cell or
nuclei, a unique barcode, reagents, and
partitioning oil.
Counting chamber device.
Method that uses antibodies to detect antigens in
a tissue sample.
Massively parallel sequencing.
Collection of similar sized DNA or cDNA
fragments with adaptors added ready for next
generation sequencing.
Separation or isolation of nuclei from cells within
a tissue sample.
Methodology to assess gene expression of
messenger RNA from isolated whole cells.
Methodology to assess gene expression of
messenger RNA from isolated nuclei.

Institutional Animal Care and Use Committee Approval
All animal use was approved and done in accordance with the Medical University
of South Carolina Institutional Animal Care and Use Committee (IACUC) and National
Institute of Health (NIH) guidelines.
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Laboratory Techniques and Analyses
Before preparing libraries for single nuclei RNA sequencing, the brain is
extracted and the nuclei must be dissociated, or separated, from the cells within the tissue
sample. The dissociated nuclei can undergo Fluorescence-Activated Cell Sorting (FACS)
to gather a highly purified high-quality sample. The nuclei then undergo library
preparation with 10X Genomics Chromium Single Cell kit. The final libraries are
sequenced on an Illumina instrument, such as the NovaSeq. Finally, the data can be
bioinformatically analyzed to assess gene expression differences not only between cell
types but also between control groups (such as wildtype versus Mef2c global
heterozygous mice). Additional techniques performed in the Cowan laboratory include
perfusion fixation, sectioning of the brain using the microtome, and
immunohistochemistry.

Figure 5.1: Single Nuclei RNAseq Workflow. Created with BioRender.com.
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Nuclei Dissociation
For the nuclei dissociation, Brandon W. Hughes in the Cowan laboratory
modified a protocol from the Day laboratory at the University of Alabama (Hughes,
2021). At the desired timepoint or age, the mouse is decapitated, and the brain rapidly
extracted. Live decapitation is necessary as anesthetics will alter gene expression,
rendering downstream analyses unreliable. The brain is briefly submerged in a nutrient
medium containing RNase inhibitor then sliced in a brain block to obtain 1mm slices.
The prefrontal cortex (PFC) and other brain regions of interest are micro-dissected out,
placed into 1.5mL tubes, and flash frozen on dry ice. Samples are then frozen at -80˚C
until the dissociation procedure is started.
For the nuclei dissociation, the frozen brain samples are thawed on wet ice then
placed on a glass Petri lid. The tissue is chopped orthogonally 60-100x to break the tissue
into smaller pieces. The chopped tissue is added to a 15mL tube with a chilled lysis
buffer to break the cell membrane. The lysis buffer component concentrations and
incubation time lyses the cell membrane but does not affect the nuclear membrane. After
lysis, the tissue pieces are triturated, or broken into smaller pieces, by pipette mixing with
different sized fire-polished Pasteur pipettes, starting with the largest to smallest
diameter. Then, the tissue is passed through a 40µm filter to remove cell debris. The
nuclei are washed with a phosphate-buffered saline mixture, then resuspended with the
same buffer mixture.
This final sample can be stained with 7-aminoactinomycin D (7AAD), a
fluorescent solution that intercalates in DNA, which allows the nuclei to be easily viewed
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and counted on a hemocytometer. 7AAD typically will not stain live cells but is able to
intercalate with DNA in dissociated nuclei. Fluorescence-activated cell sorting (FACS)
can be performed on the sample to further isolate high-quality nuclei, which are needed
before proceeding with single nuclei RNA sequencing. When viewed in a hemocytometer
under the microscope, high quality nuclei will have a well-defined intact nuclear
membrane.

Fluorescence-Activated Cell Sorting (FACS)
Fluorescence-Activated Cell Sorting (FACS) is a technique to sort cells based on
fluorescence from staining, size, and granularity and yields a highly purified sample
(Basu et al., 2010). This method can also be used for nuclei sorting. Typically, the cells
are tagged with a fluorescently labelled antibody specific to a cell surface protein (Alexa
Fluor 488-conjugated anti-NeuN for single nuclei). Using high sensitivity flow cytometry
(such as the BD fascaria III sorter), the solution of cells or nuclei is passed as a droplet
stream in front of a fluorescence-detecting laser. When the specified fluorescence is
detected, the machine applies a charge to that droplet allowing it to be electrostatically
deflected and thus separated from non-charged droplets.
After FACS, the nuclei are placed in a saline solution. Therefore, an additional
step is needed to resupply the correct buffer. The nuclei are rinsed, pelleted, and again
resuspended in the same phosphate buffered saline mixture from the dissociation
protocol. The hemocytometer step is repeated to view the post-FACS sorted sample. The
final sample should have 1500 nuclei per µL and may require diluting the sample to the
correct concentration. At this point, the sample is ready for 10x Genomics Chromium
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Single Cell library preparation, then sent for sequencing on an Illumina NovaSeq 6000 at
a core laboratory.

Single Nuclei RNA Sequencing
10X Genomics Chromium Single Cell Library Preparation
After quality nuclei are dissociated, libraries are prepared for single nuclei RNA
sequencing using the 10X Genomics Chromium Single Cell 3’ Reagent Kit. Although
this step is not performed within the Cowan laboratory, it is helpful to understand the
complete process of snRNAseq from dissociation to final data output. For library
preparation, the first step of the 10X Chromium single-cell method is to generate Gel
Beads-in-Emulsions (GEMs) and barcode each individual cell or nuclei (10X Genomics,
2019). A pool of roughly 3.5 million unique barcodes (16 nucleotide sequences), the cell
or nuclei solution, reagents, and portioning oil are loaded onto the Chromium Next GEM
Chip G, which uses microfluidics at the nano-liter level to stream and combine one
individual cell and one individual unique barcode, creating GEMs (Figure 5.1). Further,
to ensure single-cell resolution, the cell solution is diluted so that most GEMs actually
contain no cell, and the remaining GEMs only contain one cell. The gel beads contain
primers consisting of an Illumina read 1 sequencing primer, the 16-nucleotide 10X
Barcode, a 12-nucleotide unique molecular identifier (UMI), and a 30-nucleotide
poly(dT) sequence. The poly(dT) is complementary to the poly-A tail of messenger RNA
(mRNA).
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Figure 5.2: Chromium Next GEM Chip G. Oil, cells combined with reagents, and beads
are loaded onto Chromium Next GEM Chip G. Within the GemCode platform, barcoded
gel beads are combined with cells and reagents to form GEMs. Reverse Transcription
PCR takes place inside each GEM, then cDNA is purified to undergo library preparation
steps.

Figure from Zheng et al., 2007. Reproduced with permission from Springer Nature via
the Creative Commons Attribution 4.0 International License
https://creativecommons.org/licenses/by/4.0/.

Next, the primers are released inside the GEM and a reverse transcription (RT)
master mix is added to convert the mRNA into barcoded cDNA (10X Genomics, 2019)
(Figure 5.2). Then, the GEMs themselves are broken to release the cDNA, which gets
amplified, enzymatically fragmented to a smaller size, and ligated with the Illumina
TruSeq Read 1 primer. The fragments undergo end repair to fill in fragment 5’ and 3’
overhangs and addition of an A-tail. Then, P5, P7, a sample index, and the Illumina
TruSeq Read 2 primer are ligated to the fragments. The P5 and P7 adapters are
complementary to adaptors in the Illumina sequencing kit for the sequencer instrument.
Lastly, there is a final PCR amplification step, resulting in the final Chromium Single
Cell 3’ libraries.
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Figure 5.3: 10X Genomics Chromium Single Cell 3’ Library Preparation Technique.

Illumina Sequencing by Synthesis
After library preparation, the libraries can be pooled, denatured, and loaded onto
the NovaSeq 6000 (or other specified Illumina sequencing platform). The first step on the
instrument is cluster generation (Illumina, 2017). The library fragments bind to the flow
cell oligo lawn, which consists of P5 and P7 oligos complementary to the ones
incorporated into the sample libraries. Each fragment is amplified into a cluster via bridge
amplification. The reverse strands are cleaved so sequencing by synthesis (SBS) can
occur on the forward strand. The instrument releases all four uniquely-fluorescent-tagged
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bases (A, T, C, G) simultaneously and when the correct base incorporates into the
growing strand, fluorescence is released and detected by the instrument. This process
continues until the entire complementary strand has been synthesized, or the specified
number of sequencing cycles met, and each incorporated base has been recorded by the
instrument. After sequencing the forward strand, bridge amplification occurs once more
to regenerate the reverse strand. The forward strand is this time cleaved for SBS to occur
on the reverse strand.

Single Nuclei RNA Sequencing Bioinformatics Analysis
The raw data generated by the Illumina sequencer undergoes the Cell Ranger
analysis pipeline to transform the raw data into workable data. The first step in this
pipeline is demultiplexing using the P7 indices to convert raw base calls into reads (What
Is Cell Ranger?, 2020). Next, reads are aligned to the mouse GRCm38/mm10 reference
genome. The reads are further demultiplexed using sample-specific indices that were
added during library preparation, which separates the data by library (which may
represent individual mice with their specific test conditions). The output file generated is
a feature-barcode matrix (where the features consist of data from the various genes,
separated out by sample-specific barcode).
This output file is then loaded into RStudio v4.0.2 for secondary analysis using
the Seurat 4.0.6 toolkit (Seurat – Guided Clustering Tool, 2022). Next, the data must
undergo a pre-processing workflow, including QC steps to filter out low-quality cells
(having less than 200 genes, as low-quality cells often have a very low gene count), cell

141

duplets and multiplets (GEMs that contained more than one cell, which bioinformatically
show extremely high gene count (value of over 2,500)), and dying cells (which show
>5% of mitochondrial gene counts). The quality reads remaining then undergo a
normalization step (such as using the “LogNormalize”) to correct for cells having
different sequencing depths from one another thus ensuring accurate comparisons
between cells. The next step is to identify highly variable features, or genes that are
highly expressed in some cells and lowly expressed in others, allowing the various cell
types within each test group to be separated in subsequent steps. This coding uses a
statistical calculation to distinguish the biological signal from technical noise (Seurat –
Guided Clustering Tool, 2022). Then, the data must be scaled using a linear
transformation to prevent highly expressed genes from dominating the downstream
analysis, giving equal chance to genes with lower expression. Alternatively, the SCT
normalization method can be used, which combines normalization, identifying highly
variable features, and scaling.
Using the variable features, Principal Component Analysis (PCA) is performed to
determine the dimensionality and see the variation and patterns within the data set. For N
number of cells, there are N-directions of variation, called principle components (PCs).
The PC with the highest variation is PC1, the second highest is PC2, and so forth. Given
the vast number of PCs in these datasets, the bioinformatician must figure out how many
PCs to take into consideration for analysis. The JackStrawPlot function is used to
visualize the p-values of each PC, allowing us to select significant PCs (those having low
p-values).
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The cells can finally be clustered using the “FindNeighbors” and “FindClusters”
codes and inputting the previously determined dimensionality of the dataset (i.e., the first
10 PCs) and a resolution parameter (typically in the range of 0.4-1.2). A higher resolution
results in a greater number of clusters. Uniform Manifold Approximation and Projection
(UMAP), a non-linear dimensional reduction technique, is used to construct a lowdimensional graph for visualization of the data. The resulting graph shows color-coded
clusters of cells, with cells within each cluster coming from the same cell type. Seurat
coding can also find cell-specific gene markers that define each cluster, allowing the user
to label each cluster by the cell type name. For example, “cluster 10” may have a high
expression of C1QA, a microglial marker. Therefore, “cluster 10” could be renamed as
“microglia”.
Further coding can be input to find differential gene expression between study
groups (such as wildtype versus Mef2c heterozygous mice). The researcher may choose
to focus solely on one cluster / cell type (such as microglia) and see differential gene
expression within that cell type between the study groups. For example, certain
microglial genes may be upregulated in Mef2c heterozygous mice as compared to wildtype mice, suggesting delayed microglial maturation. This pattern was noted on previous
unbiased RNAseq data (Harrington, Bridges, et al., 2020) and will be investigated further
using single nuclei RNAseq.
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Tissue Fixation Methods for Mice
Whole-body perfusion fixation of mice can be used to preserve tissue
throughout the entire body, after which the fixed tissue of interest (such as the brain) can
be extracted for downstream assays. This perfusion fixation method uses the circulatory
system of the mouse to deliver fixatives, penetrating every region of the body at a quick
and steady rate (Gage, Kipke, & Shain, 2012). This method is beneficial for larger
specimens as opposed to immersion fixation, which would not reach all regions of the
tissue in time before the biological responses to hypoxia commence.
First, the mice are weighed to determine the appropriate amount of anesthesia (a
mixture of ketamine at 100 mg/mL and xylazine at 20 mg/mL) to administer by
intraperitoneal injection. Before proceeding with perfusion, the mice should be
thoroughly checked for toe-pinch pain reflex. Once fully sedated (unresponsive to toepinch), the mouse is placed belly side up on a work block and the forepaws and hindpaws
are taped to the side. The work block is placed in a collection bin inside a chemical fume
hood (Figure 5.3). Using forceps, the skin on the stomach above the xiphoid process is
pulled up and a cut is made laterally using scissors. The next cut is through the
diaphragm, avoiding cutting any organs, then cut upwards through the ribs on both sides.
The resulting flap is clamped above the head to expose the liver and heart.
Next, a butterfly needle attached via tubing to a perfusion pump is inserted in the
left ventricle next to the apex. An incision is made in the right atrium to allow the blood
and perfusion buffers to drain. The pump is turned on and the valve switched on to allow
1X Phosphate Buffered Saline (PBS) perfusate to flow through the mouse. 1X PBS is
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used to flush the tissue and prevent fixing erythrocytes in place which would block access
to smaller vessels. The liver will turn white as blood is replaced with 1X PBS. After
about four minutes, the 1X PBS valve is closed and the 1.5% paraformaldehyde (PFA)
valve is opened with perfusion occurring for another four minutes. After completion, the
desired fixed tissues can be collected and stored.

Figure 5.4: Perfusion setup inside chemical fume hood, prior to attaching the lines and
handling the mice. Setup includes an ice bath with beakers to hold 1X PBS and 1.5%
PFA, collection bin in the middle to collect draining fluids during the procedure, racks
within the collection bin to act as a platform to hold the working block and mouse, and
perfusion pump and lines in the back right corner.
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Extraction of the Brain
For an extraction of either a fresh or fixed brain, the mouse is first decapitated.
The excess muscle is trimmed to help expose the back of the skull. Next, the skin is cut
down the midline to expose the top of the skull. Scissors are inserted through the foramen
magnum and carefully cut upwards through the skull to avoid damaging the brain
underneath. The scissors are gently pushed slightly behind the eyes and the blades slowly
opened to fully open the skull and expose the brain. The pieces of skull are pulled aside,
and forceps are slid under the brain to gently remove it from the cranium (Figure 5.4).
The brain is post-fixated in 1.5% PFA for one hour then transferred the brain into 1X
PBS + NaN3 for long-term storage.

Figure 5.5: Mouse brain extracted after perfusion fixation. Photo Credit: Jessica Cooley
Coleman.
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Brain Sectioning using Microtome
To section the fixed brain for downstream immunohistochemistry (IHC), the
microtome can be used. The microtome is an instrument containing a sharp knife that is
manually drawn across frozen tissue to cut the tissue into thin sections (Figure 5.5). The
desired thickness of each slice can be set, and after each pass of the knife the instrument
mechanically lowers the knife by the preset amount allowing uniformly cut sections.
First, the top row of a 24-well culture plate is filled with 1mL of 1X PBS NaN3 for postslicing storage. Next, the brain mounting platform is leveled, and dry ice is carefully
added into the surrounding trough using a spoon. The bottom portion of the fixed brain
(occipital lobe, or caudal section) is cut slightly with a razor blade to make a flat surface
for mounting onto the microtome platform. OCT (optimal cutting temperature
compound) is applied to the platform, and the brain must be quickly positioned in the
liquid before it freezes. The OCT and the brain must freeze completely (turn white)
before proceeding with sectioning (Figure 5.6).
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Figure 5.6: Microtome instrument (prior to installing the platform and knife). Photo
Credit: Jessica Cooley Coleman.
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Figure 5.7: A) Mounted fixed brain on the Microtome platform using OCT. B) The brain
was allowed to freeze completely before proceeding with sectioning. Photo Credit:
Jessica Cooley Coleman.

After the brain is completely frozen on the platform, the knife is installed and you
can proceed with making slices. A thin paintbrush is used to collect each brain slice and
alternating placing them across in the top row (6 wells) of the prefilled 24-well culture
dish. The dry ice should be replenished as necessary during slicing to keep the brain
frozen. Slicing continues until all desired brain regions are collected (Figure 5.7). The
brain slices can be stored in the refrigerator until IHC or other assays are performed.
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Figure 5.8: Brain during microtome slicing. Photo Credit: Jessica Cooley Coleman.

Immunohistochemistry
Immunohistochemistry is a technique to detect antigens present in sections of
tissue. To perform IHC, the brain sections are first washed with 1X PBS and then
incubated in a blocking solution consisting of serum (normal goat serum and normal
donkey serum) and proteins (bovine serum albumin, or BSA) to bind to reactive sites,
thus helping prevent non-specific antibody binding in subsequent steps. Next, the
sections are incubated overnight in a primary antibody solution specific to the antigen or
protein of interest (such as NeuN for neurons and Iba1 for microglia). After the overnight
incubation, the slices are washed then incubated with a fluorescently tagged secondary
antibody (such as Alexa Fluor 488 donkey anti-mouse). This secondary antibody is not
protein specific, and instead interacts with the primary antibody and delivers fluorescence
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to later image the cells. The slices are washed again and Hoechst or DAPI (4′,6diamidino-2-phenylindole) stain is added to stain the nucleus. This step ensures that cells
are stained, as now the cell membrane and nucleus are individually stained and both can
be viewed to help differentiate from potential debris. Finally, the slices are positioned
onto microscope slides, a few drops of ProLong Gold Antifade Mountant with additional
DAPI is placed on the slices, and a coverslip is placed on top (Figure 5.9). The slide is
allowed to cure for 24 hours then can be imaged. The fluorescence can be detected on a
light microscope to visualize the intended target (neurons) within the tissue sample
(Figure 5.10).

Figure 5.9: Brain slices arranged on a slide prior to addition of mountant. Photo Credit:
Jessica Cooley Coleman.
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Figure 5.10: Final images from immunohistochemistry of a wildtype mouse brain stained
with DAPI for cells (blue) and NeuN for neurons (green). A: Nissl (left) and anatomical
annotations (right) from the Allen Mouse Brain Atlas and Allen Reference Atlas - Mouse
Brain, at the same slice position as B. B: Brain section with prefrontal cortex (red box) at
5X. C: Prefrontal cortex at 40X. D: Nissl (left) and anatomical annotations (right) from
the Allen Mouse Brain Atlas and Allen Reference Atlas - Mouse Brain, at the same slice
position as E. E: Brain section with somatosensory cortex (upper red box) and
hippocampus (middle red circle) at 5X. F: Somatosensory cortex and hippocampus at
20X.
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Conclusion
Mef2c global and conditional heterozygous mice share phenotypic similarities
with human patients affected with MEF2C-related disorders, including repetitive
behaviors and social deficits. These similarities make the mouse an excellent animal
model to study the gene and the associated disorder. Nuclei dissociation with purification
by FACS, single nuclei RNAseq, whole mice body perfusion, fresh and fixed brain
extraction and slicing, and immunohistochemistry are some of the many current
techniques used to research Mef2c in mice. Performing single nuclei RNAseq can help
elucidate MEF2C’s role in the development and maturation of neurons, microglia, and
other cell types, and reveal gene dysregulation between wildtype and Mef2c heterozygous
mice.
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CHAPTER SIX
CONCLUSIONS

MEF2C-related disorders are neurodevelopmental disorders characterized by
intellectual disability, developmental delay, lack of speech, seizures, hypotonia, and brain
abnormalities. This disorder is rare with only 117 patients reported in the literature to
date, making the disorder difficult to recognize clinically. This research sought to
thoroughly describe the genotypes leading to MEF2C-related disorders, elucidate the
phenotypic features, and assess MEF2C’s role in gene regulation. The purpose of this
work is to advance what is known about MEF2C-related disorders with the goal of
improving diagnosis, patient care, and future development of treatments.
First, the MEF2C gene was described (Chapter 1), including its history and
discovery. The transcription factor MEF2C contains the highly conserved MADS domain
followed by the MEF2 domain (conserved across only the MEF2 family), which are
responsible for dimerization, cofactor binding, and DNA binding. We have described in
detail the structure of MEF2C, including exact amino acids encompassing the MADS and
MEF2 domains, total number of nucleotides, number of exons, and number of different
isoforms due to differential splicing found in the human body. We also covered the
history of MEF2C-related disorders. Additionally, we discussed methodologies for rare
disease research, specifically including concept analyses, systematic literature reviews,
natural history study surveys, and animal model studies (all of which are used in
subsequent chapters).
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In Chapter 2, we performed a concept analysis of tremors following the Walker &
Avant method (Walker & Avant, 2005). According to a February 2020 search, tremors
are associated with 594 potential genetic conditions and genes. MEF2C-related disorders
were not among this list; however, the literature reported at least two patients with
MEF2C-related disorders having tremors, one of whom had a periodic tremor in infancy
and the other had a childhood hand tremor. The concept of tremors has been complicated
by vague definitions and numerous categorization methods; therefore, we chose to
perform a concept analysis to clarify the concept and develop an operational definition of
tremors. Using the Walker and Avant method involved determining the aims of the
analysis and uses of the concept, defining attributes, highlighting a model case and other
cases, identifying the antecedents and consequences, and defining empirical referents.
This process allowed us to develop an operational definition that tremors are a movement
disorder characterized by shaking motions that are involuntary, oscillatory, rhythmic,
non-painful, always present although variable in severity, and can be repressed by
changing posture or going into a rest position. This concept analysis will assist providers,
nurses, and researchers to correctly recognize and categorize tremors and provide the best
treatment and care to their patients. This concept analysis was peer reviewed and
published Nursing Open in 2021 (Cooley Coleman et al., 2021a).
To further investigate the symptoms, features, and overall phenotype of MEF2Crelated disorders, we performed a systematic literature review (Chapter 3) to answer the
research question: What is the comprehensive phenotype of all human patients reported
in the literature with a MEF2C-related disorder? We derived keywords and MeSH terms
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from the research question to search Web of Science, PubMed, and MEDLINE for
articles meeting our inclusion criteria. A total of 43 articles met the inclusion criteria and
were fully reviewed, revealing phenotypic information on 117 patients with MEF2Crelated disorders. Most patients had features including intellectual disability,
developmental delay, seizures, hypotonia, absent speech, inability to walk, stereotypic
movements, and MRI abnormalities. We also found cardiac issues to be of higher
prevalence than previously appreciated. Non-classical features included a question mark
ear, jugular pit, and a unique neuroendocrine finding. Additionally, we found nine
patients with the phenotype of MEF2C-related disorders who had deletions not
containing MEF2C, revealing a potential positional effect. This systematic review further
characterizes the disorder, providing information that healthcare providers can use to
better diagnose and care for patients. This review was published in the American Journal
of Medical Genetics, Part A in 2021 (Cooley Coleman et al., 2021b).
Next, we developed a natural history study in the format of a parent survey to
gather additional developmental and clinical information on a large single cohort of
patients with MEF2C-Related Disorders (Chapter 4). A total of 73 parents completed the
survey. Limited speech (82.1%), seizures (86.3%), bruxism (87.7%), repetitive
movements (94.5%), and high pain tolerance (79.5%) were some of the prominent
features. Additionally, these features and percentages were closely aligned with those
revealed by the literature review. A total of 39.7% of parents reported a MEF2C variant
and 54.8% reported a deletion involving MEF2C. Statistical analyses showed patients
with MEF2C variants were similarly affected as those with deletions, and females
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showed higher verbal abilities. This study obtained comprehensive phenotypic
information on the largest single cohort of patients with a MEF2C-related disorder. The
information provided by the study can be useful to healthcare providers in diagnosing and
caring for patients and can also be a valuable resource for researchers performing
additional analysis (such as genotype-phenotype correlations) or developing further
studies. This study was accepted for publication in Molecular Genetics & Genomic
Medicine (Cooley Coleman et al., 2022).
Finally, we used the mouse as an animal model to investigate MEF2C’s role in
expression and gene regulation in the brain. Previous unbiased RNA sequencing showed
a dysregulation of genes associated with microglia, excitatory neurons, and autism
spectrum disorder risk genes in Mef2c global heterozygous mice compared to control
mice. To further investigate the role of MEF2C within microglia and GABAergic subtype
neurons, we decided to pursue single nuclei RNA sequencing (snRNAseq). The
workflow entails performing nuclei dissociation on dissected sections of the brain
(particularly prefrontal cortex), purifying the nuclei using Fluorescence-Activated Cell
Sorting (FACS), and sending the sample off for library preparation and single nuclei
RNA sequencing. When the data is returned by the sequencing core lab, bioinformatic
analysis is performed to cluster the data into cell types in order to investigate differential
gene expression within microglia and GABAergic neurons. This study is still ongoing,
and results will be a part of a larger publication in the future. We also learned other
current laboratory techniques including perfusion fixation, brain extraction and slicing,
and immunohistochemistry.
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Throughout this research, we have expanded on the phenotype through a concept
analysis, systematic literature review, and natural history study parent survey. We have
also thoroughly cataloged the pathogenic alterations (genotype) of patients having
MEF2C-related disorders reported in the literature. The data from both our literature
review and parent survey can be useful for future genotype-phenotype correlation studies.
Of the 43 manuscripts identified in the literature review, some manuscripts focused on a
specific feature (i.e. cardiac issues); therefore, some features or symptoms may not have
been reported, which changed our N for each feature (as we could not assume the patient
lacked that symptom just because it was not mentioned). One future direction could entail
contacting the authors of these 43 manuscripts to gather the same clinical information
across all reported patients. This would allow a more accurate assessment of the
phenotype, prevalence of each feature, and allow for more statistical analyses.
Other future directions could include initiating a clinical longitudinal study of
individuals with MEF2C-related disorders. Our survey could work as a baseline for such
a study, with a similar survey being sent out at another time frame (i.e. 5 years later) to
measure any changes over time. It would also be beneficial to have additional
information on adults with a MEF2C-related disorder, as most individuals from the
systematic review and survey were in the childhood range. A longitudinal study of
individuals would allow capturing information of current patients as adults in the future.
The longitudinal study could be based on more parent surveys, or the patients could be
seen clinically (in person or via telemedicine) to allow for gathering objective
information by a healthcare provider. Another future project could entail performing a
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quality of life assessment for individuals with a MEF2C-related disorder. A MEF2Crelated disorders online patient registry could be beneficial in housing the information
obtained from these studies. Lastly, additional functional studies on MEF2C, such as
those being performed by the Cowan laboratory, will advance the knowledge about
MEF2C and MEF2C-related disorders. Ultimately, it is our hope that this research and
future research studies will advance our knowledge, guide treatment development, and
help improve the lives of people with MEF2C-related disorders.
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Appendix A
Abbreviations
7AAD: 7-aminoactinomycin D
ADHD: Attention deficit hyperactivity disorder
AHA: Acquired hemophilia A
ASD: Autism spectrum disorder
bHLH: Basic-helix-loop-helix
BSA: Bovine serum albumin
BU: Bethesda units
CNV: Copy number variation
CoCoPop: Condition, Context, and Population
DAPI: 4′,6-diamidino-2-phenylindole
DBS: Deep brain stimulation
DCM: Dilated cardiomyopathy
ddNTPs: Dideoxynucleotides
DNA: Deoxyribonucleic acid
dNTPs: Deoxynucleotides
DORV: Double outlet right ventricle
EEG: Electroencephalogram
ERG: Electroretinograms recording
ET: Essential tremor
FACS: Fluorescence-Activated Cell Sorting

165

FISH: Fluorescence in situ hybridization
FORWARD: Fragile X Online Registry with Accessible Research Database
FTM: Fahn-Tolosa-Marin Tremor Rating Scale
FXTAS: Fragile X-associated tremor/ataxia syndrome
GEMs: Gel beads-in-emulsions
GERD: Gastroesophageal reflux disease
GGC: Greenwood Genetic Center
IACUC: Institutional Animal Care and Use Committee
IHC: Immunohistochemsitry
IRB: Institutional Review Board
MADS-box region: from the first four protein member identified in this group, MCM1,
AG, DEFA, and SRF
MARRVEL: Model Organism Aggregated Resources for Rare Variant ExpLoration
MCHS: MEF2C Haploinsufficiency Syndrome
MDS-UPDRS: Movement Disorder Society United Parkinson’s Disease Rating Scale
MEF2: MADS box transcription enhancer 2
MEF2A: MADS box transcription enhancer 2A
MEF2B: MADS box transcription enhancer 2B
MEF2C: MADS box transcription enhancer 2C
MEF2D: MADS box transcription enhancer 2D
MRI: Magnetic resonance imaging
mRNA: Messenger RNA
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MUSC: Medical University of South Carolina
NGS: Next generation sequencing
NIH: National Institute of Health
NPY: Neuropeptide Y
OCT: Optimal cutting temperature compound
OHRP: Office for Human Research Protections
OMIM: Online Mendelian Inheritance in Man
PBS: Phosphate buffered saline
PCA: Principal component analysis
PCs: Principal components
PDA: Patent ductus arteriosus
PECS: Picture exchange communication system
PFA: Paraformaldehyde
PFC: Prefrontal cortex
PICO: Patient/Population problem, Intervention, Comparison or Control, Outcome
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PS: Pulmonary stenosis
QUEST: Quality of Life in Essential Tremor Questionnaire
REDCap: Research Electronic Data Capture
RNA: Ribonucleic acid
RT: Reverse transcription
SBS: Sequencing by synthesis
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scRNAseq: Single cell RNA sequencing
SD: Standard deviation
SNP: Single nucleotide polymorphism
snRNAseq: Single nuclei RNA sequencing
SNV: Single nucleotide variant
SPECT: Single-photon emission computerized tomography
SSRIs: Selective serotonin reuptake inhibitors
TETRAS: The Essential Tremor Rating Assessment Scale
UMAP: Uniform manifold approximation and projection
UMI: Unique molecular identifier
UTRs: Untranslated region
VSD: Ventricular septal defect
WHIGET: Washington Heights-Inwood Genetic Study of Essential Tremor
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Appendix B
Supplemental PROSPERO Systematic Literature Review Protocol

Comprehensive Investigation of the Phenotype of MEF2C-Related Disorders in
Human Patients: A Systematic Review.
Jessica A. Cooley Coleman
Citation
Cooley Coleman, Jessica A.. Comprehensive Investigation of the Phenotype of MEF2CRelated Disorders in Human Patients: A Systematic Review. PROSPERO 2021
CRD42021238965
Available from:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021238965

Review question
What is the comprehensive phenotype of human patients with MEF2C-related disorder?
Searches
The following electronic databases will be searched: Web of Science, PubMed, and
MEDLINE.
The search strategy will include only terms relating to the framework. The search terms
will be adapted for database-specific filters. The search will only include peer-reviewed
publications. There will be no restriction to publication dates. Only articles in the English
language will be included.
Concept (CoCoPop)
Co: Condition
MEF2C-related disorder

Keywords
“MEF2C” OR “MEF2C-related
disorder” OR “MEF2C
haploinsufficiency”

Co: Context
Phenotype

“phenotype” OR “present*”
OR “presentation” OR
“clinical presentation” OR
“feature*” OR “character*”
“human” OR “patient” OR
“male” OR “female”

Pop: Population
Human Patients

MeSH terms
Haploinsufficiency (MeSH
term to only be used in
conjunction with “AND
MEF2C”)
Phenotype

Humans OR Patients OR
Male or Female

PubMed:
((((MEF2C[Title/Abstract] OR MEF2C-related disorder[Title/Abstract] OR
MEF2C haploinsufficiency[Title/Abstract] OR (MEF2C[Title/Abstract] AND
Haploinsufficiency[MeSH Terms])) AND (phenotype OR present* OR presentation
OR clinical presentation OR feature* OR character* OR phenotype[MeSH
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Terms])) AND (human OR patient OR male OR female OR Humans[MeSH Terms]
OR Patients[MeSH Terms] OR Male[MeSH Terms] OR Female[MeSH Terms])))
MEDLINE:
AB ( MEF2C OR “MEF2C-related disorder” OR “MEF2C haploinsufficiency” OR (MH
haploinsufficiency AND MEF2C)) AND ( phenotype OR present* OR presentation OR
“clinical presentation” OR feature* OR character* OR MH Phenotype ) AND (human
OR patient OR male OR female OR MH humans OR MH patients OR MH Male OR MH
Female )
Web of Science:
TOPIC: (MEF2C OR “MEF2C-related disorder” OR "MEF2C haploinsufficiency")
AND TOPIC: (phenotype OR present* OR presentation OR clinical presentation OR
feature* OR character*) AND TOPIC: (human OR patient OR male OR female)

Types of study to be included
Any study type that includes phenotypic information on human cases of MEF2C-related
disorder will be included for review. Cell or animal studies will be excluded.
Condition or domain being studied
MEF2C-related disorders, also referred to as MEF2C haploinsufficiency disorder.
Participants/population
Individuals of any age with a diagnosis MEF2C-related disorders, also referred to as
MEF2C haploinsufficiency disorder confirmed by genetic testing.
Intervention(s), exposure(s)
Phenotype of individuals with a MEF2C-related disorder.
Comparator(s)/control
No control conditions are required.
Main outcome(s)
To compile an up-to-date list of reported patients and their phenotypes in order to further
characterize the phenotype of the disorder.
Additional outcome(s)
None.
Data extraction (selection and coding)
Search results from the three databases will be saved into one library using the reference
manager Zotero. Duplicate records will be removed.
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Titles and/or abstracts of studies retrieved will be screened by two review authors to
identify articles that may meet the inclusion criteria. For the articles that pass the
title/abstract review, the full text will be retrieved and independently assessed by two
review team members. Any disagreement between the two reviewers will be resolved
through discussion with a third reviewer.
Data extracted from the articles will include the study design, study population,
population demographics, population phenotypic information, as well as any other useful
information pertaining to the patient’s disorder.
Risk of bias (quality) assessment
Two review authors will independently assess the articles, thus decreasing the risk of bias
of the articles included in the study.
Strategy for data synthesis
A qualitative synthesis of the phenotypic findings from the included studies will comprise
the data synthesis.
Analysis of subgroups or subsets
None.
Contact details for further information
Jessica A. Cooley Coleman
cooley8@g.clemson.edu
Organizational affiliation of the review
Clemson University, Greenwood Genetic Center.
Review team members and their organizational affiliations
Jessica A. Cooley Coleman, MB(ASCP)CM, Doctoral Student, School of Nursing,
Clemson University
Sara M. Sarasua, PhD, MSPH, Assistant Professor, School of Nursing, Clemson
University
Luigi Bocutto, MD, Lecturer, School of Nursing, Clemson University
Hannah Warren Moore, MS, CGC, Clinical Genetic Counselor, Greenwood Genetic
Center
Steven Skinner, MD, Director, Greenwood Genetic Center
Jane M. DeLuca PhD, RN, CPNP, Associate Professor, School of Nursing, Clemson
University
Type and method of review
Systematic review
Anticipated or actual start date
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29 September 2020
Anticipated completion date
31 March 2021
Funding sources/sponsors
None.
Conflicts of interest
None.
Language
English
Country
United States of America
Stage of review
Review Ongoing
Subject index terms
MEF2C, MEF2C-related disorders, MEF2C haploinsufficiency
Date of registration in PROSPERO
25 March 2021
Date of first submission
23 February 2021
Stage of review at time of this submission
Review Ongoing
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Appendix E
Supplemental Tables for “Clinical Findings from the Landmark MEF2C-Related
Disorders Natural History Study”
Authors: Jessica A. Cooley Coleman1, 2, Sara M. Sarasua1, Hannah Warren Moore2, Luigi
Boccuto1, Christopher W. Cowan3, Steven A. Skinner2, Jane M. DeLuca1, 2
1
School of Nursing, Clemson University, 2Greenwood Genetic Center, 3Department of
Neuroscience, Medical University of South Carolina
Clinical Genetics, 2021.

Table S1: Overall Responses to the MEF2C Natural History Study
Totals (N=73)
Who is Completing the Survey
Parent
Child’s Gender
Female
Male
Ethnicity
Hispanic, Latino, or Spanish origin
Not Hispanic, Latino, or Spanish origin
Unknown
Race
White or Caucasian
Black or African American
Asian
American Indian or Alaskan Native
Unknown
Child’s Current Age
Infant (9 months to < 24 months)
Preschool (2 years to < 6 years)
Child (6 years to < 13 years)
Adolescent (13 years to < 19 years)
Adult (19 years to < 45 years)
Average
Range
Child’s Current Weight
Average
Range
Child’s Current Height

73 (100%)
35 (47.9%)
38 (52.1%)
6 (8.2%)
63 (86.3%)
4 (5.5%)
67 (91.7%)
3 (4.1%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
8 (11.0%)
36 (49.3%)
11 (15.1%)
10 (13.7%)
8 (11.0%)
8.12 yr (SD 7.21 yr)
9 mo – 38 yr
25.4 kg
8.8 – 96.2 kg
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Average
Range
Gestational Age
Before 38 weeks
38-42 weeks
After 42 weeks
Birth Weight
Extremely low birth weight (less than 0.992kg)
Very low birth weight (between 0.993kg and 1.616kg)
Low birth weight (between 1.617kg and 2.495kg)
Normal birth weight (between 2.496kg and 3.997kg)
High birth weight (greater than 3.997kg)
Mother’s Age When Child Was Born
Average
Range
Father’s Age When Child Was Born
Average
Range
Pregnancy Exposures
Tobacco
Secondhand Smoke
Alcohol
Chemicals
Prescription Medicine
(zofran, ranitidine, sertraline, levothyroxine, antibiotics,
nifedipine, oxycontin, amoxicillin, lovenox)
Unknown
Other
(Linoleum glue, lawn pesticides, hair chemicals, fast food smoke,
laboratory chemicals, waste incineration, progesterone
suppositories, Wifi)
Not answered
Pregnancy Complications
Premature labor
Preeclampsia
Low amniotic fluid
Gestational diabetes
Placenta Previa
Illness/ Infection
Unknown
Other
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1.17 m
0.71 – 1.75 m
18 (24.7%)
55 (75.3%)
0 (0%)
1 (1.4%)
0 (0%)
13 (17.8%)
57 (78.1%)
2 (2.7%)
31.8 yr (SD 5.12 yr)
20-41 yr
33.6 yr (SD 7.07 yr)
21-57 yr
25 (34.2%)
6 (8.2%)
6 (8.2%)
4 (5.5%)
1 (1.4%)

9 (12.3%)
1 (1.4%)

7 (9.6%)
4 (5.5%)
30 (41.1%)
6 (8.2%)
4 (5.5%)
1 (1.4%)
3 (4.1%)
0 (0.0%)
4 (5.5%)
2 (2.7%)
19 (26.0%)

(intrauterine growth restriction (IUGR), vaginal bleeding, loss of
twin, dilated fetal kidneys, hypertension, polyhydramnios,
maternal wrist fracture, subchorionic hemorrhage, cerebral
abnormalities, preterm contractions, single umbilical artery, fetal
intestine cyst, nuchal fold, breech)
Not answered
Birth Complications
Breech position
Failure to Progress
Fetal meconium aspiration
Fetal Distress
Unknown
Other
(Oxygen deprivation, forceps delivery, vacuum delivery, long
labor, cesarean, neonatal jaundice, maternal hemorrhaging,
external cephalic version, reduced/absent fetal movement, probe
to find heartbeat, absent dropping, resuscitation, fetal ejection
reflex, retained placenta, cervix dilation failure,
hyperbilirubinemia)
Not answered
Developmental
Roll over
Sit up
Crawl
Reach for objects
Transfer items from hand to hand
Pincer grasp
Finger feed self
Feed self using utensils (>18 months of age)
Gestures or waves
Points for wants
Follows commands
Diagnosed with intellectual disability
Language
Nonverbal/ no signs
Nonverbal but using signing in a meaningful way
Babbling/vocalizations
A small number of words or signs for minimal communication
Series of single words or 2-word combinations used meaningfully
Phrases/sentences of 3 words or more
Alternate Speech Methods
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2 (2.7%)
35 (47.9%)
6 (8.2%)
8 (11.0%)
4 (5.5%)
14 (19.2%)
1 (1.4%)

16 (21.9%)
2 (2.7%)
N=73
66 (90.4%)
59 (80.8%)
45 (61.6%)
60 (82.2%)
53 (72.6%)
17 (23.3%)
33 (45.2%)
15 (21.7%)
22 (30.1%)
13 (17.8%)
28 (38.4%)
54 (74.0%)
N=73
26 (35.6)
6 (8.2)
33 (45.2)
6 (8.2)
1 (1.4)
1 (1.4)
N=71*

Signing
Picture exchange communication system (PECS) or equivalent
Apps on an iPad/iPhone, smart phone, or tablet
Augmentative communication device
Other
(hand leading, singing nursery rhymes, and vocalizations for
agreement, annoyance, and attention)
None of the above
Motor
Runs Unaided
Walks Unaided
Walks with Support
Stands Unaided
Stands with Support
Crawls
Sits Unaided
Sits with Support
Rolls
Unable to Roll
If walking, walking unsteady
Yes
Muscle Tone
Normal
Low muscle tone
Increased muscle tone
Toilet trained
Bowel and urine
Bowel only
Urine only
Time trained only
No
Social
Likes giving affection
Likes receiving affection
Resists holding hands
Reduced concern with environmental threat
Seek social interaction
Recognizes family
Poor eye contact
Attention problems
Hyperactivity
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14 (19.2%)
19 (26.0%)
9 (12.3%)
12 (16.4%)

4 (5.5%)
36 (49.3%)
N=73
6 (8.2)
22 (30.1)
12 (16.4)
0 (0.0)
7 (9.6)
4 (5.5)
9 (12.3)
8 (11.0)
4 (5.5)
1 (1.4)
N=49
40 (81.6%)
N=73
14 (19.2%)
53 (72.6%)
6 (8.2%)
N=73
1 (1.4%)
0 (0.0%)
0 (0.0%)
7 (9.6%)
65 (89.0%)
50 (68.5%)
58 (79.5%)
40 (54.8%)
53/67 (79.1%)
34 (46.6%)
52 (71.2%)
44 (60.3%)
50/71 (70.4%)
27/72 (37.5%)

Anxiety
Diagnosed with autism
Sensory Systems
Vision impairments
Hearing impairments
(bilateral sensorineural hearing loss, deafness in one ear, mild to
moderate loss of certain tones, moderate mixed hearing loss)
Sensitive to loud noises
High pain tolerance
Sensitivity to clothing textures
Issues with food textures
Vision Impairment Types
Myopia
Hyperopia
Problems with depth perception
Cortical visual impairment
Strabismus
Other
(esotropia, nystagmus, astigmatism, or wrote that they were
unsure of their child’s potential vision impairment)
Temperature Sensitivity
Yes, to heat
Yes, to cold
Yes, both heat and cold
No
Sleep Issues
Falling asleep: yes, currently
Falling asleep: yes, previously but no longer an issue
Staying asleep: yes, currently
Staying asleep: yes, previously but no longer an issue
Take medications to help with sleeping
Medicines: melatonin, Zonegran, Cicardin, Clonidine, Gabapentin,
Trazadone, Cyproheptadine, in addition to essential oils and CBD and
CBN oil.
Medical Conditions
Diabetes
Congenital heart defect
Asthma or other respiratory issues
Thyroid problems
Sleep apnea
Other
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12/70 (17.1%)
18/70 (25.7%)
44/72 (61.1%)

6/72 (8.3%)
45 (61.6%)
58 (79.5%)
5 (6.8%)
26/71 (36.1%)
N=44
12 (27.3%)
13 (29.5%)
17 (38.6%)
17 (38.6%)
21 (47.7%)

7 (15.9%)
N=73
20 (27.4%)
3 (4.1%)
17 (23.3%)
33 (45.2%)
N=73
31 (42.5%)
23 (31.5%)
36 (49.3%)
20 (27.4%)
28 (38.4%)

N=73
0 (0.0%)
5 (6.8%)
8 (11.0%)
1 (1.4%)
4 (5.5%)
24 (32.9%)

(hypoglycemia, hip dysplasia, laryngomalacia, tracheomalacia,
eosinophilic esophagitis due to allergy, dermatitis, atrial septal
defect, ventricular septal defect, hypotonia, pre-osteoporosis,
pectus excavatum, congenital diaphragmatic hernia, and
undescended testicles)
None
Digestion Issues
Diarrhea
Constipation
Reflux
Gall bladder dysfunction
Abdominal distention/ bloating
Other
(potential undiagnosed reflux, milk protein intolerance, extreme
slow intestinal motility, and food intolerances that cause painful
bloating and gas)
None
Health Related
Scoliosis
Hyper flexibility
Regressions
Puberty
Frequent illnesses
Improvement in skills with a fever
Seizures
Taking medications for seizures
Seizure medications helped
Neuropsychological
Tremors
Hyperventilation
Breath holding
Swallowing air
Food pocketing
Problems with chewing and swallowing
Teeth grinding
Repetitive hand movements
Fascination with water
Recurrent Immune-related Problems or Frequent Illness
Frequent illnesses
Frequent fevers
Severe allergic reactions
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41 (56.2%)
N=73
10 (13.7%)
52 (71.2%)
30 (41.1%)
0 (0.0%)
10 (13.7%)

9 (12.3%)
11 (15.1%)
N=73
9 (12.3%)
52 (71.2%)
25 (34.2%)
19 (26.0%)
31 (42.5%)
12 (16.4%)
63 (86.3%)
38/62 (61.3%)
37/38 (97.4%)
22 (30.1%)
22 (30.1%)
25/72 (34.7%)
19/72 (26.4%)
27/72 (37.5%)
48 (65.8%)
64 (87.7%)
69 (94.5%)
50/72 (69.4%)
N=31
26 (83.9%)
13 (41.9%)
3 (9.7%)

Joint inflammation
Skin issues (such as eczema)
Other
(respiratory infections, tonsilitis, frequent colds and pneumonia,
and chronic ear infections)
Seizure Type
Generalized
Partial
Febrile
Other
(generalized tonic-clonic, absence, drop or atonic, myoclonic
seizures and jerks, atypical complex febrile, infantile spasms)
Unknown
Seizure occurrence
More than one a day
Daily
Weekly
Monthly
Less than monthly
No seizures currently
Taking Seizure Medications
Yes
Medicine: Keppra (20), valproic acid (9), clobazam (6), topiramate
(5), and oxcarbazepine (4), CBD oil (4), cannabidiol (2), diazepam
(2), ethosuximide (2), ketogenic diet (2), lamotrigine (2), baclofen
(1), brivaracetam (1), clonazepam (1), midazolam (1), phenobarbital
(1), prednisone (1), vigabatrin (1), zonisamide (1)
Previous Imaging
MRI
Abnormal MRI
Specific MEF2C alteration type
Variant (point mutation or INDEL)
Deletion involving the MEF2C gene
Uncertain
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0 (0.0%)
9 (29.0%)

6 (19.4%)
N=62
16 (25.8%)
5 (8.1%)
21 (33.9%)

17 (27.4%)
3 (4.8%)
N=61
10 (16.4%)
7 (11.5%)
1 (1.6%)
2 (3.3%)
13 (21.3%)
28 (45.9%)
N=63
38 (61.3%)

69/72 (95.8%)
40/68 (58.8%)
N=73
29 (39.7%)
40 (54.8%)
4 (5.5%)

Table S2: Developmental Milestones by Age Group
Roll over
Age Group
N=73
Infant (9 months to
9
<24 months)
Preschool (>2 years
35
to <6 years)
Child (>6 years to
11
<13 years)
Adolescent (>13
10
years to <19 years)
Adult (>19 years to
8
<45 years)

Age Group
N=73
Infant (9 months to
9
<24 months)
Preschool (2 years
35
to <6 years)
Child (6 years to
11
<13 years)
Adolescent (13
10
years to <19 years)
Adult (19 years to
8
<45 years)

Sit Up

Reach for
Objects

Crawl

Yes

No

Yes

No

Yes

No

Yes

No

7

2

4

5

2

7

5

4

34

1

27

8

23

12

29

6

9

2

10

1

9

2

9

2

9

1

10

0

6

4

9

1

7

1

8

0

5

3

8

0

Transfer
Items from
Hand to
Hand
Yes
No

Uses Pincer
Grasp

Finger Feeds
Self

Feeds Self
Using Utensils

Yes

No

Yes

No

Yes

No

4

5

2

7

2

7

1

8

26

9

8

27

13

22

5

30

7

4

4

7

7

4

2

9

8

2

2

8

6

4

3

7

8

0

1

7

5

3

4

4
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Table S3: Proportions of patients >2 years of age able to use words to communicate
(either “a small number of words or signs for minimal communication”, “series of single
words of 2-word combinations used meaningfully, or “phrase/sentences of 3 words or
more”) by alteration type, gender, and age group.
Total
Group (N)

Uses
Words

Does Not Use
Words

Association
Test p-value

1- Alteration Type
Deletion
Variant

62
36
26

2 (5.6%)
5 (19.2%)

34 (94.4%)
21 (80.8%)

0.1194†
-

2- Gender
Male
Female

64
34
30

0 (0.0%)
7 (23.3%)

34 (100.0%)
23 (76.7%)

0.0033†*
-

3- Age Group
Preschool (2 years to <6 years)
Child (6 years to <13 years)
Adolescent (13 years to <19
years)
Adult (19 years to <45 years)

64
35
11

1 (2.9%)
2 (18.2%)

34 (97.1%)
9 (81.8%)

0.0416§*
-

10

2 (20.0%)

8 (80.0%)

-

8

2 (25.0%)

6 (75.0%)

-

Variable

* Significant at p<0.05
† Fisher's Exact Test
§ Cochran-Armitage Trend Test
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Table S4: Proportions of patients >18 months of age able to walk by alteration type,
gender, and age group.
Total Group
(N)

Able to
Walk

Unable to
Walk

Association Test
p-value

1- Alteration Type
Deletion
Variant

65
38
27

17 (44.8%)
17 (63.0%)

21 (55.3%)
10 (37.0%)

0.2083†
-

2- Gender
Male
Female

67
36
31

15 (41.7%)
20 (64.5%)

21 (58.3%)
11 (35.5%)

0.0867†
-

3- Age Group
Infant (>18 months to
<24 months)
Preschool (2 years to
<6 years)
Child (6 years to <13
years)
Adolescent (13 years
to <19 years)
Adult (19 years to
<45 years)

67

-

-

0.0483§*

3

1 (33.3%)

2 (66.7%)

-

35

14 (40.0%)

21 (60.0%)

-

11

8 (72.7%)

3 (27.3%)

-

10

6 (60.0%)

4 (40.0%)

-

8

6 (75.0%)

2(25.0%)

-

Variable

* Significant at p<0.05
† Chi-Square Test
§ Cochran-Armitage Trend Test
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Table S5: Proportions of respondents reporting hyperactivity and anxiety by alteration
type, gender, and age group.
Does your child have hyperactivity?
Total
Group (N)

Yes

No

Association
Test p-value

1- Alteration Type†
Deletion
Variant

68
39
29

12 (30.8%)
15 (51.7%)

27 (69.2%)
14 (48.3%)

0.0807
-

2- Gender†
Male
Female

72
37
35

14 (37.8%)
13 (37.1%)

23 (62.2%)
22 (62.9%)

0.9515
-

3- Age Group§
Infant (9 months to <24 months)
Preschool (2 years to <6 years)
Child (6 years to <13 years)
Adolescent (13 years to <19 years)
Adult (19 years to <45 years)

72
8
35
11
10
8

1 (12.5%)
14 (40.0%)
7 (63.6%)
2 (20.0%)
3 (37.5%)

7 (87.5%)
21 (60.0%)
4 (36.4%)
8 (80.0%)
5 (62.5%)

0.5971
-

Variable

Does your child have anxiety?
Total
Group (N)

Yes

No

Association
Test p-value

1- Alteration Type†
Deletion
Variant

66
37
29

6 (16.2%)
6 (20.7%)

31 (83.8%)
23 (79.3%)

0.6400
-

2- Gender†
Male
Female

70
37
33

5 (13.5%)
7 (21.2%)

32 (86.5%)
26 (78.8%)

0.3936
-

3- Age Group§
Infant (9 months to <24 months)
Preschool (2 years to <6 years)
Child (6 years to <13 years)
Adolescent (13 years to <19 years)
Adult (19 years to <45 years)

70
7
34
11
10
8

0 (0.0%)
6 (17.7%)
2 (18.2%)
2 (20.0%)
2 (25.0%)

7 (100.0%)
28 (82.3%)
9 (81.8%)
8 (80.0%)
6 (75.0%)

0.6655
-

Variable

† Chi-Square Test
§ Cochran-Armitage Trend Test
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Table S6: Proportions of respondents reporting seizures by alteration type, gender, and
age group.
Does your child have seizures?
Total
Group (N)

Yes

No

Association
Test p-value

1- Alteration Type†
Deletion
Variant

69
40
29

37 (92.5%)
25 (86.2%)

3 (7.5%)
4 (13.8%)

0.3928
-

2- Gender†
Male
Female

73
38
35

34 (89.5%)
29 (82.9%)

4 (10.5%)
6 (17.1%)

0.4114
-

3- Age Group§
Infant (9 months to <24 months)
Preschool (2 years to <6 years)
Child (6 years to <13 years)
Adolescent (13 years to <19 years)
Adult (19 years to <45 years)

73
9
35
11
10
8

7 (77.8%)
30 (85.7%)
11 (100.0%)
9 (90.0%)
6 (75.0%)

2 (22.2%)
5 (14.3%)
0 (0.0%)
1 (10.0%)
2 (25.0%)

0.8165
-

Variable

† Chi-Square Test
§ Cochran-Armitage Trend Test
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Table S7: Proportions of respondents reporting an abnormal MRI by alteration type,
gender, and age group.
Abnormal MRI?
Total
Group (N)

Yes

No

Association
Test p-value

1- Alteration Type†
Deletion
Variant

64
37
27

23 (62.2%)
15 (55.6%)

14 (37.8%)
12 (44.4%)

0.5951
-

2- Gender†
Male
Female

68
37
31

23 (62.2%)
17 (54.8%)

14 (37.8%)
14 (45.2%)

0.5411
-

3- Age Group§
Infant (9 months to
<24 months)
Preschool (2 years to
<6 years)
Child (6 years to <13
years)
Adolescent (13 years
to <19 years)
Adult (19 years to
<45 years)

68

-

-

0.0669

8

4 (50.0%)

4 (50.0%)

-

34

17 (50.0%)

17 (50.0%)

-

10

7 (70.0%)

3 (30.0%)

-

9

7 (77.8%)

2 (22.2%)

-

7

5 (71.4%)

2 (28.6%)

-

Variable

† Chi-Square Test
§ Cochran-Armitage Trend Test
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Appendix F
IRB Documents for MEF2C-Related Disorders Natural History Survey

MEF2C-Related Disorders Natural History Survey Project Protocol
A. Background and Significance
MEF2C-related disorders are neurodevelopmental disorders caused by
pathogenic variants in the MEF2C gene or by microdeletions or duplications of
the 5q14.3 region containing part or all of the MEF2C gene. These disorders
display some similarities to Rett syndrome and other neurodevelopmental
disorders. It is characterized by intellectual disability, lack of verbal language,
motor delay, abnormal movements, autistic behaviors, and often epilepsy
(Paciorkowski et al., 2014). The available literature regarding MEF2C-related
disorders is limited with only approximately 90 variants being described to date.
A larger scale study would be beneficial to gather additional data and improve
the clinical description.
The goal of this research is to gather information about MEF2C-related disorders
by collection of developmental and medical history by use of a survey designed
for parents of children with this condition. Researchers at the Greenwood
Genetic Center, Clemson University, and the Medical University of South
Carolina will analyze and report the data collected by the surveys to raise
awareness and increase knowledge regarding MEF2C-related disorders. This
information could assist clinicians in better recognizing and diagnosing patients,
and could better prepare researchers for clinical trials or drug development.

B. Design and Methods
(1)

Study Design
This study will involve researchers at Greenwood Genetic Center, Clemson
University, and the Medical University of South Carolina obtaining consent from
patient families to gather clinical information via an online survey through
REDCap. The patients will be chosen based on a previous diagnosis with a
MEF2C variant or deletion or duplication involving the MEF2C gene. Responses
to the survey will be analyzed to gain a better understanding of MEF2C-related
disorders.

(2)

Patient Selection and Inclusion/Exclusion Criteria
Patient families will be made aware of the survey via email, social media, and
verbal communications. Any patient with a previously reported MEF2C alteration
(variant, deletion, duplication) will qualify to participate. The
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family/parent/guardian filling out the survey will have the option to submit
identifying contact information via email for any future studies or opportunities,
but this is optional and not required for taking the survey. The survey responses
will remain completely anonymous.
(3)

Data Collection Methods
The surveys will be completed by the patient’s parent, guardian, or caregiver
online via REDCap. These surveys will be electronically returned to the
Greenwood Genetic Center. Only the researchers and reviewing faculty at the
Greenwood Genetic Center, Clemson University, and Medical University of South
Carolina will have access to the survey responses, including any identifying
protected health information if the patient families consent to provide this
information.

C. Adverse Event Criteria and Reporting Procedures
This study is considered minimal risk. As with any study involving collection of
data, there is the possibility that unauthorized individuals may gain access
thereby breaching the confidentiality of the data. Every precaution will be taken to
secure the participants' personal information to ensure confidentiality. The
investigators do not foresee any adverse events, but any adverse event will be
reported to the IRB immediately.

D. Data Management Methods
The patient survey will be collected and securely saved within the HIPAA
compliant web-based application REDCap (Harris et al., 2009). The patient
survey response data will be extracted from REDCap and stored on a password
protected computer at the Greenwood Genetic Center to which only the
researchers have access. Greenwood Genetic Center is fully compliant with
HIPAA regulations. Survey responses may be uploaded to Box online, which
allows data sharing between Greenwood Genetic Center, Clemson University,
and Medical University of South Carolina. Only the researchers involved in this
project at these institutions will have access to Box. The Box platform and
associated products have been compliant with HIPAA, HITECH, and the final
HIPAA Omnibus rule since November 2012 (Box – Secure File Sharing). Only
survey answers will be added to Box, and no patient identifiers will be added to
Box. Any paper copies will be stored in a locked file cabinet to which only the
research team has access.
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E. Data Analysis Plan
Descriptive analyses will be calculated from the data obtained from the survey.
This data will be evaluated to gain a better understanding and knowledge base of
MEF2C-related disorders.

F. References
Box - Secure File Sharing, Storage, and Collaboration. (n.d.). Retrieved from
https://www.box.com/
Harris, P. A., Taylor, R., Thielke, R., Rayne, J., Gonzalez, N., Conde, J.G.. (2009)
Research electronic data capture (REDCap) – A metadata-driven methodology
and workflow process for providing translational research informatics support.
Journal of Biomedical Informatics. 42(2), 377-81.
http://www.sciencedirect.com/science/article/pii/S1532046408001226
Paciorkowski, A., Traylor, R., Rosenfeld, J., Hoover, J., Harris, C., Winter, S., … BerryKravis, E. (2013). MEF2C Haploinsufficiency features consistent hyperkinesis,
variable epilepsy, and has a role in dorsal and ventral neuronal developmental
pathways. Neurogenetics, 14(2), 99–111. https://doi.org/doi:10.1007/s10048013-0356-y
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INSTITUTIONAL REVIEW BOARD
Request for Waiver of the Requirement to Obtain Signed Consent from
Subjects
(not applicable to FDA regulated studies)
The only record linking the subject and the research would be the consent
document and the principal risk would be the harm resulting from breach of
confidentiality. (Note: Each subject must be asked whether they want documentation.)
Explain why:
OR
✓ The research presents no more than minimal risk* and involves no more
procedures for which written consent is normally required.
Explain why:
The research is in the form of an online survey in which there will be no link to
personal identifiers and the survey responses. Subjects will have the option to provide
their contact information to be contacted for future studies, but this information will not
be linked to their survey responses.
*minimal risk means that the probability and magnitude of harm or discomfort anticipated
in the research are not greater in and of themselves than those ordinarily encountered in
daily life or during the performance of routine physical or psychological examinations or
tests.

If documentation is waived, will the subjects be provided with a written statement
regarding research?
✓ YES. Attach copy of written statement that will be provided.
NO. Explain below why a written statement is not necessary or appropriate:
Subjects will see written information prior to starting the survey (like a consent form,
however they won’t be signing anything). Since the survey is online and subjects can
take the survey in various locations, they will not be provided with a physical copy.
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Patient Informed Consent
MEF2C-Related Disorders Natural History Survey
Principal Investigator
Steven A. Skinner, MD
Greenwood Genetic Center
106 Gregor Mendel Circle
Greenwood, SC 29646
864-941-8164
sas@ggc.org
Study Coordinator
Jessica A. Cooley Coleman, MB(ASCP)CM

Greenwood Genetic Center
106 Gregor Mendel Circle
Greenwood, SC 29646
864-941-8188
jcooley@ggc.org
Purpose of Study
You are being asked to take part in a research study. Before you decide to participate in this
study, it is important that you understand why the research is being done and what it will involve.
Please read the following information carefully. Please ask the researcher if there is anything that
is not clear or if you need more information.
The purpose of this study is to gather information to better characterize the symptoms of MEF2Crelated disorders.
Study Procedures
Patients who carry a MEF2C variant or deletion or duplication involving the MEF2C gene are
eligible to participate in this survey study. We hope to enroll approximately 50 individuals in this
survey, but there will not be a limit to how many individuals can participate.
Parents/Guardians agree:
1. to complete a survey in which their child’s medical information will be collected and
stored in the web-based application REDCap.
2. to have the survey responses uploaded to Box, an online application that will allow data
sharing between researchers at Greenwood Genetic Center, Clemson University, and
Medical University of South Carolina.
It is estimated that it will take 20-30 minutes to complete the survey.
Risks
This study presents minimal risks. Any time health information is collected, there is a risk that
unauthorized individuals may gain access thereby breaching the confidentiality of the data.
However, the data is stored in a secure location which should not be accessible to people outside
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of the research team, and precautions including password protections will be taken to secure
personal information.
You may decline to answer any or all questions and you may terminate your involvement at any
time if you choose.
Benefits
The benefits of this study include developing a large information databank which will help
physicians better diagnose and better understand this genetic condition in future patients.
Confidentiality
You will be asked for contact information; however, you may opt out of giving this information.
Regardless if you give information or opt out, the data collected in the survey will remain
anonymous. If you provide contact information, there may be future approved studies for which
you would be contacted for additional information. Every effort will be made by the researcher to
preserve your confidentiality, including the following:
• Assigning code names/numbers for participants that will be used on all research notes
and documents
• Keeping notes, interview transcriptions, and any other identifying participant
information in a locked file cabinet or locked computer document in the personal
possession of the researcher.
Participant data will be kept confidential except in cases where the researcher is legally obligated
to report specific incidents. These incidents include, but may not be limited to, incidents of abuse
and suicide risk.
Compensation
You will not be paid for participation in this study.

Authorization to Use or Disclose Protected Health Information
By proceeding with this survey, you are authorizing the Greenwood Genetic Center to
use and disclose (share) your protected health information for this research. You must
authorize this use and sharing of your information to be in the study. The protected health
information used for this research will include information collected about you and your
child during the survey.
Greenwood Genetic Center is required by law to protect your health information. This is
detailed in the Greenwood Genetic Center Notice of Privacy Practices, which is available
at www.ggc.org and can be provided upon request. The researchers in this study agree to
use your protected health information only as directed by you and as required by state
and federal law. Several people and organizations may access your protected health
information. They will need this information to conduct the research or to assure the
quality or safety of the research. These groups include:
•
•

members of the research team and other authorized staff at Greenwood Genetic
Center, Clemson University, and Medical University of South Carolina,
the Institutional Review Board (IRB) of Self Regional Healthcare,
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•

and the Office for Human Research Protections (OHRP) or possibly other federal or
state government agencies.

You may change your mind and withdraw your permission to use and share your protected health
information at any time. To take back your permission, you must email Jessica Cooley Coleman
[jcooley@ggc.org] or Dr. Steven Skinner [sas@ggc.org].
The results of this study may be shown at scientific meetings or published in scientific journals to
inform other doctors and health professionals. As the data is anonymous, your identity will not be
included in any publication or presentation.

Consent for Use of Information for Future Research
As part of the study, we will collect information. If you provide your contact information,
we may wish to contact you for a future study about MEF2C-related disorders.
Information that can identify you may be kept permanently in a laboratory, repository, or
computer database at the Greenwood Genetic Center. Only members of the research team
and other authorized staff at the Greenwood Genetic Center, Clemson University, and
Medical University of South Carolina will be able to see information that can identify
you.
Contact Information
If you have questions at any time about this study, or you experience adverse effects as the result
of participating in this study, you may contact the researcher whose contact information is
provided on the first page. If you have questions regarding your rights as a research participant, or
if problems arise which you do not feel you can discuss with the Primary Investigator, please
contact the Institutional Review Board at (864) 725-4252 or (864) 725-4851.

Voluntary Participation
Your participation in this study is voluntary. It is up to you to decide whether or not to
take part in this study. If you decide to take part in this study, you will be asked to give
your consent in order to proceed with the survey. After you consent to the survey, you are
still free to withdraw at any time and without giving a reason. Withdrawing from this
study will not affect the relationship you have, if any, with the researcher.
____________________________________________________________________
Consent
If you would like to participate, you are consenting that you have read and understand the
provided information and have had the opportunity to ask questions. You understand that your
participation is voluntary and that you are free to withdraw at any time, without giving a reason
and without cost. If you consent, please check the box below and then proceed with the survey
online. Your answers will not be submitted until you have completed and submitted the survey.

Do you consent to taking this survey?
o
o

Yes
No
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Advertising Script
MEF2C-Related Disorders Natural History Survey
My name is Jessica Cooley Coleman and I am a doctoral student in the Healthcare
Genetics PhD program at Clemson University. For my research, I have decided to study
MEF2C. My fellow researchers at Clemson and I have collaborated with researchers at
the Greenwood Genetic Center and Medical University of South Carolina (MUSC) to
create a survey so that we can better characterize the symptoms of MEF2C-related
disorders, sometimes referred to as MEF2C haploinsufficiency syndrome. Currently,
there is limited information in the literature about individuals who carry an alteration in
the MEF2C gene. We are hoping to collect information from families by use of this
survey and increase knowledge regarding MEF2C-related disorders. We hope this
information will help medical providers better diagnose and understand this condition in
the future. Also, this survey will help direct future research efforts. I hope you will
consider taking our survey. I will be happy to answer any survey-related questions you
may have via email at jcooley@ggc.org.
Additionally, if you would like to provide your contact information in the case of future
studies or opportunities, please send an email containing your first and last name and
preferred email address to MEF2C@ggc.org. Please note that this email address is only
for providing contact information for the possibility of future contact and therefore will
not be monitored for questions. This contact information will not be linked to your survey
responses and providing your contact information is optional and not required for taking
the survey. Thank you for your time and consideration.
To proceed with the survey, please visit:
https://redcap.healthsciencessc.org/surveys/?s=M3NRP9MXMM
-Jessica Cooley Coleman
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Survey instrument may be available upon request.
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Appendix G
Clemson University – Medical University of South Carolina
MEF2C RNAseq Visiting Researcher Proposal

Background
MEF2C is a transcription factor in the MEF2 (myocyte enhancer factor 2) family,
expressed in the nervous, muscular, and immune system. In the brain, MEF2C
orchestrates the expression of numerous genes critical for neurotypical brain development
and function. MEF2C is particularly known to play a role in neurogenesis, synaptic
formation, and remodeling (Assali et al., 2019). MEF2C is expressed in different brain
cell types, including excitatory and inhibitory neurons, as well as microglia, which
regulate synapse formation and elimination.
Pathogenic variants in the MEF2C gene or microdeletions of the 5q14.3 region
containing part or all of the MEF2C gene cause MEF2C Haploinsufficiency Syndrome
(MCHS) in humans. MCHS is characterized by intellectual disability, lack of verbal
language, motor delay, abnormal movements, autistic behaviors, and often epilepsy
(Paciorkowski et al., 2013). These symptoms are thought to be caused by
haploinsufficiency of MEF2C particularly in the neurons. Mef2c global heterozygous
mice and microglia-restricted conditional Mef2c heterozygous mice (Mef2c cHetCx3cr1)
display social deficits and repetitive behaviors, reminiscent of autism-like behaviors
(Harrington, Bridges et al., 2020). In addition, the loss of one copy of Mef2c in
GABAergic neurons (Mef2c cHetVGat) induces deficits in social preference and working
memory (unpublished data), both prefrontal cortex (PFC)-dependent behaviors. These
different mutant mice can therefore serve as animal models for the human syndrome,
MCHS, to study the role of Mef2c in autism-like behaviors, brain function, and gene
expression.
Project Plan
Previous RNAseq studies in global Mef2c heterozygous mice showed
dysregulation of hundreds of genes in the cortex as well as an upregulation of microglial
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genes (Harrington, Bridges et al., 2020). The authors hypothesized that microglia have a
delayed maturation in the Mef2c heterozygous mice as certain genes are enriched in the
postnatal day 35 mice that should no longer be active under normal microglia
development.
Given previous findings, the next step is to isolate cortical microglia nuclei and
perform single nuclei RNAseq to assess gene expression differences between global
Mef2c heterozygous mouse microglia and wildtype microglia.
Since Mef2c seems to play an important role in GABAergic cells, another
interesting direction is to assess gene expression differences between Mef2c cHetVgat mice
and wildtype mice, in the specific GABAergic subtype neurons of the PFC, using singlenuclei RNA-seq.
Jessica Cooley Coleman, doctoral candidate in the Healthcare Genetics PhD
program at Clemson University, will perform the role of visiting researcher at MUSC
from June to December 2021, with research and data analysis extending to May 2022 if
necessary. The project consists of three potential phases.
1) Isolate the nucleus of the specific cell type of interest (i.e., microglia or VgatCre; Mef2cfl/+ neurons).
- Nuclei will be sent to a core laboratory for RNAseq library preparation and
sequencing.
2) Learn and perform bioinformatic analysis of data generated by the RNAseq
runs to determine which genes are dysregulated due to the hypofunction of
Mef2c.
3) Validate significant up/down-regulated genes from the RNAseq results by
performing qPCR, or RNAscope, to quantify the level of gene expression.
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https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode

_______________________________________________________________

Nursing Open
Published by Wiley (the
"Owner")

LICENSE AGREEMENT FOR PUBLISHING CC-BYNC-ND
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published by John Wiley & Sons Ltd ("Wiley")
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Dear Contributor(s):
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing
process and enable Wiley to disseminate your Contribution to the fullest extent, we need to have this Agreement
executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this
Agreement will be null andvoid.
Publication cannot proceed without a signed copy of this Agreement and payment of the
appropriate articlepublication charge.

A. TERMS OF USE
1. The Contribution will be made Open Access under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivatives License which permits use, distribution and
reproduction in any medium, provided that the Contribution is properly cited, the use is
non-commercial and no modifications or adaptations are made.
2. For an understanding of what is meant by the terms of the Creative Commons License,
please refer toWiley's Open Access Terms and Conditions
(http://www.wileyauthors.com/OAA).
3. Notwithstanding acceptance, the Owner or Wiley may (but is not obliged to) require changes
to the Contribution, including changes to the length of the Contribution, and/or elect not to
publish the Contribution if for any reason, in the Owner’s or Wiley’s reasonable judgment,
such publication would be inconsistent with the Core Practices and associated guidelines set
forth by the Committee on Publication Ethics (a not-for-profit organization based in the UK:
https://publicationethics.org/core- practices) or would result in legal liability, violation of
Wiley’s ethical guidelines, or violation of journal ethical practices. If the Owner (or Wiley,
where Wiley is not the Owner) decides not to publish the Contribution, no Article Processing
Charge or any other fee shall be charged. The Contributor is free to submit the Contribution to
any other journal from any other publisher.
B. RETAINED RIGHTS
The Contributor or, if applicable, the Contributor's Employer, retains all proprietary rights in
addition tocopyright, such as patent rights in any process, procedure or article of manufacture
described in the Contribution.
C. LICENSE
In addition to the non-exclusive rights to the Contribution the Owner has under the CC-BYNC-ND license, the Contributor grants to the Owner, during the full term of the Contributor’s
copyright and anyextensions or renewals, an exclusive license of all rights of copyright in and
to the Contribution that the Contributor does not grant under the CC-BY-NC-ND license, and
all rights therein, including but not limited to the right to publish, republish, transmit, sell,
distribute and otherwise use the Contribution in whole or in part in electronic and print
editions of the Journal and in derivative works throughout the world, in all languages and in all
media of expression now known or later developed, for commercial purposes, and to license or
permit others to do so. Such exclusive rights do not conflict with the rights granted to users
under the terms of the Creative Commons Attribution-Non-Commercial-NoDerivs License.
For the avoidance of doubt, “Contribution” is defined to only include the article submitted by
the Contributor for publication in the Journal (including any embedded rich media) and does
not extend to any supporting information submitted with or referred to in the Contribution
(“Supporting Information”). To the extent that any Supporting Information is submitted to the
Journal, the Owner is granted a perpetual, non-exclusive license to publish, republish, transmit,
sell, distribute and otherwise use this Supporting Information in whole or in part in electronic
and print editions of the Journal and in derivative works throughout the world, in all languages
and in all media of expression now known or later developed, and to license or permit others
to do so. If the Contribution was shared as a preprint, the Contributor grants to the Owner
exclusivity as to any rights retained by the Contributor in the preprint.
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D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor's
employment as a "work-made-for-hire" and the employer owns the copyright in the
Contribution, the employer company
/institution agrees to the terms of use set forth in paragraph A above and must execute this
Agreement (inaddition to the Contributor) in the space provided below. In such case, the
company/institution hereby grants to the Owner, during the full term of copyright, an exclusive
license of all rights of copyright in and to the Contribution throughout the world for commercial
purposes and/or to create derivative works as specified in paragraph C above.
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S.
Government may reproduce, without charge, all or portions of the Contribution and may
authorize others to do so, forofficial U.S. Government purposes only, if the U.S. Government
contract or grant so requires. (U.S. Government, U.K. Government, and other government
employees: see notes at end.)
F. COPYRIGHT NOTICE
Owner (and Wiley, where Wiley is not the Owner), the Contributor, and the
company/institution agree that any and all copies of the Contribution or any part thereof
distributed or posted by them in print or electronic format as permitted will include the notice
of copyright as stipulated in the Journal and a fullcitation to the final published version of the
Contribution in the Journal as published by Wiley.
G. CONTRIBUTOR'S REPRESENTATIONS
The Contributor represents that: (i) the Contributor and all co-Contributors have the full power,
authorityand capability to enter into this Agreement, to grant the rights and license granted
herein and to perform all obligations hereunder; (ii) neither the Contributor nor any coContributor has granted exclusive rightsto, or transferred their copyright in, any version of the
Contribution to any third party; (iii) the Contribution is the Contributor’s original work, all
individuals identified as Contributors actually contributed to the Contribution, and all
individuals who contributed are included; (iv) if the Contributionwas prepared jointly, the
Contributor has informed the co-Contributors of the terms of this Agreement and has obtained
their signed written permission to execute this Agreement on their behalf as their agent;
(v) the Contribution is submitted only to this Journal and has not been published before, has not
been included in another manuscript, and is not currently under consideration or accepted for
publication elsewhere; (vi) if excerpts from copyrighted works owned by third parties are
included, the Contributor shall obtain written permission from the copyright owners for all uses
as set forth in the standard permissions form and the Journal’s Author Guidelines, and show
credit to the sources in the Contribution; (vii) the Contribution and any submitted Supporting
Information contain no libelous or unlawful statements, do not infringe upon the rights
(including without limitation the copyright, patent ortrademark rights) or the privacy of others,
do not breach any confidentiality obligation, do not violate a contract or any law, or do not
contain material or instructions that might cause harm or injury, and only utilize data that has
been obtained in accordance with applicable legal requirements and Journal policies;
(viii) there are no conflicts of interest relating to the Contribution, except as disclosed.
Accordingly, theContributor represents that the following information shall be clearly
identified on the title page of the Contribution: (1) all financial and material support for the
research and work; (2) any financial interests the Contributor or any co-Contributors may have
in companies or other entities that have an interest in the information in the Contribution or
any submitted Supporting Information (e.g., grants, advisory boards, employment,
consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock
ownership); and (3) indication of no such financial interests if appropriate.
H. USE OF INFORMATION
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The Contributor acknowledges that, during the term of this Agreement and thereafter (for as
long as necessary), the Owner (and Wiley, where Wiley is not the Owner) may process the
Contributor’s personal data, including storing or transferring data outside of the country of the
Contributor’s residence,in order to process transactions related to this Agreement and to
communicate with the Contributor, and that the Publisher has a legitimate interest in processing
the Contributor's personal data. By entering into this Agreement, the Contributor agrees to the
processing of the Contributor’s personal data (and, where applicable, confirms that the
Contributor has obtained the permission from all other contributors to process their personal
data). Wiley shall comply with all applicable laws, statutes and regulations relating to data
protection and privacy and shall process such personal data in accordance with Wiley’s Privacy
Policy located at: https://www.wiley.com/en-us/privacy.

[ X ] I agree to the OPEN ACCESS AGREEMENT as shown above, consent to execution and delivery of the Open
Access Agreement electronically and agree that an electronic signature shall be given the same legal force as a
handwritten signature,and have obtained written permission from all other contributors to execute this Agreement
on their behalf.

Contributor's signature (type name here):

Jessica A. Cooley

ColemanDate:

March 02, 2021

SELECT FROM OPTIONS BELOW:
[ X ] Contributorowned work
[ ] U.S. Government
work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public
domain in the United States. If the Contribution was not prepared as part of the employee's duties, or is not an
official U.S. government publication, or if at least one author is not a U.S. government employee, it is not a
U.S. Government work. If at least one author is not a U.S. government employee, then the non-government
author should also sign the form, selecting the appropriate additional ownership selection option. If more than
one author is not a U.S. government employee, one maysign on behalf of the others.
[ ] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other
Crown body aspart of his/her official duties, or which is an official government publication, belong to the
Crown and must be made available under the terms of the Open Government License. Contributors must
ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If
your status as a government employee legally prevents you from signing this Agreement, please contact the
Journal production editor. If this selection does not apply to at least one author in the group, this author
should also sign the form, indicating transfer of those rights which that author has and selecting the
appropriate additional ownership selection option. If this applies to more than one author,one may sign on
behalf of the others.
[ ] Other
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Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If you are employed by the World Health Organization or UNU-WIDER, please download a copy of the
license agreement from http://www.wileyauthors.com/licensingFAQ and upload the form to the Wiley
Author Services Dashboard. If your status as a government or non-governmental organisation employee
legally prevents you fromsigning this Agreement, please contact the Journal production editor.

Name of Government/Non-Governmental Organisation:

[ ] Company/institution owned work (made for hire in the course of employment)
If this selection does not apply to at least one author in the group, this author should also sign the form,
indicating transfer of those rights which that author has and selecting the appropriate additional ownership
selection option. If thisapplies to more than one author, one may sign on behalf of the others.

Name of Company/Institution:

Authorized Signature of Employer:

___________________________________________

Date:

___________________________________________

Signature of Employee:

___________________________________________

Date:

___________________________________________
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permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only,
theterms of the license are extended to include subsequent editions and for
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whole in situ anddoes not involve the separate exploitation of the permitted
figures or extracts, You may not alter, remove or suppress in any manner any
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branding ("Marks") of WILEY or its licensors is granted hereunder, and you
agree that you shall not assert any such right, license or interest with respect
thereto
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in the United States of America and each party hereby consents and submits
to the personal jurisdiction of such court, waives any objection to venue in
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Wiley Publishes Open Access Articles in fully Open Access Journals and in
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Access journals publish open access articles under the terms of the Creative
Commons Attribution (CC BY) Licenseonly, the subscription journals and a
few of the Open Access Journals offer a choice of Creative Commons Licenses.
The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy,
distribute andtransmit an article, adapt the article and make commercial use
of the article. The CC-BY license permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License
permits use, distribution and reproduction in any medium, provided the
original work is properly citedand is not used for commercial purposes.(see
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Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CCBY-NC-ND)permits use, distribution and reproduction in any medium,
provided the original work is properly cited, is not used for commercial
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Use by commercial "for-profit" organizations
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Use of Wiley Open Access articles for commercial, promotional, or marketing
purposesrequires further explicit permission from Wiley and will be subject to a
fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA
/Section/id-410895.html

Other Terms and Conditions:
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for publication in Molecular Genetics & Genomic Medicine (the
"Journal")published by Wiley Periodicals LLC ("Wiley")

Dear Contributor(s):
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing
process and enable Wiley to disseminate your Contribution to the fullest extent, we need to have this
Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is
subsequently rejected, this Agreement will be null and void.
Publication cannot proceed without a signed copy of this Agreement and payment of the
appropriate article publication charge in full (without deduction of any taxes or fees).

A. TERMS OF USE
1. The Contribution will be made Open Access under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives License which permits use,
distribution and reproduction in any medium, provided that the Contribution is
properly cited, the use is non- commercial and no modifications or adaptations are
made.
2. For an understanding of what is meant by the terms of the Creative Commons
License, please refer to Wiley's Open Access Terms and Conditions
(http://www.wileyauthors.com/OAA).
3. Notwithstanding acceptance, the Owner or Wiley may (but is not obliged to) require
changes tothe Contribution, including changes to the length of the Contribution,
and/or elect not to publishthe Contribution if for any reason, in the Owner’s or Wiley’s
reasonable judgment, such publication would be inconsistent with the Core Practices
and associated guidelines set forth by the Committee on Publication Ethics (a not-forprofit organization based in the UK: https://publicationethics.org/core-practices) or
would result in legal liability, violation of Wiley’s ethical guidelines, or violation of
journal ethical practices. If the Owner (or Wiley, where Wiley is not the Owner)
decides not to publish the Contribution, no Article Processing Charge or any other fee
shall be charged. The Contributor is free to submit the Contribution to any other
journal from any other publisher.
B. RETAINED RIGHTS
The Contributor or, if applicable, the Contributor's Employer, retains all proprietary
rights in addition to copyright, such as patent rights in any process, procedure or article
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of manufacture described in the Contribution.
C. LICENSE
In addition to the non-exclusive rights to the Contribution the Owner has under the CCBY-NC- ND license, the Contributor grants to the Owner, during the full term of the
Contributor’s copyright and any extensions or renewals, an exclusive license of all
rights of copyright in and to the Contribution that the Contributor does not grant under
the CC-BY-NC-ND license, and all rights therein, including but not limited to the right to
publish, republish, transmit, sell, distribute and otherwise use the Contribution in whole
or in part in electronic and print editions of the Journal and in derivative works
throughout the world, in all languages and in all media of expression now known or
later developed, for commercial purposes, and to license or permit others to do so.
Such exclusive rights do not conflict with the rights granted to users under the terms of
the Creative Commons Attribution-Non-Commercial-NoDerivs License. “Contribution”
means the article submitted by the Contributor for publication in the Journal (including
any embedded rich media) and all subsequent versions. The definition of Contribution
does not extend to any supporting information submitted with or referred to in the
Contribution (“Supporting Information”). To the extent that any Supporting Information
is submitted to the Journal, the Owner is granted a perpetual, non-exclusive license to
publish, republish, transmit, sell, distribute and otherwise use this Supporting
Information in whole or in part in electronic and print editions of the Journal and in
derivative works throughout the world, in all languages and in all media of expression
now known or later developed, and to license or permit others to do so. If the
Contribution was shared as a preprint, the Contributor grants to the Owner exclusivity
as to any rights retained by the Contributor in the preprint.
D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor's
employment as a "work-made-for-hire" and the employer owns the copyright in the
Contribution, the employer company/institution agrees to the terms of use set forth in
paragraph A above and must execute this Agreement (in addition to the Contributor) in
the space provided below. In such case, the company/institution hereby grants to the
Owner, during the full term of copyright,an exclusive license of all rights of copyright in
and to the Contribution throughout the world for commercial purposes and/or to create
derivative works as specified in paragraph C above.
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the
U.S. Government may reproduce, without charge, all or portions of the Contribution

284

and may authorize others to do so, for official U.S. Government purposes only, if the
U.S. Government contract or grant so requires. (U.S. Government, U.K. Government,
and other government employees: see notes at end.)
F. COPYRIGHT NOTICE
Owner (and Wiley, where Wiley is not the Owner), the Contributor, and the
company/institution agree that any and all copies of the Contribution or any part thereof
distributed or posted by them in print or electronic format as permitted will include the
notice of copyright as stipulated inthe Journal and a full citation to the final published
version of the Contribution in the Journal as published by Wiley.
G. CONTRIBUTOR'S REPRESENTATIONS
The Contributor represents that: (i) the Contributor and all co-Contributors have the full
power, authority and capability to enter into this Agreement, to grant the rights and
license granted herein and to perform all obligations hereunder; (ii) neither the
Contributor nor any co- Contributor has granted exclusive rights to, or transferred their
copyright in, any version of the Contribution to any third party; (iii) the Contribution is
the Contributor’s original work, all individuals identified as Contributors actually
contributed to the Contribution, and all individualswho contributed are included; (iv) if
the Contribution was prepared jointly, the Contributor has informed the co-Contributors
of the terms of this Agreement and has obtained their signed written permission to
execute this Agreement on their behalf as their agent; (v) the Contribution is submitted
only to this Journal and has not been published before, has not been included in
another manuscript, and is not currently under consideration or accepted for
publication elsewhere; (vi) if excerpts from copyrighted works owned by third parties
are included, the Contributor shall obtain written permission from the copyright owners
for all uses as set forth inthe standard permissions form and the Journal’s Author
Guidelines, and show credit to the sources in the Contribution; (vii) the Contribution
and any submitted Supporting Information contain no libelous or unlawful statements,
do not infringe upon the rights (including without limitation the copyright, patent or
trademark rights) or the privacy of others, do not breach any confidentiality obligation,
do not violate a contract or any law, or do not contain material or instructions that might
cause harm or injury, and only utilize data that has been obtained in accordance with
applicable legal requirements and Journal policies; (viii) there are no conflicts of
interest relating to the Contribution, except as disclosed. Accordingly, the Contributor
represents that the following information shall be clearly identified on the title page of
the Contribution: (1) all financial and material support for the research and work; (2)
any financial interests the Contributor or any co-Contributors may have in companies
or other entities that have an interest in the information in the Contribution or any
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submitted Supporting Information (e.g., grants, advisory boards, employment,
consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock
ownership); and (3) indication of no such financial interests if appropriate.

H. USE OF INFORMATION
The Contributor acknowledges that, during the term of this Agreement and thereafter
(for as long as necessary), the Owner (and Wiley, where Wiley is not the Owner) may
process the Contributor’s personal data, including storing or transferring data outside
of the country of the Contributor’s residence, in order to process transactions related to
this Agreement and to communicate with the Contributor, and that the Publisher has a
legitimate interest in processingthe Contributor's personal data. By entering into this
Agreement, the Contributor agrees to the processing of the Contributor’s personal data
(and, where applicable, confirms that the Contributor has obtained the permission from
all other contributors to process their personal data). Wiley shall comply with all
applicable laws, statutes and regulations relating to data protection and privacy and
shall process such personal data in accordance with Wiley’s Privacy Policy located at:
https://www.wiley.com/en-us/privacy.

[ X ] I agree to the OPEN ACCESS AGREEMENT as shown above, consent to execution and delivery of
the Open Access Agreement electronically and agree that an electronic signature shall be given the same
legal force as a handwritten signature, and have obtained written permission from all other contributors to
execute this Agreement on their behalf.

Contributor's signature (type name here):

Jessica A. Cooley Coleman

Date:

February 28, 2022

SELECT FROM OPTIONS BELOW:
[ X ] Contributor-owned work
[ ] U.S. Government work
Note to U.S. Government Employees
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A contribution prepared by a U.S. federal government employee as part of the employee's official duties,
or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the
public domain in the United States. If the Contribution was not prepared as part of the employee's duties,
or is not an official U.S. government publication, or if at least one author is not a U.S. government
employee, it is not a
U.S. Government work. If at least one author is not a U.S. government employee, then the nongovernment author should also sign the form, selecting the appropriate additional ownership selection
option. If more than one author is not a U.S. government employee, one may sign on behalf of the others.
[ ] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other
Crown body as part of his/her official duties, or which is an official government publication, belong to the
Crown and must be made available under the terms of the Open Government License. Contributors must
ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If
your status as a government employee legally prevents you from signing this Agreement, please contact
the Journal production editor. If this selection does not apply to at least one author in the group, this
author should also sign the form, indicating transfer of those rights which that author has and selecting
the appropriate additional ownership selection option. If this applies to more than one author, one may
sign on behalf of the others.
[ ] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation
Employees If you are employed by the World Health Organization or UNU-WIDER, please
download a copy of the
license agreement from http://www.wileyauthors.com/licensingFAQ and upload the form to the Wiley Author
Services Dashboard. If your status as a government or non-governmental organisation employee legally
prevents you from signing this Agreement, please contact the Journal production editor.

Name of Government/Non-Governmental Organisation:

[ ] Company/institution owned work (made for hire in the course of employment)
If this selection does not apply to at least one author in the group, this author should also sign the form,
indicating transfer of those rights which that author has and selecting the appropriate additional ownership
selection option. If this applies to more than one author, one may sign on behalf of the others.
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Name of Company/Institution:

Authorized Signature of Employer:

___________________________________________

Date:

___________________________________________

Signature of Employee:

___________________________________________

Date:

___________________________________________
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49 Spadina Ave. Suite 200
Toronto ON M5V 2J1 Canada
www.biorender.com

Confirmation of Publication and Licensing Rights
February 11th, 2022
Science Suite Inc.
Subscription:
Agreement number:
Journal name:

Student Plan
YM23JWHD4N
Tiger Print Institutional Repository

To whom this may concern,
This document is to confirm that Jessica Cooley coleman has been granted a license to use the
BioRender content, including icons, templates and other original artwork, appearing in the
attached completed graphic pursuant to BioRender's Academic License Terms. This license permits
BioRender content to be sublicensed for use in journal publications.
All rights and ownership of BioRender content are reserved by BioRender. All completed graphics must
be accompanied by the following citation: “Created with BioRender.com”.
BioRender content included in the completed graphic is not licensed for any commercial uses beyond
publication in a journal. For any commercial use of this figure, users may, if allowed, recreate it in
BioRender under an Industry BioRender Plan.

For any questions regarding this document, or other questions about publishing with BioRender refer to
our BioRender Publication Guide, or contact BioRender Support at support@biorender.com.
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